# kidney INTERNATIONAL

Volume 45, 1994

**Founding Editor**
**Roscoe R. Robinson,** Nashville

**Editor**
**Thomas E. Andreoli,** Little Rock

**Associate Editors**
**Claude Amiel,** Paris
**Harry Jacobson,** Nashville
**James P. Knochel,** Dallas
**Jan J. Weening,** Amsterdam

**Editors, Nephrology Forum**
**Jordan T. Cohen,** Stony Brook
**John T. Harrington,** Boston
**Nicolaos E. Madias,** Boston

**Editor, Historical Archives**
**Carl W. Gottschalk,** Chapel Hill

**Consulting Editors**
**Robert J. Alpern,** Dallas
**Victoria Cattell,** London
**William G. Couser,** Seattle
**Jean-Pierre Grünfeld,** Paris
**Kiyoshi Kurokawa,** Tokyo
**Terry B. Strom,** Boston
**Pierre Verroust,** Paris

**Editorial Board**
**Hanna E. Abboud,** San Antonio
**Horacio J. Adrogué,** Houston
**Oladipo O. Akinkugbe,** Ibadan
**Anita Aperia,** Stockholm
**Peter S. Aronson,** New Haven
**Robert C. Atkins,** Melbourne
**Knut Aukland,** Bergen
**Ellis D. Avner,** Seattle
**Rashad S. Barsoum,** Guiza
**Laurent Baud,** Paris
**J.H.M. Berden,** Nijmegen
**Michel Bergeron,** Montreal
**Tomas Berl,** Denver
**Ori S. Better,** Haifa
**W. Kline Bolton,** Charlottesville
**Jean-Philippe Bonjour,** Geneva
**Wayne A. Border,** Salt Lake City
**D. Craig Brater,** Indianapolis
**James C.M. Chan,** Richmond
**Cyril Chantler,** London
**Russell W. Chesney,** Memphis
**Alfred Cheung,** Salt Lake City
**Anthony R. Clarkson,** North Terrace
**Jack W. Coburn,** Los Angeles
**Giuseppe D'Amico,** Milan
**John T. Daugirdas,** Chicago
**Marc E. de Broe,** Antwerp
**Natale G. De Santo,** Naples
**Vincent W. Dennis,** Durham
**Evert J. Dorhout Mees,** Izmir
**Philippe Druet,** Paris
**Jesus Egido,** Madrid
**A. Meguid El Nahas,** Sheffield
**Leon G. Fine,** London
**Gerard Friedlander,** Paris
**Michel Goldman,** Brussels
**Walter Guder,** Munich
**William Guggino,** Baltimore
**Jean-Pierre Guignard,** Lausanne
**Raymond M. Hakim,** Nashville
**Steven C. Hebert,** Boston
**J. Harold Helderman,** Nashville
**William L. Henrich,** Dallas
**Jaime Herrera-Acosta,** Mexico City
**Klaus Hierholzer,** Berlin
**Stephen Holdsworth,** Melbourne
**Billy G. Hudson,** Kansas City
**Iekuni Ichikawa,** Nashville
**Masashi Imai,** Tochigi
**Yashpal S. Kanwar,** Chicago
**Brigitte Kaissling,** Zurich
**George A. Kaysen,** Sacramento
**William Keane,** Minneapolis
**Vicki E. Rubin Kelley,** Boston
**Rajiv Kumar,** Rochester, MN
**David Z. Levine,** Ottawa
**Francisco Llach,** Los Angeles
**Martin Lockwood,** London
**David H. Lovett,** San Francisco
**Robert G. Luke,** Cincinnati
**Kirsten M. Madsen,** Gainesville
**S. Michael Mauer,** Minneapolis
**Paolo Menè,** Rome
**Chandra Mistry,** Mid Glamorgan
**William E. Mitch,** Atlanta
**Yuri V. Natochin,** St. Petersburg
**Thomas J. Neale,** Wellington
**Eric G. Neilson,** Philadelphia
**Jean Olson,** Baltimore
**Mordecai M. Popovtzer,** Jerusalem
**Andrew Rees,** London
**Giuseppe Remuzzi,** Bergamo
**Helmut G. Rennke,** Boston
**Eberhard Ritz,** Heidelberg
**Gianfranco Rizzoni,** Rome
**Jose L. Rodicio,** Madrid
**Claudio Ronco,** Vicenza
**Pierre M. Ronco,** Paris
**David J. Salant,** Boston
**James A. Schafer,** Birmingham
**Detlef Schlondorff,** New York
**Anton C. Schoolwerth,** Richmond
**Sudhir V. Shah,** Little Rock
**Stefan Silbernagl,** Wurzburg
**Karl L. Skorecki,** Toronto
**Gunter Stein,** Jena
**R. Bernd Sterzel,** Erlangen-Nürnberg
**Liliane Striker,** Bethesda
**Nobuhiro Sugino,** Tokyo
**Gilbert T. Thiel,** Basel
**C. Craig Tisher,** Gainesville
**Edward J. Weinman,** Los Angeles
**Christopher S. Wilcox,** Gainesville

**Manuscript Editor**
**Shellie T. Newell,** Little Rock

**Editorial Assistants**
**Mary Couey,** Nashville
**Susan Hoffman,** Amsterdam
**Josseline Nicolet,** Paris
**Joni Owens,** Little Rock
**Vickie A. Parker,** Dallas
**Julie Robinson,** Little Rock

Blackwell Scientific Publications

# kidney INTERNATIONAL

Volume 45, 1994

**Founding Editor**
**Roscoe R. Robinson,** Nashville

**Editor**
**Thomas E. Andreoli,** Little Rock

**Associate Editors**
**Claude Amiel,** Paris
**Harry Jacobson,** Nashville
**James P. Knochel,** Dallas
**Jan J. Weening,** Amsterdam

**Editors, Nephrology Forum**
**Jordan T. Cohen,** Stony Brook
**John T. Harrington,** Boston
**Nicolaos E. Madias,** Boston

**Editor, Historical Archives**
**Carl W. Gottschalk,** Chapel Hill

**Consulting Editors**
**Robert J. Alpern,** Dallas
**Victoria Cattell,** London
**William G. Couser,** Seattle
**Jean-Pierre Grünfeld,** Paris
**Kiyoshi Kurokawa,** Tokyo
**Terry B. Strom,** Boston
**Pierre Verroust,** Paris

**Editorial Board**
**Hanna E. Abboud,** San Antonio
**Horacio J. Adrogué,** Houston
**Oladipo O. Akinkugbe,** Ibadan
**Anita Aperia,** Stockholm
**Peter S. Aronson,** New Haven
**Robert C. Atkins,** Melbourne
**Knut Aukland,** Bergen
**Ellis D. Avner,** Seattle
**Rashad S. Barsoum,** Guiza
**Laurent Baud,** Paris
**J.H.M. Berden,** Nijmegen
**Michel Bergeron,** Montreal
**Tomas Berl,** Denver
**Ori S. Better,** Haifa
**W. Kline Bolton,** Charlottesville
**Jean-Philippe Bonjour,** Geneva
**Wayne A. Border,** Salt Lake City
**D. Craig Brater,** Indianapolis
**James C.M. Chan,** Richmond
**Cyril Chantler,** London
**Russell W. Chesney,** Memphis
**Alfred Cheung,** Salt Lake City
**Anthony R. Clarkson,** North Terrace
**Jack W. Coburn,** Los Angeles
**Giuseppe D'Amico,** Milan
**John T. Daugirdas,** Chicago
**Marc E. de Broe,** Antwerp
**Natale G. De Santo,** Naples
**Vincent W. Dennis,** Durham
**Evert J. Dorhout Mees,** Izmir
**Philippe Druet,** Paris
**Jesus Egido,** Madrid
**A. Meguid El Nahas,** Sheffield
**Leon G. Fine,** London
**Gerard Friedlander,** Paris
**Michel Goldman,** Brussels
**Walter Guder,** Munich
**William Guggino,** Baltimore
**Jean-Pierre Guignard,** Lausanne
**Raymond M. Hakim,** Nashville
**Steven C. Hebert,** Boston
**J. Harold Helderman,** Nashville
**William L. Henrich,** Dallas
**Jaime Herrera-Acosta,** Mexico City
**Klaus Hierholzer,** Berlin
**Stephen Holdsworth,** Melbourne
**Billy G. Hudson,** Kansas City
**Iekuni Ichikawa,** Nashville
**Masashi Imai,** Tochigi
**Yashpal S. Kanwar,** Chicago
**Brigitte Kaissling,** Zurich
**George A. Kaysen,** Sacramento
**William Keane,** Minneapolis
**Vicki E. Rubin Kelley,** Boston
**Rajiv Kumar,** Rochester, MN
**David Z. Levine,** Ottawa
**Francisco Llach,** Los Angeles
**Martin Lockwood,** London
**David H. Lovett,** San Francisco
**Robert G. Luke,** Cincinnati
**Kirsten M. Madsen,** Gainesville
**S. Michael Mauer,** Minneapolis
**Paolo Menè,** Rome
**Chandra Mistry,** Mid Glamorgan
**William E. Mitch,** Atlanta
**Yuri V. Natochin,** St. Petersburg
**Thomas J. Neale,** Wellington
**Eric G. Neilson,** Philadelphia
**Jean Olson,** Baltimore
**Mordecai M. Popovtzer,** Jerusalem
**Andrew Rees,** London
**Giuseppe Remuzzi,** Bergamo
**Helmut G. Rennke,** Boston
**Eberhard Ritz,** Heidelberg
**Gianfranco Rizzoni,** Rome
**Jose L. Rodicio,** Madrid
**Claudio Ronco,** Vicenza
**Pierre M. Ronco,** Paris
**David J. Salant,** Boston
**James A. Schafer,** Birmingham
**Detlef Schlondorff,** New York
**Anton C. Schoolwerth,** Richmond
**Sudhir V. Shah,** Little Rock
**Stefan Silbernagl,** Wurzburg
**Karl L. Skorecki,** Toronto
**Gunter Stein,** Jena
**R. Bernd Sterzel,** Erlangen-Nürnberg
**Liliane Striker,** Bethesda
**Nobuhiro Sugino,** Tokyo
**Gilbert T. Thiel,** Basel
**C. Craig Tisher,** Gainesville
**Edward J. Weinman,** Los Angeles
**Christopher S. Wilcox,** Gainesville

**Manuscript Editor**
**Shellie T. Newell,** Little Rock

**Editorial Assistants**
**Mary Couey,** Nashville
**Susan Hoffman,** Amsterdam
**Josseline Nicolet,** Paris
**Joni Owens,** Little Rock
**Vickie A. Parker,** Dallas
**Julie Robinson,** Little Rock

Blackwell Scientific Publications

# Author Index For Volume 45


A

Abou-Samra A-B *See* Ureña P et al ..... 605
Abramson RG *See* Knorr BA et al ..... 727
Abreo K, Glass J, Jain S, Sella ML: Aluminum alters the compartmentalization of iron in Friend erythroleukemia cells ..... 636
Ackermann D (abst) ..... 1783, 1785
Adam W (abst) ..... 1278
Adam WR (abst) ..... 1255
Adam WR *See* Saunders JR et al ..... 817
Adams JL *See* Albrightson CR et al ..... 1301
Adams MA *See* Friberg P et al ..... 485
Ader J-L, Tack I, Lloveras J-J, Tran-Van T, Rostaing L, Praddaude F, Durand D, Suc J-M: Renal functional reserve in cyclosporin-treated recipients of kidney transplant ..... 1657
Adler S: Integrin matrix receptors in renal injury ..... 45:S-86
Aglibut S (abst) ..... 1261, 1276
Aguilera G *See* Ray PE et al ..... 177
Aitken RE (abst) ..... 1267
Akai Y *See* Harris RC et al ..... 45:S-17
Akkerman S *See* Pollard TA et al ..... 232
Albrightson CR, Short B, Dytko G, Zabko-Potapovich B, Brickson B, Adams JL, Griswold DE: Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat ..... 1301
Alcázar JM *See* Ruilope LM et al ..... 45:S-171
Aldred GP (abst) ..... 1259
Alford F (abst) ..... 1270
Allan P (abst) ..... 1278
Allen A *See* Harper SJ et al ..... 836
Allen T (abst) ..... 1270
Allgren R *See* Rahman SN et al ..... 1731
Almeída C (abst) ..... 282
Almeida E (abst) ..... 286
Alpers CE *See* Giachelli CM et al ..... 515
Alvo M *See* Bofill P et al ..... 672
Amaro MJ (abst) ..... 284
Ambühl PM (abst) ..... 1785
Amiel C: Report of the Secretary General ..... 44:S-121
Aminian A (abst) ..... 1278
Aminian A *See* Saunders JR et al ..... 817
Amiry-Moghaddam M, Nagelhus E, Ottersen OP: Light- and electronmicroscope distribution of taurine, an organic osmolyte, in rat renal tubule cells ..... 10
Anderson RJ, Sponsel HT, Kroll DJ, Jackson S, Breckon R, Hoeffler JP: Escape from the antiproliferative effect of transforming growth factor-$\beta_1$ in LLC-PK$_1$ renal epithelial cells ..... 642
Anderson S: Relevance of single nephron studies to human glomerular function ..... 384
Anderson W (abst) ..... 1254
Ando T *See* Tamaki K et al ..... 525
Andoh TF *See* Burdmann EA et al ..... 684
Andreoli TE: Report of the Editor ..... 44:S-125
Andreoli TE *See* Winters CJ et al ..... 803
Andreucci VE *See* Sabbatini M et al ..... 1355
Anpalahan A (abst) ..... 1273
Antonioli V (abst) ..... 1792
Antunes NL (abst) ..... 290
Aperia A *See* Ohtomo Y et al ..... 1606
Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease ..... 45:S-174
Arakawa T *See* Inishi Y et al ..... 1318
Arakelian S *See* D'Haese PC et al ..... 76
Araujo Pereira ME (abst) ..... 286
Araujo R (abst) ..... 289
Ardaillou R *See* Baud L et al ..... 45:S-32
Argilés A (abst) ..... 1253
Argilés A, Ootaka T, Hill PA, Nikolic-Paterson DJ, Hutchinson P, Kraft NE, Atkins RC: Regulation of human renal adenocarcinoma cell growth by retinoic acid and its interactions with epidermal growth factor ..... 23
Arieff AI: Dialysis disequilibrium syndrome: Current concepts on pathogenesis and prevention (Editorial Review) ..... 629
Arima S, Ren YL, Juncos LA, Carretero OA, Ito S: Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles ..... 650
Arisz L *See* Struijk DG et al ..... 1739
Armada Rdguez E (abst) ..... 291
Armada Rdgz E (abst) ..... 291
Armada Rguez E (abst) ..... 292
Arrobas M *See* Caravaca F et al ..... 845
Askew R *See* Lingrel JB et al ..... 44:S-32
Asper R (abst) ..... 1791
Atkins RC (abst) ..... 1257, 1257, 1257, 1259, 1262, 1271, 1272, 1272
Atkins RC: Role of macrophages in glomerular injury and leukocyte adhesion molecules: Summary and concluding remarks ..... 45:S-98
Atkins RC *See* Argilés A et al ..... 23
Atkins RC *See* Hill PA et al ..... 32
Atkins RC *See* Hill PA et al ..... 700
Atkins RC *See* Nikolic-Paterson DJ et al ..... 45:S-79
Atluru D *See* Kasiske BL et al ..... 45:S-51
Auriche P *See* Meyrier A et al ..... 1446
Austin HA III, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data ..... 544
Azatian G (abst) ..... 1791
Azevedo J (abst) ..... 287, 288

B

Babishckin S *See* Roth D et al ..... 238
Babloyan A (abst) ..... 1791
Babloyan A *See* D'Haese PC et al ..... 76
Bachmann J *See* Barenbrock M et al ..... 1397
Bagros P *See* Delarue J et al ..... 1147
Bailey RR (abst) ..... 1256, 1258, 1266, 1267, 1273
Bain RP *See* Breyer JA et al ..... 45:S-156
Baldaia J (abst) ..... 282, 283, 283
Ballard FJ (abst) ..... 1277
Ballèvre L (abst) ..... 1786

Balow JE *See* Austin HA III et al ..... 544
Bannister K (abst) ..... 1269
Barata JD (abst) ..... 291
Barden A (abst) ..... 1274
Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, Hoeks APG, Rahn K-H: Studies of the vessel wall properties in hemodialysis patients ..... 1397
Barlet-Bas C (abst) ..... 1789
Barnes JL *See* Brem AS et al ..... 679
Barratt LJ (abst) ..... 1256, 1263
Barreira M (abst) ..... 288
Barreto JC (abst) ..... 283
Barrios R *See* Truong LD et al ..... 201
Barros H (abst) ..... 282
Barthelmebs M *See* Michel B et al ..... 1587
Bartholomay D *See* Quarles LD et al ..... 1710
Bartle AJ (abst) ..... 1267
Basgen JM, Steffes MW, Stillman AE, Mauer SM: Estimating glomerular number *in situ* using magnetic resonance imaging and biopsy ..... 1668
Bason L (abst) ..... 1267, 1275, 1277
Batsford SR *See* Morioka T et al ..... 991
Baud L, Ardaillou R: Tumor necrosis factor alpha in glomerular injury ..... 45:S-32
Baylis C (abst) ..... 1255
Baylis PH *See* Sturrock NDC et al ..... 1203
Beathard GA: Mechanical versus pharmacomechanical thrombolysis for the treatment of thrombosed dialysis access grafts ..... 1401
Beavan LA *See* Couchman JR et al ..... 328
Beck JC *See* Knorr BA et al ..... 727
Becker G (abst) ..... 1258, 1273, 1278
Becker GJ (abst) ..... 1262, 1264, 1265, 1271, 1273
Becker GJ, Whitworth JA, Ihle BU, Shahinfar S, Kincaid-Smith PS: Prevention of progression in non-diabetic chronic renal failure ..... 45:S-167
Beckman JK *See* Yoshioka T et al ..... 211
Beilin L (abst) ..... 1274
Bellazzi R *See* Maggi E et al ..... 876
Bellizzi V *See* Cianciaruso B et al ..... 852
Bellomo G *See* Maggi E et al ..... 876
Benador D (abst) ..... 1791
Benador N (abst) ..... 1784, 1791
Bennett WM *See* Burdmann EA et al ..... 684
Bental T *See* Ravid M et al ..... 45:S-161
Berezesky IK *See* Yamamoto N et al ..... 1093
Bernard A *See* Kabanda A et al ..... 1689
Berney T *See* Fulpius T et al ..... 962
Bernheim J, Boner G, Popovtzer MM: Editorial ..... 44:S-3
Bertram JF (abst) ..... 1271
Bertram JF *See* Ricardo SD et al ..... 1057
Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G: Alternative pathway activation of complement by cultured human proximal tubular epithelial cells ..... 451
Bigotte N (abst) ..... 283
Bina B *See* Brem AS et al ..... 679
Binswanger U (abst) ..... 1785, 1785, 1786, 1789, 1791
Birch D (abst) ..... 1273
Birchall IE (abst) ..... 1271
Bird SD (abst) ..... 1277
Birmingham DJ *See* Hebert LA et al ..... 493
Björck S *See* Mulec H et al ..... 45:S-141
Blake PG *See* Lindsay RM et al ..... 44:S-85
Blanchard DK *See* Garin EH et al ..... 1311
Blau N (abst) ..... 1791
Bleisch J (abst) ..... 1785, 1786
Bleyer AJ, Fumo P, Snipes ER, Goldfarb S, Simmons DA, Ziyadeh FN: Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule ..... 659
Bloom RD *See* Kelley VR et al ..... 45:S-83
Blum WF *See* Tönshoff B et al ..... 1085
Blumberg A (abst) ..... 1786
Blumenstein M (abst) ..... 1253
Boadle RA (abst) ..... 1255, 1268, 1271
Boadle RA *See* Nankivell BJ et al ..... 1006
Bobik A *See* Friberg P et al ..... 485
Bock A (abst) ..... 1788, 1788, 1790, 1792, 1793
Bock HA (abst) ..... 1784, 1793
Boelaert JR, Van Cutsem J, de Locht M, Schneider Y-J, Crichton RR: Deferoxamine augments growth and pathogenicity of *Rhizopus*, while hydroxypyridinone chelators have no effect ..... 667
Boer P, Braam B, Fransen R, Boer WH, Koomans HA: Reliable atomic absorption analysis of sodium and potassium in rat renal tubular fluid (Technical Note) ..... 1211
Boer WH *See* Boer P et al ..... 1211
Boeschoten EW *See* Struijk DG et al ..... 1739
Bofill P, Goecke IA, Bonilla S, Alvo M, Marusic ET: Tissue-specific modulation of Na, K-ATPase $\alpha$-subunit gene expression in uremic rats ..... 672
Bogdanoska V (abst) ..... 1268
Bohle A *See* Erley CM et al ..... 1425
Bolle J-F (abst) ..... 1792
Bolton WK *See* Lebovitz HE et al ..... 45:S-150
Boman S-O *See* Friberg P et al ..... 485
Boner G *See* Bernheim J et al ..... 44:S-3
Bonilla E *See* Szabolcs MJ et al ..... 1388
Bonilla S *See* Bofill P et al ..... 672
Bonjour J-P *See* Ruedin P et al ..... 245
Booth NA *See* Brown PAJ et al ..... 43
Boquinhas JM (abst) ..... 283
Boquinhas MH (abst) ..... 284
Bordalo J (abst) ..... 288
Border WA *See* Ruoslahti E et al ..... 44:S-17
Border WA *See* Yamamoto T et al ..... 916
Botey A *See* Poch E et al ..... 1037
Bouhtiauy I, Lajeunesse D, Christakos S, Brunette MG: Two vitamin $D_3$-dependent calcium binding proteins increase calcium reabsorption by different mechanisms I. Effect of CaBP 28K ..... 461
Bouhtiauy I, Lajeunesse D, Christakos S, Brunette MG: Two vitamin $D_3$-dependent calcium binding proteins increase calcium reabsorption by different mechanisms II. Effect of CaBP 9K ..... 469
Boulton H *See* Harty JC et al ..... 103
Boumpas DT *See* Austin HA III et al ..... 544
Bover J, Rodriguez M, Trinidad P, Jara A, Martinez ME, Machado L, Llach F, Felsenfeld AJ: Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat ..... 953
Bovi G *See* Cianciaruso B et al ..... 852
Braam B *See* Boer P et al ..... 1211
Brady HR: Leukocyte adhesion molecules and kidney diseases (Editorial Review) ..... 1285
Brady HR, Papayianni A, Serhan CN: Leukocyte adhesion promotes biosynthesis of lipoxygenase products by transcellular routes ..... 45:S-90
Braegger C (abst) ..... 1783
Bray AE (abst) ..... 1266

Breckon R *See* Anderson RJ et al ..... 642
Bregman R (abst) ..... 287, 287
Brem AS, Bina B, Matheson KL, Barnes JL, Morris DJ: Developmental changes in rat renal 11β-hydroxysteroid dehydrogenase ..... 679
Brenner BM *See* Dirks JH et al ..... 45:S-22
Brenner BM *See* Keane WF et al ..... 45:S-1
Breyer JA, Hunsicker LG, Bain RP, Lewis EJ, Collaborative Study Group: Angiotensin converting enzyme inhibition in diabetic nephropathy ..... 45:S-156
Brezis ML *See* Heyman SN et al ..... 981
Brickson B *See* Albrightson CR et al ..... 1301
Brighouse G *See* Fulpius T et al ..... 962
Briner VA (abst) ..... 1784
Briner VA *See* Caramelo C et al ..... 66
Broadstone V *See* Lebovitz HE et al ..... 45:S-150
Broe MED *See* Nouwen EJ et al ..... 1510
Broneer D *See* Meyrier A et al ..... 1446
Brouwer E, Huitema MG, Mulder AHL, Heeringa P, van Goor H, Tervaert JWC, Weening JJ, Kallenberg CGM: Neutrophil activation *in vitro* and *in vivo* in Wegener's granulomatosis ..... 1120
Brown MA (abst) ..... 1269, 1270, 1277
Brown PAJ, Wilson HM, Reid FJ, Booth NA, Simpson JG, Morrison L, Power DA, Haites NE: Urokinase-plasminogen activator is synthesized *in vitro* by human glomerular epithelial cells but not by mesangial cells ..... 43
Bruggeman LA *See* Ray PE et al ..... 177
Brunette MG *See* Bouhtiauy I et al ..... 461
Brunette MG *See* Bouhtiauy I et al ..... 469
Brunner FP (abst) ..... 1784, 1786, 1793, 1793
Buchanan R (abst) ..... 1257
Buddle ML (abst) ..... 1269, 1270
Burckhardt JJ (abst) ..... 1787
Burdmann EA, Andoh TF, Rosen S, Lindsley J, Munar MY, Elzinga LW, Bennett WM: Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A ..... 684
Burke BA *See* Paulsen EP et al ..... 1132
Burke GW *See* Roth D et al ..... 238
Burke JR (abst) ..... 1267
Burkhart KM *See* Zager RA et al ..... 1760
Burrell LM (abst) ..... 1261
Bushinsky DA, Kim M, Sessler N, Nakagawa Y, Coe FL: Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats ..... 58
Bustorff M (abst) ..... 282
Butkowski RJ *See* Zhu D et al ..... 425
Buttimore AL (abst) ..... 1262

C

Cabrita A (abst) ..... 286, 287
Calado F (abst) ..... 284
Calado J (abst) ..... 285, 290
Caldas A (abst) ..... 288
Caldas L (abst) ..... 287, 287
Calise D *See* Moullier P et al ..... 1220
Callard P *See* Meyrier A et al ..... 1446
Cambi V *See* Biancone L et al ..... 451
Cameron JS: Report of the incoming ISN President .. 44:S-119
Camez AA *See* Vanholder RC et al ..... 1754
Campbell SB (abst) ..... 1262
Campos M (abst) ..... 284
Camussi G *See* Biancone L et al ..... 451
Canaud B (abst) ..... 1253
Candeias J (abst) ..... 283, 283
Capasso G, Manic G, Wang T, Geibisch G: Acidification in mammalian cortical distal tubule (Editorial Review) ..... 1543
Capuano A *See* Cianciaruso B et al ..... 852
Car B (abst) ..... 1792
Car BD (abst) ..... 1788
Caramelo C, López-Farré A, Riesco A, Olivera A, Okada K, Cragoe EJ Jr., Tsai P, Briner VA, Schrier RW: Atrial natriuretic peptide and cGMP inhibit $Na^+/H^+$ antiporter in vascular smooth muscle cells in culture ..... 66
Caravaca F, Pizarro JL, Arrobas M, Cubero JJ, García MC, Perez-Miranda M: Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients ..... 845
Carey RM *See* Norwood VF et al ..... 1333
Cario GM (abst) ..... 1269, 1270, 1277
Carlos Barreto J (abst) ..... 283, 284
Carlsson B *See* Tönshoff B et al ..... 1085
Carlton MA (abst) ..... 1269, 1270, 1277
Carney SL (abst) ..... 1255
Carreira A (abst) ..... 289
Carretero OA *See* Arima S et al ..... 650
Carroll BA *See* Quarles LD et al ..... 1710
Carvalho B (abst) ..... 289, 289, 289
Carvalho D (abst) ..... 290
Carvalho F (abst) ..... 284, 284, 284, 285, 285, 288, 290
Carvalho L (abst) ..... 283, 290
Carvalho T (abst) ..... 287, 287
Casley D (abst) ..... 1261
Caspurro S (abst) ..... 287
Castro Henriques A (abst) ..... 288
Castro R (abst) ..... 286, 287, 288
Caterson RJ (abst) ..... 1268
Cattell V: Macrophages in acute glomerular inflammation (Editorial Review) ..... 945
Cattell V *See* Jansen A et al ..... 1215
Cerutti JA (abst) ..... 1787
Chaimovitz C: Peritoneal dialysis (Nephrology Forum) ..... 1226
Chambers S (abst) ..... 1267, 1275, 1277
Chambers ST (abst) ..... 1256
Chan L *See* Shapiro JI et al ..... 45:S-100
Chana RS *See* Wheeler DC et al ..... 1628
Chang L (abst) ..... 1257, 1257
Chang PC *See* Oudenhoven LFIJ et al ..... 884
Chao SM (abst) ..... 1264
Chapman JR (abst) ..... 1254, 1254
Chapman T *See* Masud T et al ..... 1182
Chapuis B (abst) ..... 1792
Charlesworth J (abst) ..... 1276
Charlesworth JA (abst) ..... 1267
Chasalow FI *See* Reyes AA et al ..... 1346
Chatenoud L, Jungers P, Descamps-Latscha B: Immunological considerations of the uremic and dialyzed patient ..... 44:S-92
Chauveau D, Pirson Y, Vereleen-Dumoulin C, Macnicol A, Gonzalo A, Grünfeld J-P: Intracranial aneurysms in autosomal dominant polycystic kidney disease ..... 1140
Chaves AP (abst) ..... 289, 289, 289
Chen J (abst) ..... 1277
Chen Y-p (abst) ..... 1271
Chevalier RL *See* Norwood VF et al ..... 1333
Chevrolet J-C (abst) ..... 1785

Christakos S *See* Bouhtiauy I et al ..... 461
Christakos S *See* Bouhtiauy I et al ..... 469
Christlieb AR *See* Krolewski AS et al ..... 45:S-125
Cianciaruso B, Bellizzi V, Capuano A, Bovi G, Nastasi A, Conte G, de Nicola L: Short-term effects of low protein-normal sodium diet on renal function in chronic renal failure ..... 852
Cirocco R *See* Roth D et al ..... 238
Clarkson A (abst) ..... 1269
Cnaan A *See* Lebovitz HE et al ..... 45:S-150
Cockayne D (abst) ..... 1260
Coe FL *See* Bushinsky DA et al ..... 58
Coe FL *See* Parks JH et al ..... 1722
Coelho A (abst) ..... 284
Coffee K *See* Raij L et al ..... 775
Cohen AH, Turner MC: Kidney in Galloway-Mowat syndrome: Clinical spectrum with description of pathology ..... 1407
Cohen MP, Hud E, Wu V-Y: Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin ..... 1673
Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression ..... 475
Colaço S (abst) ..... 288, 290, 291
Coleman M (abst) ..... 1256
Coles GA, Davies M, Williams JD: Introduction ..... 299
Coles GA *See* Donovan KL et al ..... 1555
Coles GA *See* Thomas DM et al ..... 411
Coles GA *See* Williams JD et al ..... 443
Collaborative Group of the Société de Néphrologie *See* Meyrier A et al ..... 1446
Collaborative Study Group *See* Breyer JA et al ..... 45:S-156
Collett P (abst) ..... 1253
Collett PV *See* Pollock CA et al ..... 897
Colombi A (abst) ..... 1783, 1791
Conger JD *See* Rahman SN et al ..... 1731
Connell H *See* Petersson C et al ..... 571
Conte G *See* Cianciaruso B et al ..... 852
Conte G *See* Sabbatini M et al ..... 1355
Cook T *See* Jansen A et al ..... 1215
Cooper M (abst) ..... 1268, 1275
Cooper ME (abst) ..... 1270
Cooperative Study Group on Pubertal Development in Chronic Renal Failure *See* Schaefer F et al ..... 1465
Coquard C *See* Michel B et al ..... 1587
Cordas L (abst) ..... 282
Cordeiro P (abst) ..... 291
Cornthwaite LJ (abst) ..... 1256
Cornu C *See* Goffin E et al ..... 551
Coronel F *See* Fontanellas A et al ..... 220
Correa-Rotter R *See* Dvergsten J et al ..... 828
Correa-Rotter R *See* Rosenberg ME et al ..... 403
Correia AM (abst) ..... 286, 288, 288
Cortes P, Riser BL, Zhao X, Narins RG: Glomerular volume expansion and mesangial cell mechanical strain: Mediators of glomerular pressure injury ..... 45:S-11
Cosio FG *See* Hebert LA et al ..... 493
Costa AM (abst) ..... 284, 284, 285, 290, 290
Costa E (abst) ..... 282
Costa PP (abst) ..... 287
Costeira MJ (abst) ..... 288
Cosyns J-P, Jadoul M, Squifflet J-P, De Plaen J-F, Ferluga D, van Ypersele de Strihou C: Chinese herbs nephropathy: A clue to Balkan endemic nephropathy? ..... 1680
Couchman JR, Beavan LA, McCarthy KJ: Glomerular matrix: Synthesis, turnover and role in mesangial expansion ..... 328
Couet C *See* Delarue J et al ..... 1147
Coulshed DS (abst) ..... 1263, 1272, 1274
Coulshed SJ (abst) ..... 1263, 1272, 1274
Couser WG *See* Eng E et al ..... 45:S-45
Couser WG *See* Johnson RJ et al ..... 352
Cragoe EJ Jr. *See* Caramelo C et al ..... 66
Craik DJ (abst) ..... 1255
Crenier L *See* Soupart A et al ..... 193
Crestani S (abst) ..... 1787
Crichton RR *See* Boelaert JR et al ..... 667
Cubero JJ *See* Caravaca F et al ..... 845
Curwell J *See* Harty JC et al ..... 103

D
Da Costa M (abst) ..... 288
D'Agati V *See* Szabolcs MJ et al ..... 1388
D'Agati V *See* Truong LD et al ..... 201
D'Amico G: Assessment of endpoints in the study of progressive renal disease: Summary and concluding remarks ..... 45:S-132
Danpure CJ (abst) ..... 1783
Darnell A *See* Poch E et al ..... 1037
David S *See* Biancone L et al ..... 451
Davidson AF *See* Phillips PA et al ..... 1028
Davies M: The mesangial cell: A tissue culture view ..... 320
Davies M *See* Coles GA et al ..... 299
Davies M *See* Donovan KL et al ..... 1555
Davies M *See* Wheeler DC et al ..... 1628
Davies PR (abst) ..... 1267
Davila N (abst) ..... 1786
Davis SM (abst) ..... 1265
Davison AM (abst) ..... 1263, 1272, 1274
de Biase V *See* Oldrizzi L et al ..... 45:S-118
De Broe ME *See* D'Haese PC et al ..... 76
De Broe ME *See* Van Der Biest I et al ..... 85
de Jong PE *See* Apperloo AJ et al ..... 45:S-174
de Jong PE *See* Gansevoort RT et al ..... 861
de Locht M *See* Boelaert JR et al ..... 667
de Nicola L *See* Cianciaruso B et al ..... 852
de Nicola L *See* Sabbatini M et al ..... 1355
De Plaen J-F *See* Cosyns J-P et al ..... 1680
de Roos A *See* Oudenhoven LFIJ et al ..... 884
de Salamanca RE *See* Fontanellas A et al ..... 220
de Werra P (abst) ..... 1787
de Zeeuw D *See* Apperloo AJ et al ..... 45:S-174
de Zeeuw D *See* Gansevoort RT et al ..... 861
Decaux G *See* Soupart A et al ..... 193
Deferrari G *See* Garibotto G et al ..... 1432
Deiss V (abst) ..... 1787
Delarue J, Maingourd C, Lamisse F, Garrigue M-A, Bagros P, Couet C: Glucose oxidation after a peritoneal and an oral glucose load in dialyzed patients ..... 1147
Delgado L (abst) ..... 291
Della Pietra V *See* Biancone L et al ..... 451
DeLuise M (abst) ..... 1270
DeMattos A *See* Roth D et al ..... 238
Demelis J (abst) ..... 1260
Denhardt DT *See* Giachelli CM et al ..... 515
Depner TA: Assessing adequacy of hemodialysis: Urea modeling (Nephrology Forum) ..... 1522
Deppisch R, Ritz E, Hänsch GM, Schöls M, Rauterberg E-W: Bioincompatibility—Perspectives in 1993 ..... 44:S-77

Descamps-Latscha B *See* Chatenoud L et al ..... 44:S-92
Descombes E (abst) ..... 1787, 1790
Detwiler RK, Falk RJ, Hogan SL, Jennette JC: Collapsing glomerulopathy: A clinically and pathologically distinct variant of focal segmental glomerulosclerosis ..... 1416
DeWitt DL *See* Martin M et al ..... 150
D'Haese PC, Lamberts LV, Verpooten GA, Vaneerdeweg W, Jurgens A, Arakelian S, Babloyan A, Digenis P, Tjalma W, De Broe ME: Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function ..... 76
Digenis P *See* D'Haese PC et al ..... 76
Dillon JJ *See* Hebert LA et al ..... 493
DiMauro S *See* Szabolcs MJ et al ..... 1388
Dinarello CA *See* Pereira BJG et al ..... 890
Ding J, Kashtan CE, Fan WW, Kleppel MM, Sun MJ, Kalluri R, Neilson EG, Michael AF: A monoclonal antibody marker for Alport syndrome identifies the Alport antigen as the $\alpha 5$ chain of type IV collagen ..... 1504
Dirks JH, Brenner BM: Mechanisms of injury in progressive renal disease: Insights from experimental data: Summary and concluding remarks ..... 45:S-22
Disney APS (abst) ..... 1263, 1268, 1274
Djeu JY *See* Garin EH et al ..... 1311
Doecke C (abst) ..... 1263
Donauer K (abst) ..... 1787, 1789, 1790
Donker AJM *See* Wee PM et al ..... 417
Donovan KL, Davies M, Coles GA, Williams JD: Relative roles of elastase and reactive oxygen species in the degradation of human glomerular basement membrane by intact human neutrophils ..... 1555
Doucet A (abst) ..... 1789
Dowling JP (abst) ..... 1278
Doyle A (abst) ..... 1266
Doyle AE (abst) ..... 1270
Drago H (abst) ..... 290
Drüeke T *See* Ureña P et al ..... 605
Duda SH *See* Erley CM et al ..... 1425
Dudli S (abst) ..... 1791
Duggan K (abst) ..... 1276
Duggin GG (abst) ..... 1258
Dunger D *See* Schaefer F et al ..... 1465
Dunlop M (abst) ..... 1258
Dunn MJ *See* Marsen TA et al ..... 336
Durand D *See* Ader J-L et al ..... 1657
Dvergsten J, Manivel JC, Correa-Rotter R, Rosenberg ME: Expression of clusterin in human renal diseases ..... 828
Dyne M (abst) ..... 1260
Dytko G *See* Albrightson CR et al ..... 1301

E

Earle K, Viberti GC: Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease ..... 434
Ebihara I *See* Nakamura T et al ..... 1593
Edén S *See* Tönshoff B et al ..... 1085
Edward A (abst) ..... 1787
Elder G (abst) ..... 1253
Elder G *See* Pollock CA et al ..... 897
Elger M *See* Kriz W et al ..... 45:S-64
Elger M *See* Kriz W et al ..... 369
Elkins N *See* Shapiro JI et al ..... 45:S-100
Elzinga LW *See* Burdmann EA et al ..... 684
Emmendörffer A *See* Radeke HH et al ..... 763
Endoh M *See* Kashem A et al ..... 868
Endre ZH (abst) ..... 1271
Eng E, Floege J, Young BA, Couser WG, Johnson RJ: Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? ..... 45:S-45
Engels K (abst) ..... 1255
Enright H *See* Nath KA et al ..... 166
Epstein FH *See* Heyman SN et al ..... 981
Erber W (abst) ..... 1263
Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, Bohle A, Risler T, Osswald H: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application ..... 1425
Eschbach JW: Erythropoietin: The promise and the facts ..... 44:S-70
Espiner EA (abst) ..... 1276
Esquenazi V *See* Roth D et al ..... 238
Esteban Morcillo J (abst) ..... 291, 291, 292
Estibeiro H (abst) ..... 291
Etoh S *See* Uriu K et al ..... 794

F

Falagas ME *See* Pereira BJG et al ..... 890
Falaschi F *See* Maggi E et al ..... 876
Falk MC (abst) ..... 1254, 1259, 1260
Falk RJ *See* Detwiler RK et al ..... 1416
Fan WW *See* Ding J et al ..... 1504
Fanha M (abst) ..... 290
Fanning G (abst) ..... 1259
Faria MS (abst) ..... 286
Favre H (abst) ..... 1785, 1789
Fawcett JP (abst) ..... 1270
Feehally J *See* Harper SJ et al ..... 836
Felicíssimo P (abst) ..... 284
Fellay G (abst) ..... 1787
Felsenfeld AJ *See* Bover J et al ..... 953
Feng L *See* Tang WW et al ..... 1077
Féraille E (abst) ..... 1789
Ferluga D *See* Cosyns J-P et al ..... 1680
Fernandes A (abst) ..... 285, 285
Fernandes J (abst) ..... 282, 283, 283
Fernandes MH (abst) ..... 290
Fernando S (abst) ..... 1263
Ferraz J (abst) ..... 286
Ferraz JO (abst) ..... 282
Ferry N *See* Moullier P et al ..... 1220
Fey GH *See* Hartner A et al ..... 1562
Fichtner K-P (abst) ..... 1271
Fick GM, Johnson AM, Gabow PA: Is there evidence for anticipation in autosomal-dominant polycystic kidney disease? ..... 1153
Field MJ (abst) ..... 1253, 1260, 1261, 1261, 1276
Field MJ *See* Pollock CA et al ..... 897
Figueira L (abst) ..... 290
Filipe A (abst) ..... 291
Finardi G *See* Maggi E et al ..... 876
Fine LG *See* Ong ACM et al ..... 345
Fink E *See* Verresen L et al ..... 1497
Firth JD (abst) ..... 1265
Fischereder M *See* Nath KA et al ..... 45:S-111
Fischereder M *See* Nath KA et al ..... 166
Flannery EM (abst) ..... 1270
Flavier JL (abst) ..... 1253
Fleming SJ (abst) ..... 1262, 1263, 1274

Floege J, Radeke HR, Johnson RJ: Glomerular cells *in vitro* versus the glomerulus *in vivo* ..... 360
Floege J *See* Eng E et al ..... 45:S-45
Fluck R (abst) ..... 1268
Fogo A: Internephron heterogeneity of growth factors and sclerosis ..... 45:S-24
Fogo A *See* Tanaka R et al ..... 537
Fonseca T (abst) ..... 289
Fontanellas A, Coronel F, Santos JL, Herrero JA, Moran MJ, Guerra P, Tornero F, de Salamanca RE: Heme biosynthesis in uremic patients on CAPD or hemodialysis ..... 220
Forjaz A (abst) ..... 285, 285
Fraenkel MB (abst) ..... 1259
França JM (abst) ..... 288
Francis D (abst) ..... 1278
Francis DMA (abst) ..... 1264, 1265
Fransen R *See* Boer P et al ..... 1211
Frattoni A *See* Maggi E et al ..... 876
Frey BM (abst) ..... 1789
Frey FJ (abst) ..... 1789
Friberg P, Sundelin B, Boman S-O, Bobik A, Nilsson H, Wickman A, Gustafsson H, Petersen J, Adams MA: Renin-angiotensin system in neonatal rats: Induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism ..... 485
Friedlander G *See* Moullier P et al ..... 1220
Fry A (abst) ..... 1278
Fuerstenberg SM *See* Ryan MJ et al ..... 48
Fujigaki Y *See* Morioka T et al ..... 991
Fujihara CK *See* Zatz R et al ..... 45:S-27
Fujishima M *See* Tamaki K et al ..... 525
Fukui M *See* Nakamura T et al ..... 1593
Fulpius T, Berney T, Lemoine R, Pastore Y, Reininger L, Brighouse G, Izui S: Glomerulopathy induced by IgG3 anti-trinitrophenyl monoclonal cryoglobulins derived from non-autoimmune mice ..... 962
Fumo P *See* Bleyer AJ et al ..... 659
Fux CA (abst) ..... 1789

G

Gabel RA *See* Kivlighn SD et al ..... 131
Gaber LW *See* Matsell DG et al ..... 159
Gabow PA *See* Fick GM et al ..... 1153
Gafter U, Kalechman Y, Orlin JB, Levi J, Sredni B: Anemia of uremia is associated with reduced *in vitro* cytokine secretion: Immunopotentiating activity of red blood cells ..... 224
Gagnon AM, Simboli-Campbell M, Welsh JE: Induction of calbindin D-28K in Madin-Darby bovine kidney cells by $1,25(OH)_2D_3$ ..... 95
Gales B *See* Salusky IB et al ..... 253
Gallery EDM (abst) ..... 1278
Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? ..... 861
Gantenbein H (abst) ..... 1786, 1787, 1791
García MC *See* Caravaca F et al ..... 845
Garibotto G, Russo R, Sofia A, Sala MR, Robaudo C, Moscatelli P, Deferrari G, Tizianello A: Skeletal muscle protein synthesis and degradation in patients with chronic renal failure ..... 1432
Garin EH, Blanchard DK, Matsushima K, Djeu JY: IL-8 production by peripheral blood mononuclear cells in nephrotic patients ..... 1311
Garrigue M-A *See* Delarue J et al ..... 1147
Gasche C *See* Sunder-Plassmann G et al ..... 1484
Gaspar A (abst) ..... 283, 284
Gaya J *See* Poch E et al ..... 1037
Gaylin DS *See* Held PJ et al ..... 1163
Gayoso P (abst) ..... 291
Gazo A *See* Maggi E et al ..... 876
Geary KM *See* Norwood VF et al ..... 1333
Geibisch G *See* Capasso G et al ..... 1543
Geissler B (abst) ..... 1253
Gelato MC *See* Tsukahara H et al ..... 598
George CRP (abst) ..... 1253
George CRP *See* Pollock CA et al ..... 897
Gerrard DF (abst) ..... 1270
Geubel A *See* Goffin E et al ..... 551
Ghuysen M-S (abst) ..... 1783
Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis ..... 515
Giebisch G: Acceptance of the 1993 A.N. Richards Award ..... 44:S-110
Giles M (abst) ..... 1275
Giliberti A *See* Sabbatini M et al ..... 1355
Gill JR Jr. *See* Hoffman A et al ..... 556
Gillespie CM (abst) ..... 1275, 1277
Gillies A *See* Harper SJ et al ..... 836
Gillin AG (abst) ..... 1254
Girardin E (abst) ..... 1784, 1791
Girton RA, Spector AA, Gordon JA: 15-HETE: Selective incorporation into inositol phospholipids of MDCK cells ..... 972
Glass J *See* Abreo K et al ..... 636
Goecke IA *See* Bofill P et al ..... 672
Goffin E, Pirson Y, Cornu C, Geubel A, Squifflet J-P, van Ypersele de Strihou C: Outcome of HCV infection after renal transplantation ..... 551
Gokal R *See* Harty JC et al ..... 103
Goldberg CA *See* Rahman SN et al ..... 1731
Goldfarb S *See* Bleyer AJ et al ..... 659
Goldstein DS *See* Hoffman A et al ..... 556
Goldsworthy SJ (abst) ..... 1263
Goligorsky MS *See* Tsukahara H et al ..... 598
Golovsky D (abst) ..... 1254
Gomes da Costa A (abst) ..... 286, 286, 288, 288
Gomes H (abst) ..... 284, 290, 290
Gomez RA *See* Norwood VF et al ..... 1333
Gonçalves L (abst) ..... 289
Gonzalo A *See* Chauveau D et al ..... 1140
Goodman WG *See* Salusky IB et al ..... 253
Goppelt-Streube M *See* Hartner A et al ..... 1562
Goppelt-Struebe M *See* Martin M et al ..... 150
Gordienko DV *See* Tsukahara H et al ..... 598
Gordon JA *See* Girton RA et al ..... 972
Gotch FA (abst) ..... 1790
Gow CB (abst) ..... 1262, 1276
Gow CB *See* Phillips PA et al ..... 1028
Graham AM (abst) ..... 1254
Graham PJ (abst) ..... 1266, 1273
Grant SL (abst) ..... 1262
Grant SL *See* Phillips PA et al ..... 1028
Grantham JJ *See* Sullivan LP et al ..... 1369
Gratwohl A (abst) ..... 1788
Grau G (abst) ..... 1784
Gray DF (abst) ..... 1272, 1274
Gray DJS (abst) ..... 1267
Gray L (abst) ..... 1261

Green CJ *See* Thorniley MS et al ..... 1489
Greenstein J (abst) ..... 1267
Grigoras O (abst) ..... 1786
Grillo FG *See* Seiken G et al ..... 1622
Grima M *See* Michel B et al ..... 1587
Griswold DE *See* Albrightson CR et al ..... 1301
Groppoli TJ *See* Zhu D et al ..... 425
Grossman E *See* Hoffman A et al ..... 556
Gruenewald K *See* Koenig P et al ..... 1507
Grünfeld J-P *See* Chauveau D et al ..... 1140
Guerra J (abst) ..... 286, 286, 288, 288
Guerra J *See* Raij L et al ..... 775
Guerra L (abst) ..... 282, 282, 285, 286
Guerra LE (abst) ..... 283, 283
Guerra MM (abst) ..... 283, 283
Guerra P *See* Fontanellas A et al ..... 220
Guerreiro MJ (abst) ..... 284
Guibentif P (abst) ..... 1791
Guidet B *See* Ueda N et al ..... 788
Guignard J-P (abst) ..... 1783, 1786, 1789
Guimarães JT (abst) ..... 282
Gunn H (abst) ..... 1788
Gustafsson H *See* Friberg P et al ..... 485
Gyory AZ (abst) ..... 1260, 1269

**H**

Hackenthal E *See* Kriz W et al ..... 369
Haites NE *See* Brown PAJ et al ..... 43
Hakim RM *See* Sreedhara R et al ..... 1477
Hall BM (abst) ..... 1272
Halushka PV *See* Rinder CA et al ..... 185
Hamburger RJ *See* Held PJ et al ..... 1163
Hammond J (abst) ..... 1270
Hannedouche TP *See* Natov S et al ..... 1457
Hänsch GM *See* Deppisch R et al ..... 44:S-77
Hansen KW, Poulsen PL, Mogensen CE: Ambulatory blood pressure and abnormal albuminuria in type 1 diabetic patients ..... 45:S-134
Hardie D (abst) ..... 1264
Hardie I (abst) ..... 1264, 1264, 1264, 1265
Harewood WF (abst) ..... 1256
Harley N (abst) ..... 1258
Harmon WE *See* Sadowski RH et al ..... 903
Harper SJ, Pringle JH, Wicks ACB, Hattersley J, Layward L, Allen A, Gillies A, Lauder I, Feehally J: Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy ..... 836
Harris DCH (abst) ..... 1255, 1268, 1271, 1277
Harris DCH *See* Nankivell BJ et al ..... 1006
Harris RC, Akai Y, Yasuda T, Homma T: The role of physical forces in alterations of mesangial cell function ..... 45:S-17
Harris S (abst) ..... 1273, 1274
Harris SJ (abst) ..... 1264
Harrison K (abst) ..... 1266
Hartner A, Sterzel RB, Reindl N, Hocke GM, Fey GH, Goppelt-Streube M: Cytokine-induced expression of leukemia inhibitory factor in renal mesangial cells ..... 1562
Harty JC, Boulton H, Curwell J, Heelis N, Uttley L, Venning MC, Gokal R: The normalized protein catabolic rate is a flawed marker of nutrition in CAPD patients ..... 103
Harvey J (abst) ..... 1255
Hashimoto O *See* Uriu K et al ..... 794
Hasnain Q (abst) ..... 1265
Hasstedt SJ *See* Williams RR et al ..... 44:S-57
Hattersley J *See* Harper SJ et al ..... 836
Haupert GT (abst) ..... 1265
Hawley C (abst) ..... 1264
Hay NM (abst) ..... 1262
Hayashi J *See* Hiromura K et al ..... 1572
Hayashida K *See* Imanishi M et al ..... 1170
Hazel SJ (abst) ..... 1275
Hebbel RP *See* Nath KA et al ..... 166
Hebert LA, Birmingham DJ, Mahan JD, Shen X-P, McAllister C, Cosio FG, Dillon JJ: Effect of chronically increased erythrocyte complement receptors on immune complex nephritis ..... 493
Hedges S *See* Petersson C et al ..... 571
Heelis N *See* Harty JC et al ..... 103
Heeringa P *See* Brouwer E et al ..... 1120
Heidenheim AP *See* Lindsay RM et al ..... 44:S-85
Heidenreich S *See* Barenbrock M et al ..... 1397
Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA: Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions ..... 1163
Helg Cl (abst) ..... 1792
Helmle-Kolb C *See* Murer H et al ..... 44:S-23
Hendtlass A (abst) ..... 1257
Hennessy A (abst) ..... 1256, 1258, 1258
Henning P (abst) ..... 1273, 1273, 1274
Henning PH (abst) ..... 1264
Henriques C (abst) ..... 282
Hensley CB, Mircheff AK: Complex subcellular distribution of sodium-dependent amino acid transport systems in kidney cortex and LLC-$PK_1$/$Cl_4$ cells ..... 110
Heriot WJ (abst) ..... 1262
Hermle M (abst) ..... 1784
Hernández E *See* Ruilope LM et al ..... 45:S-171
Herrera-Acosta J: The role of systemic and glomerular hypertension in progressive glomerular injury ..... 45:S-6
Herrero JA *See* Fontanellas A et al ..... 220
Hess B (abst) ..... 1783, 1785
Hewitson T (abst) ..... 1273
Heyman SN, Rosen S, Epstein FH, Spokes K, Brezis ML: Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney ..... 981
Hiestand P (abst) ..... 1788
Hill P (abst) ..... 1272
Hill PA, Lan HY, Nikolic-Paterson DJ, Atkins RC: ICAM-1 directs migration and localization of interstitial leukocytes in experimental glomerulonephritis ..... 32
Hill PA, Lan HY, Nikolic-Paterson DJ, Atkins RC: The ICAM-1/LFA-1 interaction in glomerular leukocytic accumulation in anti-GBM glomerulonephritis ..... 700
Hill PA *See* Argilés A et al ..... 23
Hill PA *See* Nikolic-Paterson DJ et al ..... 45:S-79
Himmelfarb J *See* Sreedhara R et al ..... 1477
Hir ML *See* Kaissling B et al ..... 709
Hiromura K, Hayashi J, Tsukada Y, Ono K, Tsuchida A, Yano S, Naruse T: FK506 inhibits renal glomerular thrombosis induced in rats by nephrotoxic serum and lipopolysaccharide ..... 1572
Hirst G (abst) ..... 1264
Hocke GM *See* Hartner A et al ..... 1562
Hoeffler JP *See* Anderson RJ et al ..... 642
Hoek FJ *See* Struijk DG et al ..... 1739
Hoeks APG *See* Barenbrock M et al ..... 1397
Hoff T *See* Martin M et al ..... 150

Hoffman A, Grossman E, Goldstein DS, Gill JR Jr., Keiser HR: Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity ..... 556
Hogan SL *See* Detwiler RK et al ..... 1416
Hogg R (abst) ..... 1273, 1274
Hogg RJ (abst) ..... 1264, 1273
Hohage H *See* Barenbrock M et al ..... 1397
Hökfelt T *See* Ohtomo Y et al ..... 1606
Holdsworth SR (abst) ..... 1256, 1260, 1260, 1260
Holmberg C *See* Kestilä M et al ..... 986
Holmes D *See* Raij L et al ..... 775
Holthöfer H, Reivinen J, Miettinen A: Nephron segment and cell-type specific expression of gangliosides in the developing and adult kidney ..... 123
Homma T *See* Harris RC et al ..... 45:S-17
Homma T *See* Iwasaki S et al ..... 592
Hommel E *See* Rossing P et al ..... 45:S-145
Hooks MA *See* Pollard TA et al ..... 232
Hooper L (abst) ..... 1267
Hoover RL *See* Yoshioka T et al ..... 211
Hopkins PN *See* Williams RR et al ..... 44:S-57
Hoppe B (abst) ..... 1783
Horikoshi S *See* Ray PE et al ..... 177
Horio T *See* Kohno M et al ..... 137
Hörkkö S, Huttunen K, Korhonen T, Kesäniemi YA: Decreased clearance of low-density lipoprotein in patients with chronic renal failure ..... 561
Horvath JS (abst) ..... 1256, 1258, 1258
Hostetter TH *See* Nath KA et al ..... 45:S-111
Hostetter TH *See* Rosenberg ME et al ..... 403
Hruby M *See* Ureña P et al ..... 605
Hsu CH *See* Patel SR et al ..... 509
Hsu CH *See* Patel SR et al ..... 1020
Huang W, Lee S-L, Sjöquist M: Effects of neurohypophyseal antagonists in postnephrectomy natriuresis in male rats ..... 692
Huang XR (abst) ..... 1260, 1260, 1260
Huarte J *See* Moll S et al ..... 500
Hubbard MJ (abst) ..... 1277
Hud E *See* Cohen MP et al ..... 1673
Hudson BG *See* Kalluri R et al ..... 721
Huitema MG *See* Brouwer E et al ..... 1120
Hull WE (abst) ..... 1271
Humphreys MH: Mechanisms and management of nephrotic edema (Nephrology Forum) ..... 266
Hunsicker LG *See* Breyer JA et al ..... 45:S-156
Hunt SC *See* Williams RR et al ..... 44:S-57
Huppert PE *See* Erley CM et al ..... 1425
Hurst P (abst) ..... 1263
Hutchinson P (abst) ..... 1257, 1257
Hutchinson P *See* Argilés A et al ..... 23
Huttunen K *See* Hörkkö S et al ..... 561
Huynh Do U (abst) ..... 1791

I
Ibels LS (abst) ..... 1268, 1269
Ichikawa I, Kiyama S, Yoshioka T: Renal antioxidant enzymes: Their regulation and function (Editorial Review) ..... 1
Ichikawa I *See* Tanaka R et al ..... 537
Ichikawa I *See* Yoshioka T et al ..... 211
Ihle BU (abst) ..... 1262
Ihle BU *See* Becker GJ et al ..... 45:S-167
Ikeda M, Yoshitomi K, Imai M, Kurokawa K: Cell $Ca^{2+}$ response to luminal vasopressin in cortical collecting tubule principal cells ..... 811
Ikeda M *See* Kohno M et al ..... 137
Ikeni A *See* Natov S et al ..... 1457
Ikram H (abst) ..... 1258
Imai M *See* Ikeda M et al ..... 811
Imanishi M, Yano M, Hayashida K, Ishida Y, Takamiya M, Kimura G, Kojima S, Kawano Y, Matsushima Y, Matsuoka H, Omae T: Aspirin renography to detect unilateral renovascular hypertension ..... 1170
Imbs J-L *See* Michel B et al ..... 1587
Inishi Y, Okuda T, Arakawa T, Kurokawa K: Insulin attenuates intracellular calcium responses and cell contraction caused by vasoactive agents ..... 1318
Innes DJ Jr. *See* Paulsen EP et al ..... 1132
Ishida Y *See* Imanishi M et al ..... 1170
Ito S *See* Arima S et al ..... 650
Iwamoto T *See* Tamaki K et al ..... 525
Iwasaki S, Homma T, Kon V: Site selective regulation in the kidney of endothelin and its receptor subtypes by cyclosporine ..... 592
Iwata M *See* Zager RA et al ..... 1760
Izui S *See* Fulpius T et al ..... 962

J
Jabs K *See* Sadowski RH et al ..... 903
Jackson B (abst) ..... 1268
Jackson C (abst) ..... 1278
Jackson S *See* Anderson RJ et al ..... 642
Jadoul M *See* Cosyns J-P et al ..... 1680
Jadoul M *See* Kabanda A et al ..... 1689
Jaeger Ph (abst) ..... 1783, 1785
Jain S *See* Abreo K et al ..... 636
James WE (abst) ..... 1263
Jannett TC, Wise MG, Shanklin NH, Sanders PW: Adaptive control of anticoagulation during hemodialysis (Technical Note) ..... 912
Jansen A, Cook T, Taylor GM, Largen P, Riveros-Moreno V, Moncada S, Cattell V: Induction of nitric oxide synthase in rat immune complex glomerulonephritis ..... 1215
Jara A *See* Bover J et al ..... 953
Jardim H (abst) ..... 288
Jassal V (abst) ..... 1274
Jennette JC *See* Detwiler RK et al ..... 1416
Jennings JG (abst) ..... 1257, 1257
Jerums G (abst) ..... 1270
Jewell-Motz E *See* Lingrel JB et al ..... 44:S-32
Jiang K-H *See* Young EW et al ..... 907
Jin H *See* Shapiro JI et al ..... 45:S-100
Johnsen SA *See* Mulec H et al ..... 45:S-141
Johnson AM *See* Fick GM et al ..... 1153
Johnson G *See* Ryan MJ et al ..... 48
Johnson J (abst) ..... 1258
Johnson JP *See* Seiken G et al ..... 1622
Johnson RJ: The glomerular response to injury: Progression or resolution? (Nephrology Forum) ..... 1769
Johnson RJ, Lovett D, Lehrer RI, Couser WG, Klebanoff SJ: Role of oxidants and proteases in glomerular injury ..... 352
Johnson RJ *See* Eng E et al ..... 45:S-45
Johnson RJ *See* Floege J et al ..... 360
Johnson RJ *See* Giachelli CM et al ..... 515
Johnston CI (abst) ..... 1261, 1261, 1275
Johnston PA (abst) ..... 1272

Jones CL (abst) ..... 1264
Jorge Correia A (abst) ..... 290, 290
Jorge R (abst) ..... 287
Jose PA *See* Norwood VF et al ..... 1333
Juncos LA *See* Arima S et al ..... 650
Jung S (abst) ..... 1785
Jungers P *See* Chatenoud L et al ..... 44:S-92
Jureidini K (abst) ..... 1273, 1274
Jureidini KF (abst) ..... 1264
Jureidini KJ (abst) ..... 1273
Jurgens A *See* D'Haese PC et al ..... 76
Jutrin I *See* Ravid M et al ..... 45:S-161

K

Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A: Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis ..... 1689
Kagami S *See* Ruoslahti E et al ..... 44:S-17
Kaissling B (abst) ..... 1792
Kaissling B, Hir ML: Characterization and distribution of interstitial cell types in the renal cortex of rats ..... 709
Kaizu K *See* Uriu K et al ..... 794
Kalechman Y *See* Gafter U et al ..... 224
Kallenberg CGM *See* Brouwer E et al ..... 1120
Kalluri R, Weber M, Netzer K-O, Sun MJ, Neilson EG, Hudson BG: COL4A5 gene deletion and production of post-transplant anti-$\alpha$3 (IV) collagen alloantibodies in Alport syndrome ..... 721
Kalluri R *See* Ding J et al ..... 1504
Kalowski S (abst) ..... 1253
Kalowski S *See* Pollock CA et al ..... 897
Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S: Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney ..... 1637
Kaneto H *See* Morrissey JJ et al ..... 998
Kapiotis S *See* Sunder-Plassmann G et al ..... 1484
Karl IE *See* Reyes AA et al ..... 782
Kashem A, Endoh M, Nomoto Y, Sakai H, Nakazawa H: Fc$\alpha$ R expression on polymorphonuclear leukocyte and superoxide generation in IgA nephropathy ..... 868
Kashgarian M (abst) ..... 1783
Kashgarian M: Lupus nephritis: Lessons from the path lab (Nephrology Forum) ..... 928
Kashtan CE *See* Ding J et al ..... 1504
Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF: Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis ..... 45:S-51
Kawamura T *See* Yoshioka T et al ..... 211
Kawano Y *See* Imanishi M et al ..... 1170
Kaysen GA *See* Sun X et al ..... 1381
Ke HQ *See* Patel SR et al ..... 509
Ke HQ *See* Patel SR et al ..... 1020
Keane WF, Brenner BM, Parving H-H: Introduction .... 45:S-1
Keane WF *See* Kasiske BL et al ..... 45:S-51
Keating F (abst) ..... 289
Keating J (abst) ..... 289, 289
Keen M (abst) ..... 1790
Kees-Folts D, Sadow JL, Schreiner GF: Tubular catabolism of albumin is associated with the release of an inflammatory lipid ..... 1697
Keiser HR *See* Hoffman A et al ..... 556
Keith DS *See* Torres VE et al ..... 1745
Kelley VR, Bloom RD, Yui MA, Martin C, Price D: Pivotal role of colony stimulating factor-1 in lupus nephritis ..... 45:S-83
Kelley VR *See* Yokoyama H et al ..... 1105
Keogh AM (abst) ..... 1254
Kerjaschki D: Dysfunctions of cell biological mechanisms of visceral epithelial cells (podocytes) in glomerular diseases ..... 300
Kerr DW (abst) ..... 1267
Kerr PG (abst) ..... 1253, 1257, 1257, 1262, 1271
Kesäniemi YA *See* Hörkkö S et al ..... 561
Kestilä M, Männikkö M, Holmberg C, Korpela K, Savolainen E-R, Peltonen L, Tryggvason K: Exclusion of eight genes as mutated loci in congenital nephrotic syndrome of the Finnish type ..... 986
Khachikian Z (abst) ..... 1791
Kim E-M, Striegel J, Kim Y, Matas AJ, Najarian JS, Mauer SM: Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection ..... 1440
Kim GE *See* Rahman SN et al ..... 1731
Kim M *See* Bushinsky DA et al ..... 58
Kim Y *See* Kasiske BL et al ..... 45:S-51
Kim Y *See* Kim E-M et al ..... 1440
Kim Y *See* Zhu D et al ..... 425
Kimura G *See* Imanishi M et al ..... 1170
Kincaid-Smith P (abst) ..... 1271
Kincaid-Smith PS (abst) ..... 1273
Kincaid-Smith PS *See* Becker GJ et al ..... 45:S-167
King AJ *See* Pereira BJG et al ..... 890
Kirk J *See* Ryan MJ et al ..... 48
Kirubakaran M (abst) ..... 1274
Kirwan PD (abst) ..... 1256
Kiss D (abst) ..... 1787, 1789, 1790
Kitamura M, Shirasawa T, Maruyama N: Gene transfer of metalloproteinase transin induces aberrant behavior of cultured mesangial cells ..... 1580
Kivlighn SD, Gabel RA, Siegl PKS: Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction ..... 131
Kiyama S *See* Ichikawa I et al ..... 1
Klaar U *See* Sunder-Plassmann G et al ..... 1484
Klahr S *See* Kaneto H et al ..... 1637
Klahr S *See* Morrissey JJ et al ..... 998
Klahr S *See* Reyes AA et al ..... 782
Klahr S *See* Reyes AA et al ..... 1346
Klebanoff SJ *See* Johnson RJ et al ..... 352
Klein A (abst) ..... 1786
Klein PS *See* Rennke HG et al ..... 1044
Kleppel MM *See* Ding J et al ..... 1504
Kleyman TR *See* Schlanger LE et al ..... 1070
Klotman PE *See* Ray PE et al ..... 177
Knelson M *See* Kovalik EC et al ..... 1177
Knight JF (abst) ..... 1254, 1259, 1260
Knoflach A (abst) ..... 1785, 1785
Knorr BA, Beck JC, Abramson RG: Classical and channel-like urate transporters in rabbit renal brush border membranes ..... 727
Koehler J *See* Erley CM et al ..... 1425
Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll H-K, Gruenewald K: Interferon treatment for chronic hepatitis C virus infection in uremic patients ..... 1507
Koeppen-Hagemann I *See* Kriz W et al ..... 45:S-64

Kohno M, Yokokawa K, Horio T, Ikeda M, Kurihara N, Mandal AK, Takeda T: Heparin inhibits endothelin-1 production in cultured rat mesangial cells ..... 137
Koide H *See* Nakamura T et al ..... 1593
Kojima S *See* Imanishi M et al ..... 1170
Komine N *See* Uriu K et al ..... 794
Kon SP *See* Torres VE et al ..... 1745
Kon V *See* Iwasaki S et al ..... 592
Kon V *See* Tanaka R et al ..... 537
Koomans HA *See* Boer P et al ..... 1211
Koomen GCM *See* Struijk DG et al ..... 1739
Korhonen T *See* Hörkkö S et al ..... 561
Korpela K *See* Kestilä M et al ..... 986
Kortas C *See* Lindsay RM et al ..... 44:S-85
Korte W (abst) ..... 1785
Kovalik EC, Newman GE, Suhocki P, Knelson M, Schwab SJ: Correction of central venous stenoses: Use of angioplasty and vascular Wallstents ..... 1177
Kraft NE *See* Argilés A et al ..... 23
Krapf R (abst) ..... 1785, 1791
Krapft R *See* Murer H et al ..... 44:S-23
Krediet RT *See* Struijk DG et al ..... 1739
Krensky AM: T cells in autoimmunity and allograft rejection ..... 44:S-50
Kretzler M *See* Kriz W et al ..... 45:S-64
Kristal B *See* Ting RH et al ..... 390
Kriz W (abst) ..... 1271
Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-Hagemann I, Tenschert S, Lemley KV: The role of podocytes in the development of glomerular sclerosis ..... 45:S-64
Kriz W, Hackenthal E, Nobiling R, Sakai T, Elger M: A role for podocytes to counteract capillary wall distension ..... 369
Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia—A determinant of renal function loss and deaths in IDDM patients with nephropathy ... 45:S-125
Kroll DJ *See* Anderson RJ et al ..... 642
Kubista H (abst) ..... 1785
Kubrusly M *See* Ureña P et al ..... 605
Kurihara N *See* Kohno M et al ..... 137
Kurnik BRC *See* Weisberg LS et al ..... 259
Kurnik PB *See* Weisberg LS et al ..... 259
Kurokawa K: The kidney and calcium homeostasis ... 44:S-97
Kurokawa K *See* Ikeda M et al ..... 811
Kurokawa K *See* Inishi Y et al ..... 1318

L
Lacour B *See* Natov S et al ..... 1457
Lacour B *See* Ureña P et al ..... 605
Lahera V *See* Ruilope LM et al ..... 45:S-171
Lajeunesse D *See* Bouhtiauy I et al ..... 461
Lajeunesse D *See* Bouhtiauy I et al ..... 469
Lalouel JM *See* Williams RR et al ..... 44:S-57
Lamb C (abst) ..... 1274
Lamberts LV *See* D'Haese PC et al ..... 76
Lamisse F *See* Delarue J et al ..... 1147
Lampasona V *See* Pollard TA et al ..... 232
Lan HY (abst) ..... 1259, 1272, 1272
Lan HY *See* Hill PA et al ..... 32
Lan HY *See* Hill PA et al ..... 700
Lan HY *See* Nikolic-Paterson DJ et al ..... 45:S-79
Landmann J (abst) ..... 1793
Lane NJ *See* Thorniley MS et al ..... 1489
Lang CC *See* Sturrock NDC et al ..... 1203
Lang R *See* Ravid M et al ..... 45:S-161
Largen P *See* Jansen A et al ..... 1215
Larkins R (abst) ..... 1258
Laske V *See* Barenbrock M et al ..... 1397
Lauder I *See* Harper SJ et al ..... 836
Laurens WEAA, Vanrenterghem YFC, Steels PSJ, Van Damme BJC: A new single nephron model of focal and segmental glomerulosclerosis in the Munich-Wistar rat ..... 143
Lauwerys R *See* Kabanda A et al ..... 1689
Lawrence D (abst) ..... 1274
Lawrence JR (abst) ..... 1253
Lawrence JR *See* Pollock CA et al ..... 897
Layward L *See* Harper SJ et al ..... 836
Lazarus JM *See* Sreedhara R et al ..... 1477
Le Hir M (abst) ..... 1792
Leal M (abst) ..... 290, 291
Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria ..... 45:S-150
Lebre L (abst) ..... 283
Lechago J *See* Truong LD et al ..... 201
Lee L (abst) ..... 1783
Lee S-L *See* Huang W et al ..... 692
Lehrer RI *See* Johnson RJ et al ..... 352
Leitão L (abst) ..... 283
Lemke H-D *See* Verresen L et al ..... 1497
Lemley KV *See* Kriz W et al ..... 45:S-64
Lemoine R *See* Fulpius T et al ..... 962
Lemoine R *See* Moll S et al ..... 500
Leski M (abst) ..... 1792
Leski M *See* Ruedin P et al ..... 245
Leumann E (abst) ..... 1783, 1791
Lever M (abst) ..... 1267, 1275, 1277
Levi J *See* Gafter U et al ..... 224
Lévy M (abst) ..... 1791
Lewis EJ *See* Breyer JA et al ..... 45:S-156
Lewis W (abst) ..... 1266
Lhotta K *See* Koenig P et al ..... 1507
Lindsay RM, Heidenheim AP, Spanner E, Kortas C, Blake PG: Adequacy of hemodialysis and nutrition—Important determinants of morbidity and mortality ... 44:S-85
Lindsley J *See* Burdmann EA et al ..... 684
Ling BN *See* Schlanger LE et al ..... 1070
Lingrel JB, Van Huysse J, O'Brien W, Jewell-Motz E, Askew R, Schultheis P: Structure-function studies of the Na,K-ATPase ..... 44:S-32
Lipkin G (abst) ..... 1266
Lishner M *See* Ravid M et al ..... 45:S-161
Llach F *See* Bover J et al ..... 953
Lloveras J-J *See* Ader J-L et al ..... 1657
Lo A (abst) ..... 1262
Lobato L (abst) ..... 286, 287, 288
Lobaugh BA *See* Quarles LD et al ..... 1710
Löffler B (abst) ..... 1788
Lombardi D *See* Giachelli CM et al ..... 515
Lonergan MA (abst) ..... 1261, 1276
Lopes J (abst) ..... 286, 288, 288
López-Farré A *See* Caramelo C et al ..... 66
Loureiro A (abst) ..... 289, 289, 289
Loureiro J (abst) ..... 290
Lovett D *See* Johnson RJ et al ..... 352
Lovett DH (abst) ..... 1783
Luxton G (abst) ..... 1267

Lynn KL (abst) ..... 1258, 1262, 1266, 1273

M
MacAllister RJ, Whitley GSJ, Vallance P: Effects of guanidino and uremic compounds on nitric oxide pathways ..... 737
Macário F (abst) ..... 284, 290, 290
Macdonald G (abst) ..... 1265
Macdonald GJ (abst) ..... 1276
Macdonald PS (abst) ..... 1254
Macedo G (abst) ..... 289, 289, 289
Machado L *See* Bover J et al ..... 953
Maciel I (abst) ..... 282
Mackay P (abst) ..... 1267
Macnicol A *See* Chauveau D et al ..... 1140
Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? ..... 876
Magoulas T (abst) ..... 1278
Magri P *See* Sabbatini M et al ..... 1355
Mahan JD *See* Hebert LA et al ..... 493
Mahony J (abst) ..... 1264
Mai B *See* Sunder-Plassmann G et al ..... 1484
Maia AM (abst) ..... 288
Maia P (abst) ..... 289
Maingourd C *See* Delarue J et al ..... 1147
Majesky M *See* Truong LD et al ..... 201
Makarious M (abst) ..... 1276
Maki A *See* Yamamoto N et al ..... 1093
Malik KU *See* Matsell DG et al ..... 159
Mallare MJ *See* Paulsen EP et al ..... 1132
Mandal AK *See* Kohno M et al ..... 137
Manek S *See* Thorniley MS et al ..... 1489
Manic G *See* Capasso G et al ..... 1543
Manivel JC *See* Dvergsten J et al ..... 828
Männikkö M *See* Kestilä M et al ..... 986
Mannstadt M *See* Ureña P et al ..... 605
Mariano MJ (abst) ..... 286
Maroni BJ *See* Masud T et al ..... 1182
Maroni BJ *See* Pollard TA et al ..... 232
Marques A (abst) ..... 284
Marques LPJ (abst) ..... 287
Marsden PA *See* Stewart RJ et al ..... 45:S-37
Marsen TA, Schramek H, Dunn MJ: Renal actions of endothelin: Linking cellular signaling pathways to kidney disease ..... 336
Marshall H (abst) ..... 1274
Marti HP (abst) ..... 1783
Martin AA (abst) ..... 1275, 1277
Martin C *See* Kelley VR et al ..... 45:S-83
Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M: Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells ..... 150
Martin P-Y (abst) ..... 1785
Martinez ME *See* Bover J et al ..... 953
Martinez-Maldonado M *See* Pimentel JL Jr. et al ..... 1614
Martins AP (abst) ..... 283
Martyn BN (abst) ..... 1265
Marumo F *See* Otsuka M et al ..... 1340
Marumo F *See* Shinohara M et al ..... 1362
Marusic ET *See* Bofill P et al ..... 672
Maruyama N *See* Kitamura M et al ..... 1580
Maschio G *See* Oldrizzi L et al ..... 45:S-118
Mashford M (abst) ..... 1270
Massry SG *See* Zhang Y-B et al ..... 1113
Masud T, Young VR, Chapman T, Maroni BJ: Adaptive responses to very low protein diets: The first comparison of ketoacids to essential amino acids ..... 1182
Matas AJ *See* Kim E-M et al ..... 1440
Matheson KL *See* Brem AS et al ..... 679
Mathew AS *See* Rahman SN et al ..... 1731
Mathew T (abst) ..... 1269
Mathew TH (abst) ..... 1263, 1268, 1274
Matsell DG, Gaber LW, Malik KU: Cytokine stimulation of prostaglandin production inhibits the proliferation of serum-stimulated mesangial cells ..... 159
Matsuoka H *See* Imanishi M et al ..... 1170
Matsushima K *See* Garin EH et al ..... 1311
Matsushima Y *See* Imanishi M et al ..... 1170
Mattingley S (abst) ..... 1262
Mauer SM: Structural-functional correlations of diabetic nephropathy (Nephrology Forum) ..... 612
Mauer SM *See* Basgen JM et al ..... 1668
Mauer SM *See* Kim E-M et al ..... 1440
Mauer SM *See* Zhu D et al ..... 425
Mauger EA *See* Young EW et al ..... 907
Maximino J (abst) ..... 286, 288
McAllister C *See* Hebert LA et al ..... 493
McCarthy J (abst) ..... 1274
McCarthy KJ *See* Couchman JR et al ..... 328
McCracken R *See* Kaneto H et al ..... 1637
McCracken R *See* Morrissey JJ et al ..... 998
McCredie MRE (abst) ..... 1268
McDougall JG (abst) ..... 1259
McGiffen DC (abst) ..... 1274
McIver M (abst) ..... 1270
McMahon A (abst) ..... 1268
McMahon LP (abst) ..... 1265
McMahon M (abst) ..... 1262
McMenamin C (abst) ..... 1270
McRae J (abst) ..... 1266
McRae JL (abst) ..... 1278
McRae JL *See* Saunders JR et al ..... 817
Mehls O *See* Tönshoff B et al ..... 1085
Meister B *See* Ohtomo Y et al ..... 1606
Melbourne Diabetic Nephropathy Study Group (abst) ..... 1270
Mendelsohn FAO (abst) ..... 1254
Mendes A (abst) ..... 285
Mendes T (abst) ..... 285, 289
Mendonça E (abst) ..... 290
Mendrick DL *See* Rennke HG et al ..... 1044
Mengel MC *See* Lebovitz HE et al ..... 45:S-150
Menzies B (abst) ..... 1264
Mermillod B (abst) ..... 1791
Mesquita M (abst) ..... 291
Meyrick BO *See* Yoshioka T et al ..... 211
Meyrier A, Noël L-H, Auriche P, Callard P, Collaborative Group of the Société de Néphrologie , Broneer D: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome ..... 1446
Miach P (abst) ..... 1264
Michael AF *See* Ding J et al ..... 1504
Michel B, Grima M, Coquard C, Welsch C, Barthelmebs M, Imbs J-L: Effects of dietary protein and uninephrectomy on renal angiotensin converting enzyme activity in the rat ..... 1587
Michel R (abst) ..... 1783
Miettinen A *See* Holthöfer H et al ..... 123

Miguel Boquinhas J (abst) ..... 284
Mihatsch M (abst) ..... 1793
Mihatschof Basel MJ (abst) ..... 1788
Miller DE *See* Yamamoto T et al ..... 916
Miller J *See* Roth D et al ..... 238
Miller R (abst) ..... 1278
Minda SA *See* Quarles LD et al ..... 1710
Mion CM (abst) ..... 1253
Mircheff AK *See* Hensley CB et al ..... 110
Mirshahi M *See* Vanholder RC et al ..... 1754
Mogensen CE *See* Hansen KW et al ..... 45:S-134
Moll S, Schifferli JA, Huarte J, Lemoine R, Vassalli J-D, Sappino A-P: LPS induces major changes in the extracellular proteolytic balance in the murine kidney ..... 500
Moncada S *See* Jansen A et al ..... 1215
Montani D *See* Morrissey JJ et al ..... 998
Monteiro J (abst) ..... 289, 289, 289, 291
Montrucchio G *See* Biancone L et al ..... 451
Moorhead JF *See* Ong ACM et al ..... 753
Morais Sarmento A (abst) ..... 288
Moran MJ *See* Fontanellas A et al ..... 220
Moreira AB (abst) ..... 282
Morgado T (abst) ..... 288
Morioka T, Woitas R, Fujigaki Y, Batsford SR, Vogt A: Histone mediates glomerular deposition of small size DNA anti-DNA complex ..... 991
Morris DJ *See* Brem AS et al ..... 679
Morris K (abst) ..... 1267
Morrison L *See* Brown PAJ et al ..... 43
Morrissey J *See* Kaneto H et al ..... 1637
Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S: Location of an inducible nitric oxide synthase mRNA in the normal kidney ..... 998
Moscatelli P *See* Garibotto G et al ..... 1432
Mota A (abst) ..... 290
Mota C (abst) ..... 282, 286, 288
Moullier P, Friedlander G, Calise D, Ronco P, Perricaudet M, Ferry N: Adenoviral-mediated gene transfer to renal tubular cells *in vivo* ..... 1220
Moura C (abst) ..... 282
Moxey-Mims MM, Noble B: Glomerular macrophage phagocytic activity in experimental immune complex nephritis ..... 1326
Mulder AHL *See* Brouwer E et al ..... 1120
Mulec H, Johnsen SA, Björck S: Long-term enalapril treatment in diabetic nephropathy ..... 45:S-141
Müller V (abst) ..... 1784
Mullins RE *See* Pollard TA et al ..... 232
Munar MY *See* Burdmann EA et al ..... 684
Murer H, Krapft R, Helmle-Kolb C: Regulation of renal proximal tubular Na/H exchange: A tissue culture approach ..... 44:S-23
Murphy B (abst) ..... 1266
Murphy BF (abst) ..... 1278
Murphy BF *See* Saunders JR et al ..... 817
Myers BD *See* Ting RH et al ..... 390

N

Nagata M *See* Kriz W et al ..... 45:S-64
Nagelhus E *See* Amiry-Moghaddam M et al ..... 10
Nai M *See* Maggi E et al ..... 876
Najarian JS *See* Kim E-M et al ..... 1440
Nakagawa Y *See* Bushinsky DA et al ..... 58
Nakamura T, Fukui M, Ebihara I, Tomino Y, Koide H: Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis ..... 1593
Nakayama M *See* Tamaki K et al ..... 525
Nakazawa H *See* Kashem A et al ..... 868
Nankivell BJ (abst) ..... 1254, 1255, 1268, 1271, 1277
Nankivell BJ, Tay Y-C, Boadle RA, Harris DCH: Dietary protein alters tubular iron accumulation after partial nephrectomy ..... 1006
Nanra RS (abst) ..... 1266
Narins RG *See* Cortes P et al ..... 45:S-11
Naruse T *See* Hiromura K et al ..... 1572
Nastasi A *See* Cianciaruso B et al ..... 852
Nath KA, Enright H, Nutter L, Fischereder M, Zou J-N, Hebbel RP: Effect of pyruvate on oxidant injury to isolated and cellular DNA ..... 166
Nath KA, Fischereder M, Hostetter TH: The role of oxidants in progressive renal injury ..... 45:S-111
Natov S, Schmitt F, Ikeni A, Lacour B, Hannedouche TP: Opposite renal effects of a $PGE_1$ analog and prostacyclin in humans ..... 1457
Neilson EG: Tubulointerstitial injury and its role in progressive renal damage: Summary and concluding remarks ..... 45:S-116
Neilson EG *See* Ding J et al ..... 1504
Neilson EG *See* Kalluri R et al ..... 721
Neilson EG *See* Strutz F et al ..... 45:S-106
Nerlich AG, Schleicher ED, Wiest I, Specks U, Timpl R: Immunohistochemical localization of collagen VI in diabetic glomeruli ..... 1648
Nery J *See* Roth D et al ..... 238
Netzer K-O *See* Kalluri R et al ..... 721
Neumann D *See* Martin M et al ..... 150
Neves F (abst) ..... 290
Newman GE *See* Kovalik EC et al ..... 1177
Neyer U *See* Koenig P et al ..... 1507
Ng B (abst) ..... 1275
Ng G (abst) ..... 1254, 1260
Ni Z *See* Zhang Y-B et al ..... 1113
Nicholls MG (abst) ..... 1276
Nickerson PW, Steurer W, Steiger J, Strom TB: In pursuit of the "Holy Grail": Allograft tolerance ..... 44:S-40
Nicol D (abst) ..... 1264
Nikolic-Paterson D (abst) ..... 1257
Nikolic-Paterson DJ (abst) ..... 1257, 1257, 1259, 1271, 1272, 1272
Nikolic-Paterson DJ, Lan HY, Hill PA, Atkins RC: Macrophages in renal injury ..... 45:S-79
Nikolic-Paterson DJ *See* Argilés A et al ..... 23
Nikolic-Paterson DJ *See* Hill PA et al ..... 32
Nikolic-Paterson DJ *See* Hill PA et al ..... 700
Nilsson H *See* Friberg P et al ..... 485
Nissim I, Sahai A, Sandler RS, Tannen RL: The intensity of acidosis differentially alters the pathways of ammoniagenesis in LLC-$PK_1$ cells ..... 1014
Nobes MS (abst) ..... 1261
Nobiling R *See* Kriz W et al ..... 369
Noble B *See* Moxey-Mims MM et al ..... 1326
Noble NA *See* Ruoslahti E et al ..... 44:S-17
Noble NA *See* Yamamoto T et al ..... 916
Noël L-H *See* Meyrier A et al ..... 1446
Nogueira AC (abst) ..... 286
Nogueira C (abst) ..... 287
Nolasco F (abst) ..... 290, 290
Nomoto Y *See* Kashem A et al ..... 868

Nonaka T, Stokes JB: Metabolic support of $Na^+$ transport by the rabbit CCD: Analysis of the use of equivalent current ..... 743
Nonoguchi H *See* Otsuka M et al ..... 1340
Nonoguchi H *See* Shinohara M et al ..... 1362
North K (abst) ..... 1263
Norton A (abst) ..... 286
Norwood VF, Carey RM, Geary KM, Jose PA, Gomez RA, Chevalier RL: Neonatal ureteral obstruction stimulates recruitment of renin-secreting renal cortical cells ..... 1333
Nouwen EJ, Broe MED: EGF and TGF-$\alpha$ in the human kidney: Identification of octopal cells in the collecting duct ..... 1510
Nouwen EJ *See* Van Der Biest I et al ..... 85
Nukii K (abst) ..... 1272
Nunes JP (abst) ..... 286
Nusslé D (abst) ..... 1791
Nutter L *See* Nath KA et al ..... 166

O
O'Brien W *See* Lingrel JB et al ..... 44:S-32
O'Bryan M (abst) ..... 1266
Odell R (abst) ..... 1253
O'Donnell MP *See* Kasiske BL et al ..... 45:S-51
Odum J (abst) ..... 1269
Oehry MJ (abst) ..... 1793
O'Farrell KA (abst) ..... 1278
O'Farrell KA *See* Saunders JR et al ..... 817
Offord KP *See* Torres VE et al ..... 1745
Ohtomo Y, Meister B, Hökfelt T, Aperia A: Coexisting NPY and NE synergistically regulate renal tubular $Na^+$, $K^+$-ATPase activity ..... 1606
Okada K *See* Caramelo C et al ..... 66
Okuda S *See* Tamaki K et al ..... 525
Okuda T *See* Inishi Y et al ..... 1318
Oldrizzi L, Rugiu C, de Biase V, Maschio G: Renal endpoints in nondiabetic patients ..... 45:S-118
Oliveira Domingos M (abst) ..... 290
Oliveira G (abst) ..... 285, 286
Oliveira H (abst) ..... 284
Oliveira JP (abst) ..... 282, 282, 282
Oliveira M (abst) ..... 288
Olivera A *See* Caramelo C et al ..... 66
Olsen S *See* Solez K et al ..... 44:S-65
Omae T *See* Imanishi M et al ..... 1170
Ong ACM, Fine LG: Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect? ..... 345
Ong ACM, Moorhead JF: Tubular lipidosis: Epiphenomenon or pathogenetic lesion in human renal disease? ..... 753
Ono K *See* Hiromura K et al ..... 1572
Ootaka T *See* Argilés A et al ..... 23
Oppenheim W *See* Salusky IB et al ..... 253
Orlin JB *See* Gafter U et al ..... 224
Orth S *See* Ritz E et al ..... 438
Osswald H *See* Erley CM et al ..... 1425
Otero Glez A (abst) ..... 292
Otero Glz A (abst) ..... 291, 291
Otsuka M, Terada Y, Yang T, Nonoguchi H, Tomita K, Marumo F: Localization of cyclophilin A and cyclophilin C mRNA in murine kidney using RT-PCR ..... 1340
Ottersen OP *See* Amiry-Moghaddam M et al ..... 10
Oudenhoven LFIJ, Pattynama PMT, de Roos A, Seeverens HJJ, Rebergen SA, Chang PC: Magnetic resonance, a new method for measuring blood flow in hemodialysis fistulae ..... 884
Owada A *See* Shinohara M et al ..... 1362

P
Packham DK (abst) ..... 1273
Painter DM (abst) ..... 1256, 1258
Panagiotopoulos S (abst) ..... 1268
Pannatier JG (abst) ..... 1786
Papayianni A *See* Brady HR et al ..... 45:S-90
Paredes F (abst) ..... 286
Parks JH, Coe FL: An increasing number of calcium oxalate stone events worsens treatment outcome ..... 1722
Parreira B (abst) ..... 288
Parving H-H: Clinical experience in the treatment of diabetic renal disease (type I and type II): Summary and concluding remarks ..... 45:S-165
Parving H-H *See* Keane WF et al ..... 45:S-1
Parving H-H *See* Rossing P et al ..... 45:S-145
Passerini P *See* Piccoli A et al ..... 1193
Pastore Y *See* Fulpius T et al ..... 962
Pataca I (abst) ..... 290, 290
Patel SR, Ke HQ, Hsu CH: Effect of vitamin D metabolites on calcitriol degradative enzymes in renal failure ..... 509
Patel SR, Ke HQ, Hsu CH: Regulation of calcitriol receptor and its mRNA in normal and renal failure rats ..... 1020
Patrício A (abst) ..... 284, 290, 290
Patrick GM (abst) ..... 1268
Pattynama PMT *See* Oudenhoven LFIJ et al ..... 884
Paulsen EP, Burke BA, Vernier RL, Mallare MJ, Innes DJ Jr., Sturgill BC: Juxtaglomerular body abnormalities in youth-onset diabetic subjects ..... 1132
Peddie BA (abst) ..... 1256, 1267
Pedroso E (abst) ..... 285, 285
Peh C (abst) ..... 1269
Pei P (abst) ..... 1786
Peltonen L *See* Kestilä M et al ..... 986
Pena JR (abst) ..... 286, 288, 290
Penfold J (abst) ..... 1273
Penninckx R *See* Soupart A et al ..... 193
Penny MJ (abst) ..... 1254, 1268
Penny R (abst) ..... 1278
Perani G *See* Maggi E et al ..... 876
Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1$\beta$, TNF$\alpha$ and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients ..... 890
Pereira E (abst) ..... 282, 289
Pereira M (abst) ..... 286, 286, 288
Perez-Miranda M *See* Caravaca F et al ..... 845
Perich R (abst) ..... 1268
Perico N *See* Remuzzi G et al ..... 44:S-8
Perier O *See* Soupart A et al ..... 193
Perricaudet M *See* Moullier P et al ..... 1220
Pestana M (abst) ..... 287, 290
Peten EP, Yang C-W, Striker GE, Striker LJ: Gene activation in glomerulosclerosis: A role for growth promoting hormones ..... 45:S-48
Petersen J *See* Friberg P et al ..... 485
Peterson MM *See* Wheeler DC et al ..... 1628

Petersson C, Hedges S, Stenqvist K, Sandberg T, Connell H, Svanborg C: Suppressed antibody and interleukin-6 responses to acute pyelonephritis in pregnancy ..... 571
Petrie J (abst) ..... 1264, 1265
Phillips PA (abst) ..... 1261, 1261, 1262, 1275, 1276
Phillips PA, Grant SL, Davidson AF, Risvanis J, Stephenson J, Gow CB: Epidermal growth factor antagonizes vasopressin *in vivo* and *in vitro* ..... 1028
Phippard AF (abst) ..... 1256, 1258
Piccoli A, Pillon L, Passerini P, Ponticelli C: Therapy for idiopathic membranous nephropathy: Tailoring the choice by decision analysis ..... 1193
Pichler R *See* Giachelli CM et al ..... 515
Pidgeon GB (abst) ..... 1258, 1276
Pillon L *See* Piccoli A et al ..... 1193
Pimentel J (abst) ..... 288
Pimentel JL Jr., Wang S, Martinez-Maldonado M: Regulation of the renal angiotensin II receptor gene in acute unilateral ureteral obstruction ..... 1614
Pindur J *See* Truong LD et al ..... 201
Pinho A (abst) ..... 282
Pinho M (abst) ..... 288
Pinto F (abst) ..... 289
Pinto T (abst) ..... 289
Pirson Y *See* Chauveau D et al ..... 1140
Pirson Y *See* Goffin E et al ..... 551
Pizarro JL *See* Caravaca F et al ..... 845
Ploth DW *See* Rinder CA et al ..... 185
P'ng K (abst) ..... 1264
Poch E, Botey A, Gaya J, Darnell A, Rivera F, Revert L: Intracellular calcium concentration and activation of the $Na^+/H^+$ exchanger in essential hypertension ..... 1037
Pochet JM *See* Kabanda A et al ..... 1689
Polihronis M (abst) ..... 1266
Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, Maroni BJ: Vancomycin redistribution: Dosing recommendations following high-flux hemodialysis ..... 232
Pollock CA (abst) ..... 1253, 1260, 1261, 1268
Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, Lawrence JR, Waugh DA, George CRP: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure ..... 897
Polónia J (abst) ..... 286
Pomer S (abst) ..... 1271
Ponticelli C *See* Piccoli A et al ..... 1193
Popovtzer MM *See* Bernheim J et al ..... 44:S-3
Porras BH *See* Reyes AA et al ..... 1346
Port FK *See* Held PJ et al ..... 1163
Port FK *See* Young EW et al ..... 907
Porter S (abst) ..... 1259
Poulsen PL *See* Hansen KW et al ..... 45:S-134
Powell HR (abst) ..... 1264
Power DA *See* Brown PAJ et al ..... 43
Praça A (abst) ..... 282
Praça AM (abst) ..... 283, 283
Praddaude F *See* Ader J-L et al ..... 1657
Praga M *See* Ruilope LM et al ..... 45:S-171
Prata MM (abst) ..... 286
Pratas J (abst) ..... 285
Price D *See* Kelley VR et al ..... 45:S-83
Prince R (abst) ..... 1275
Pringle JH *See* Harper SJ et al ..... 836
Prommegger R *See* Koenig P et al ..... 1507
Provoost AP: Spontaneous glomerulosclerosis: Insights from the fawn-hooded rat ..... 45:S-2
Pugsley D (abst) ..... 1274
Pussell BA (abst) ..... 1267

Q
Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD ..... 1710
Queirós J (abst) ..... 286, 286, 288
Quiza CG (abst) ..... 1272

R
Racusen LC *See* Solez K et al ..... 44:S-65
Radeke HH, Emmendörffer A, Uciechowski P, von der Ohe J, Schwinzer B, Resch K: Activation of autoreactive T-lymphocytes by cultured syngeneic glomerular mesangial cells ..... 763
Radeke HR *See* Floege J et al ..... 360
Raffaele J (abst) ..... 1270
Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW, Conger JD: Effects or atrial natriuretic peptide in clinical acute renal failure ..... 1731
Rahn K-H *See* Barenbrock M et al ..... 1397
Raij L, Coffee K, Guerra J, Holmes D: Glomerular thrombosis in pregnancy: Role of the L-arginine-nitric oxide pathway ..... 775
Raine AEG (abst) ..... 1266, 1268, 1275
Rainone S (abst) ..... 1257
Rainone SR (abst) ..... 1257
Ramirez JA *See* Salusky IB et al ..... 253
Ramm HC (abst) ..... 1272
Ramos A (abst) ..... 284, 285, 285, 285
Rato Q (abst) ..... 285, 285
Rauterberg E-W *See* Deppisch R et al ..... 44:S-77
Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II .. 45:S-161
Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to $AT_1$ receptors ..... 177
Read LC (abst) ..... 1275, 1277
Rebergen SA *See* Oudenhoven LFIJ et al ..... 884
Reddy S (abst) ..... 1260
Redman CWG (abst) ..... 1265
Rees AJ: The immunogenetics of glomerulonephritis ..... 377
Reeves WB *See* Winters CJ et al ..... 803
Rego F (abst) ..... 286, 288, 288
Reid FJ *See* Brown PAJ et al ..... 43
Reindl N *See* Hartner A et al ..... 1562
Reininger L *See* Fulpius T et al ..... 962
Reiss OK *See* Shapiro JI et al ..... 45:S-100
Reiter L (abst) ..... 1277
Reivinen J *See* Holthöfer H et al ..... 123
Remédio F (abst) ..... 284, 285
Remuzzi A, Remuzzi G: Glomerular perm-selective function ..... 398
Remuzzi G: Glomerular hypertrophy and progression: Summary and concluding remarks ..... 45:S-30
Remuzzi G, Zoja C, Perico N: Proinflammatory mediators of glomerular injury and mechanisms of activation of autoreactive T cells ..... 44:S-8
Remuzzi G *See* Remuzzi A et al ..... 398
Ren YL *See* Arima S et al ..... 650

Rennke HG: Cellular mechanisms of glomerular injury II: Summary; concluding remarks ..... 45:S-78
Rennke HG: How does glomerular epithelial cell injury contribute to progressive glomerular damage? ..... 45:S-58
Rennke HG, Klein PS, Sandstrom DJ, Mendrick DL: Cell-mediated immune injury in the kidney: Acute nephritis induced in the rat by azobenzenearsonate ..... 1044
Resch K *See* Martin M et al ..... 150
Resch K *See* Radeke HH et al ..... 763
Revert L *See* Poch E et al ..... 1037
Reyes A *See* Kaneto H et al ..... 1637
Reyes AA, Karl IE, Yates J, Klahr S: Low plasma and renal tissue levels of L-arginine in rats with obstructive nephropathy ..... 782
Reyes AA, Porras BH, Chasalow FI, Klahr S: L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis ..... 1346
Ribeiro F (abst) ..... 284, 285, 290
Ricardo SD (abst) ..... 1271
Ricardo SD, Bertram JF, Ryan GB: Reactive oxygen species in puromycin aminonucleoside nephrosis: *In vitro* studies ..... 1057
Richards AM (abst) ..... 1276
Richet G: Acceptance of the 1993 Jean Hamburger Award ..... 44:S-113
Richet GC: Osmotic diuresis before Homer W. Smith: A winding path to renal physiology (Historical Archive) ..... 1241
Riesco A *See* Caramelo C et al ..... 66
Riesen W (abst) ..... 1787
Rigby R (abst) ..... 1264, 1264, 1265
Rinder CA, Halushka PV, Sens MA, Ploth DW: Thromboxane $A_2$ receptor blockade improves renal function and histopathology in the post-obstructive kidney ..... 185
Ringoir S *See* Vanholder RC et al ..... 1754
Rioja LS (abst) ..... 287
Riser BL *See* Cortes P et al ..... 45:S-11
Risler T *See* Erley CM et al ..... 1425
Risvanis J (abst) ..... 1261, 1261, 1275
Risvanis J *See* Phillips PA et al ..... 1028
Ritz E (abst) ..... 1271
Ritz E: Presentation of the 1993 Jean Hamburger Award to Gabriel Richet ..... 44:S-112
Ritz E: Presentation of the 1993 Jean Hamburger Award to Hugh E. de Wardener ..... 44:S-114
Ritz E, Orth S, Weinreich T, Wagner J: Systemic hypertension versus intraglomerular hypertension in progression ..... 438
Ritz E *See* Deppisch R et al ..... 44:S-77
Rivera F *See* Poch E et al ..... 1037
Riveros-Moreno V *See* Jansen A et al ..... 1215
Rizzoli R *See* Ruedin P et al ..... 245
Robaudo C *See* Garibotto G et al ..... 1432
Robertson WR *See* Schaefer F et al ..... 1465
Robinson ICAF *See* Tönshoff B et al ..... 1085
Robinson RR: Report of the President to the ISN General Assembly ..... 44:S-116
Robson MR (abst) ..... 1267
Robson R (abst) ..... 1267, 1275, 1277
Robson RA (abst) ..... 1258, 1266, 1273
Rocha G (abst) ..... 288
Rodger A (abst) ..... 1277
Rodicio JL: Clinical experience in the treatment of non-diabetic renal disease: Summary and concluding remarks ..... 45:S-179
Rodicio JL *See* Ruilope LM et al ..... 45:S-171
Rodrigues L (abst) ..... 289
Rodriguez M *See* Bover J et al ..... 953
Roe CJ (abst) ..... 1266
Roger SD (abst) ..... 1266, 1268, 1275
Romanini D *See* Maggi E et al ..... 876
Ronco P *See* Moullier P et al ..... 1220
Rosa FC (abst) ..... 290
Rosen S *See* Burdmann EA et al ..... 684
Rosen S *See* Heyman SN et al ..... 981
Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease ..... 403
Rosenberg ME *See* Dvergsten J et al ..... 828
Rosenblum ND: The mesangial matrix in the normal and sclerotic glomerulus ..... 45:S-73
Rosenfeld JB: Introduction ..... 44:S-1
Rösler I (abst) ..... 1789
Rosman J (abst) ..... 1787, 1790
Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy ..... 45:S-145
Rostaing L *See* Ader J-L et al ..... 1657
Roth D, Zucker K, Cirocco R, DeMattos A, Burke GW, Nery J, Esquenazi V, Babishckin S, Miller J: The impact of hepatitis C virus infection on renal allograft recipients ..... 238
Rousselot M (abst) ..... 1789
Rowe J (abst) ..... 1278
Roy LP (abst) ..... 1254, 1259, 1260, 1269
Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour J-P: Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure ..... 245
Ruef C (abst) ..... 1784
Rugiu C *See* Oldrizzi L et al ..... 45:S-118
Ruilope LM, Alcázar JM, Hernández E, Praga M, Lahera V, Rodicio JL: Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension ..... 45:S-171
Ruoslahti E, Noble NA, Kagami S, Border WA: Integrins ..... 44:S-17
Russ GR (abst) ..... 1274
Russo R *See* Garibotto G et al ..... 1432
Ryan GB (abst) ..... 1271
Ryan GB *See* Ricardo SD et al ..... 1057
Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B: HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney ..... 48
Ryffel B (abst) ..... 1788, 1792

S

Sabbatini M, Sansone G, Uccello F, de Nicola L, Giliberti A, Sepe V, Magri P, Conte G, Andreucci VE: Functional versus structural changes in the pathophysiology of acute ischemic renal failure in aging rats ..... 1355
Sadow JL *See* Kees-Folts D et al ..... 1697
Sadowski RH, Harmon WE, Jabs K: Acute hemodialysis of infants weighing less than five kilograms ..... 903
Sahai A *See* Nissim I et al ..... 1014
Sakai H *See* Kashem A et al ..... 868
Sakai T *See* Kriz W et al ..... 369

Saker B (abst) ..... 1263
Sala MR *See* Garibotto G et al ..... 1432
Salipan-Moore N (abst) ..... 1260
Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD ..... 253
Sampaio M (abst) ..... 288
Sampaio MJ (abst) ..... 286, 288
Sandberg T *See* Petersson C et al ..... 571
Sanders PW *See* Jannett TC et al ..... 912
Sandler RS *See* Nissim I et al ..... 1014
Sands JM (abst) ..... 1254
Sandstrom DJ *See* Rennke HG et al ..... 1044
Sansone G *See* Sabbatini M et al ..... 1355
Santana A (abst) ..... 283
Santoro-Lopes G (abst) ..... 287, 287
Santos JL *See* Fontanellas A et al ..... 220
Santos NT (abst) ..... 288
Santos OR (abst) ..... 287
Sappino A-P *See* Moll S et al ..... 500
Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy ..... 578
Sargent P (abst) ..... 1267
Sarkissian A (abst) ..... 1791
Sarmento M (abst) ..... 282
Saunders J (abst) ..... 1266
Saunders JR (abst) ..... 1278
Saunders JR, Aminian A, McRae JL, O'Farrell KA, Adam WR, Murphy BF: Clusterin depletion enhances immune glomerular injury in the isolated perfused kidney ..... 817
Savage COS: The biology of the glomerulus: Endothelial cells ..... 314
Savdie E (abst) ..... 1254
Savige J (abst) ..... 1257
Savige JA (abst) ..... 1257
Savin H *See* Ravid M et al ..... 45:S-161
Savolainen E-R *See* Kestilä M et al ..... 986
Schaefer F, Veldhuis JD, Robertson WR, Dunger D, Schärer K, Cooperative Study Group on Pubertal Development in Chronic Renal Failure: Immunoreactive and bioactive luteinizing hormone in pubertal patients with chronic renal failure ..... 1465
Schärer K *See* Schaefer F et al ..... 1465
Schaudies RP *See* Seiken G et al ..... 1622
Schifferli J (abst) ..... 1791
Schifferli JA *See* Moll S et al ..... 500
Schifferli JA *See* Sarasin FP et al ..... 578
Schimpf BA *See* Zager RA et al ..... 1760
Schindhelm K (abst) ..... 1253
Schlanger LE, Kleyman TR, Ling BN: $K^+$-sparing diuretic actions of trimethoprim: Inhibition of $Na^+$ channels in A6 distal nephron cells ..... 1070
Schleicher ED *See* Nerlich AG et al ..... 1648
Schlepckow S *See* Erley CM et al ..... 1425
Schlondorff D: Cellular mechanism of glomerular injury: Metabolic factors in progressive renal injury .. 45:S-54
Schmid M (abst) ..... 1791
Schmidli M (abst) ..... 1787, 1791
Schmitt F *See* Natov S et al ..... 1457
Schneider Y-J *See* Boelaert JR et al ..... 667
Schoch Zysset Y (abst) ..... 1790
Schöls M *See* Deppisch R et al ..... 44:S-77
Schramek H *See* Marsen TA et al ..... 336
Schreiner GF *See* Kees-Folts D et al ..... 1697
Schrieber L (abst) ..... 1278
Schrier RW *See* Caramelo C et al ..... 66
Schrier RW *See* Rahman SN et al ..... 1731
Schrier RW *See* Shapiro JI et al ..... 45:S-100
Schubiger G (abst) ..... 1783
Schultheis P *See* Lingrel JB et al ..... 44:S-32
Schwab SJ *See* Kovalik EC et al ..... 1177
Schwartz SL *See* Lebovitz HE et al ..... 45:S-150
Schwartz SM *See* Giachelli CM et al ..... 515
Schwinzer B *See* Radeke HH et al ..... 763
Scown R (abst) ..... 1267
Seeverens HJJ *See* Oudenhoven LFIJ et al ..... 884
Segal R *See* Lebovitz HE et al ..... 45:S-150
Segre GV *See* Salusky IB et al ..... 253
Segre GV *See* Ureña P et al ..... 605
Seigle R *See* Szabolcs MJ et al ..... 1388
Seiken G, Grillo FG, Schaudies RP, Johnson JP: Modulation of renal EGF in dichromate-induced acute renal failure treated with thyroid hormone ..... 1622
Seixas A (abst) ..... 289
Seixas F (abst) ..... 289, 289
Seldin DW: Presentation of the 1993 A.N. Richards Award to Gerhard Giebisch ..... 44:S-106
Sella ML *See* Abreo K et al ..... 636
Semama DS (abst) ..... 1789
Senn M (abst) ..... 1787
Sens MA *See* Rinder CA et al ..... 185
Sepe V *See* Sabbatini M et al ..... 1355
Serhan CN *See* Brady HR et al ..... 45:S-90
Serna M-J (abst) ..... 1791
Sessler N *See* Bushinsky DA et al ..... 58
Seymour A (abst) ..... 1269
Shah SV *See* Ueda N et al ..... 788
Shahinfar S *See* Becker GJ et al ..... 45:S-167
Shahinfar S *See* Lebovitz HE et al ..... 45:S-150
Shand BI (abst) ..... 1266, 1273
Shanklin NH *See* Jannett TC et al ..... 912
Shanske S *See* Szabolcs MJ et al ..... 1388
Shapiro JI, Elkins N, Reiss OK, Suleymanlar G, Jin H, Schrier RW, Chan L: Energy metabolism following reduction of renal mass ..... 45:S-100
Shapiro L *See* Pereira BJG et al ..... 890
Shehan BP (abst) ..... 1255
Shen X-P *See* Hebert LA et al ..... 493
Shinohara M, Nonoguchi H, Ujiie K, Terada Y, Owada A, Tomita K, Marumo F: Effects of hyperosmolality on ANP-stimulated cGMP generation in rat inner medullary collecting duct ..... 1362
Shirasawa T *See* Kitamura M et al ..... 1580
Short B *See* Albrightson CR et al ..... 1301
Sica DA *See* Lebovitz HE et al ..... 45:S-150
Siegl PKS *See* Kivlighn SD et al ..... 131
Silva I (abst) ..... 286
Silva JG (abst) ..... 286
Silva M (abst) ..... 283, 286
Silve C *See* Ureña P et al ..... 605
Simboli-Campbell M *See* Gagnon AM et al ..... 95
Simmons DA *See* Bleyer AJ et al ..... 659
Simões J (abst) ..... 283, 284
Simões Jacinto (abst) ..... 283
Simpson JG *See* Brown PAJ et al ..... 43
Sizeland P (abst) ..... 1267, 1275, 1277
Sjöquist M *See* Huang W et al ..... 692
Slosman D *See* Ruedin P et al ..... 245
Slosman DO (abst) ..... 1791

Smidt UM *See* Rossing P et al ..... 45:S-145
Smith AH (abst) ..... 1267
Smith KGC (abst) ..... 1262, 1265
Smith LJ *See* Rosenberg ME et al ..... 403
Smith MW *See* Yamamoto N et al ..... 1093
Smith SD, Wheeler MA, Weiss RM: Nitric oxide synthase: An endogenous source of elevated nitrite in infected urine ..... 586
Smogorzewski M *See* Zhang Y-B et al ..... 1113
Snelling P (abst) ..... 1258
Snipes ER *See* Bleyer AJ et al ..... 659
Soares-da-Silva P (abst) ..... 290
Soden V (abst) ..... 1274
Sofia A *See* Garibotto G et al ..... 1432
Solez K, Racusen LC, Olsen S: New approaches to renal biopsy assessment in acute renal failure: Extrapolation from renal transplantation ..... 44:S-65
Song K (abst) ..... 1254
Soria C *See* Vanholder RC et al ..... 1754
Soria J *See* Vanholder RC et al ..... 1754
Soupart A, Penninckx R, Crenier L, Stenuit A, Perier O, Decaux G: Prevention of brain demyelination in rats after excessive corection of chronic hyponatremia by serum sodium lowering ..... 193
Sousa A (abst) ..... 287
Spanner E *See* Lindsay RM et al ..... 44:S-85
Specks U *See* Nerlich AG et al ..... 1648
Spector AA *See* Girton RA et al ..... 972
Spieker C *See* Barenbrock M et al ..... 1397
Spinelli A (abst) ..... 1272
Spoendlin M (abst) ..... 1788, 1792
Spokes K *See* Heyman SN et al ..... 981
Spöndlin M (abst) ..... 1793
Sponsel HT *See* Anderson RJ et al ..... 642
Spratt PM (abst) ..... 1254
Spritzer CE *See* Quarles LD et al ..... 1710
Squifflet J-P *See* Cosyns J-P et al ..... 1680
Squifflet J-P *See* Goffin E et al ..... 551
Sredni B *See* Gafter U et al ..... 224
Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective randomized double-blind study ..... 1477
Star RA (abst) ..... 1254
Steels PSJ *See* Laurens WEAA et al ..... 143
Steffes MW *See* Basgen JM et al ..... 1668
Steffes MW *See* Zhu D et al ..... 425
Steiger J *See* Nickerson PW et al ..... 44:S-40
Stenqvist K *See* Petersson C et al ..... 571
Stenuit A *See* Soupart A et al ..... 193
Stephenson J (abst) ..... 1261, 1261, 1275
Stephenson J *See* Phillips PA et al ..... 1028
Sterzel RB *See* Hartner A et al ..... 1562
Steurer W *See* Nickerson PW et al ..... 44:S-40
Stewart JH (abst) ..... 1268
Stewart K (abst) ..... 1263
Stewart RJ, Marsden PA: Vascular endothelial cell activation in models of vascular and glomerular injury ... 45:S-37
Stillman AE *See* Basgen JM et al ..... 1668
Stirling JW (abst) ..... 1256
StJohn A (abst) ..... 1274, 1275
Stokes JB *See* Nonaka T et al ..... 743
Stricker PD (abst) ..... 1254
Striegel J *See* Kim E-M et al ..... 1440
Striker GE: Cellular mechanisms of glomerular injury I: Summary and concluding remarks ..... 45:S-56
Striker GE *See* Peten EP et al ..... 45:S-48
Striker LJ *See* Peten EP et al ..... 45:S-48
Strohmaier WL *See* Erley CM et al ..... 1425
Strom JA *See* Pereira BJG et al ..... 890
Strom TB *See* Nickerson PW et al ..... 44:S-40
Strom TB *See* Yokoyama H et al ..... 1105
Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Hoek FJ, Arisz L: A prospective study of peritoneal transport in CAPD patients ..... 1739
Struthers AD *See* Sturrock NDC et al ..... 1203
Strutz F, Neilson EG: The role of lymphocytes in the progression of interstitial disease ..... 45:S-106
Stummvoll H-K *See* Koenig P et al ..... 1507
Sturgill BC *See* Paulsen EP et al ..... 1132
Sturrock NDC, Lang CC, Baylis PH, Struthers AD: Sequential effects of cyclosporine therapy on blood pressure, renal function and neurohormones ..... 1203
Suc J-M *See* Ader J-L et al ..... 1657
Suhocki P *See* Kovalik EC et al ..... 1177
Suki W *See* Truong LD et al ..... 201
Suleymanlar G *See* Shapiro JI et al ..... 45:S-100
Sullivan LP, Wallace DP, Grantham JJ: Coupling of cell volume and membrane potential changes to fluid secretion in a model of renal cysts ..... 1369
Sun MJ *See* Ding J et al ..... 1504
Sun MJ *See* Kalluri R et al ..... 721
Sun X, Kaysen GA: Albumin and transferrin synthesis are increased in H4 cells by serum from analbuminemic or nephrotic rats ..... 1381
Sundelin B *See* Friberg P et al ..... 485
Sunder-Plassmann G, Kapiotis S, Gasche C, Klaar U, Mai B: Functional characterization of cytokine autoantibodies in chronic renal failure patients ..... 1484
Suranyi M (abst) ..... 1265
Surveyor I (abst) ..... 1274, 1275
Suter PM (abst) ..... 1785
Svanborg C *See* Petersson C et al ..... 571
Sweeney A (abst) ..... 1273
Switzerland (abst) ..... 1788
Szabolcs MJ, Seigle R, Shanske S, Bonilla E, DiMauro S, D'Agati V: Mitochondrial DNA deletion: A cause of chronic tubulointerstitial nephropathy ..... 1388

T

THeng Pan (abst) ..... 1261
Tabor B (abst) ..... 1253
Tack I *See* Ader J-L et al ..... 1657
Takamiya M *See* Imanishi M et al ..... 1170
Takeda T *See* Kohno M et al ..... 137
Takkinen R (abst) ..... 1783
Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M: TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy ..... 525
Tan M-MTT *See* Ureña P et al ..... 605
Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms ..... 537
Tang WW, Feng L, Xia Y, Wilson CB: Extracellular matrix accumulation in immune-mediated tubulointerstitial injury ..... 1077
Tange M (abst) ..... 1267
Tannen RL *See* Nissim I et al ..... 1014
Tavares J (abst) ..... 286
Tay CY (abst) ..... 1271
Tay YC (abst) ..... 1255, 1277

Tay Y-C *See* Nankivell BJ et al ..... 1006
Taylor GM *See* Jansen A et al ..... 1215
Tenschert S *See* Kriz W et al ..... 45:S-64
Terada Y *See* Otsuka M et al ..... 1340
Terada Y *See* Shinohara M et al ..... 1362
Tervaert JWC *See* Brouwer E et al ..... 1120
Tesch GH (abst) ..... 1271, 1272
Thatcher B (abst) ..... 1274
Thatcher G (abst) ..... 1263, 1264
Thatcher GN (abst) ..... 1259
Thiel G (abst) ..... 1784, 1786, 1788, 1788, 1790, 1792, 1793, 1793, 1793
Thomas A (abst) ..... 1269
Thomas DM, Coles GA, Williams JD: What does the renal reserve mean? ..... 411
Thomas M (abst) ..... 1263, 1274, 1275
Thomas MAB (abst) ..... 1259
Thomson N (abst) ..... 1264
Thomson NM (abst) ..... 1256
Thonney M (abst) ..... 1789
Thorniley MS, Lane NJ, Manek S, Green CJ: Non-invasive measurement of respiratory chain dysfunction following hypothermic renal storage and transplantation ..... 1489
Tiercy J-M (abst) ..... 1792
Tiller D (abst) ..... 1264
Tiller DJ (abst) ..... 1258, 1258
Timpl R *See* Nerlich AG et al ..... 1648
Ting RH, Kristal B, Myers BD: The biophysical basis of hypofiltration in nephrotic humans with membranous nephropathy ..... 390
Tipping PG (abst) ..... 1256, 1260, 1260, 1260
Tisher CC: Report of the Treasurer, 1990–1993 ..... 44:S-123
Tizianello A *See* Garibotto G et al ..... 1432
Tjalma W *See* D'Haese PC et al ..... 76
Togni M (abst) ..... 1789
Tom K *See* Pollard TA et al ..... 232
Tomino Y *See* Nakamura T et al ..... 1593
Tomita K *See* Otsuka M et al ..... 1340
Tomita K *See* Shinohara M et al ..... 1362
Tonkin J (abst) ..... 1274
Tönshoff B, Edén S, Weiser E, Carlsson B, Robinson ICAF, Blum WF, Mehls O: Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia ..... 1085
Tonshoff B *See* Tsukahara H et al ..... 598
Topley N *See* Wheeler DC et al ..... 1628
Tornero F *See* Fontanellas A et al ..... 220
Torok-Storb B *See* Ryan MJ et al ..... 48
Torres VE, Keith DS, Offord KP, Kon SP, Wilson DM: Renal ammonia in autosomal dominant polycystic kidney disease ..... 1745
Tracey R (abst) ..... 1263
Tran-Van T *See* Ader J-L et al ..... 1657
Trinder D (abst) ..... 1275
Trinidad P *See* Bover J et al ..... 953
Trump BF *See* Yamamoto N et al ..... 1093
Truong LD, Pindur J, Barrios R, D'Agati V, Lechago J, Suki W, Majesky M: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions ..... 201
Tryggvason K *See* Kestilä M et al ..... 986
Tsai P *See* Caramelo C et al ..... 66
Tsuchida A *See* Hiromura K et al ..... 1572
Tsukada Y *See* Hiromura K et al ..... 1572
Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS: Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells ..... 598
Turenne MN *See* Held PJ et al ..... 1163
Turner MC *See* Cohen AH et al ..... 1407

U

Uccello F *See* Sabbatini M et al ..... 1355
Uciechowski P *See* Radeke HH et al ..... 763
Ueda N, Guidet B, Shah SV: Measurement of intracellular generation of hydrogen peroxide by rat glomeruli *in vitro* ..... 788
Uehlinger DE (abst) ..... 1790
Uiker S *See* Kriz W et al ..... 45:S-64
Ujiie K *See* Shinohara M et al ..... 1362
Umlauft F *See* Koenig P et al ..... 1507
Ureña P, Kubrusly M, Mannstadt M, Hruby M, Tan M-MTT, Silve C, Lacour B, Abou-Samra A-B, Segre GV, Drüeke T: The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure ..... 605
Uriel B (abst) ..... 291
Uriu K, Kaizu K, Hashimoto O, Komine N, Etoh S: Acute and chronic effects of thromboxane $A_2$ inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats ..... 794
Uttley L *See* Harty JC et al ..... 103

V

Vale JM (abst) ..... 286
Vallance P *See* MacAllister RJ et al ..... 737
Van Cutsem J *See* Boelaert JR et al ..... 667
Van Damme BJC *See* Laurens WEAA et al ..... 143
Van Der Biest I, Nouwen EJ, Van Dromme SA, De Broe ME: Characterization of pure proximal and heterogeneous distal human tubular cells in culture ..... 85
Van Dromme SA *See* Van Der Biest I et al ..... 85
van Goor H *See* Brouwer E et al ..... 1120
Van Huysse J *See* Lingrel JB et al ..... 44:S-32
van Renen M (abst) ..... 1273, 1274
van Ypersele de Strihou C *See* Cosyns J-P et al ..... 1680
van Ypersele de Strihou C *See* Goffin E et al ..... 551
van Ypersele de Strihou C *See* Kabanda A et al ..... 1689
Vaneerdeweg W *See* D'Haese PC et al ..... 76
Vanholder RC, Camez AA, Veys NM, Soria J, Mirshahi M, Soria C, Ringoir S: Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis ..... 1754
Vanrenterghem Y *See* Verresen L et al ..... 1497
Vanrenterghem YFC *See* Laurens WEAA et al ..... 143
Vassalli J-D *See* Moll S et al ..... 500
Vaughan EM *See* Austin HA III et al ..... 544
Vehaskari M *See* Morrissey JJ et al ..... 998
Veldhuis JD *See* Schaefer F et al ..... 1465
Venning MC *See* Harty JC et al ..... 103
Vereleen-Dumoulin C *See* Chauveau D et al ..... 1140
Vernier RL *See* Paulsen EP et al ..... 1132
Verpooten GA *See* D'Haese PC et al ..... 76
Verresen L, Fink E, Lemke H-D, Vanrenterghem Y: Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes ..... 1497
Versaggi JA *See* Lebovitz HE et al ..... 45:S-150
Veys NM *See* Vanholder RC et al ..... 1754
Viberti GC: Outcome variables in the assessment of progression of diabetic kidney disease ..... 45:S-121
Viberti GC *See* Earle K et al ..... 434

Vila Lobos A (abst) ..... 284, 284, 285, 290
Vila-Lobos A (abst) ..... 290
Vilarinho A (abst) ..... 289
Villiger L (abst) ..... 1785
Vinhas J (abst) ..... 285, 285
Vishwanath B (abst) ..... 1789
Vogel G (abst) ..... 1787, 1790
Vogel W *See* Koenig P et al ..... 1507
Vogt A *See* Morioka T et al ..... 991
von Albertini B (abst) ..... 1793
von der Ohe J *See* Radeke HH et al ..... 763
von Grünigen Ch (abst) ..... 1784
Vonlanthen M (abst) ..... 1791

W
Wagner J *See* Ritz E et al ..... 438
Walder E (abst) ..... 1787
Walker AM (abst) ..... 1256
Walker R (abst) ..... 1278
Walker RG (abst) ..... 1264, 1265
Walker RJ (abst) ..... 1270, 1277
Wall D (abst) ..... 1264, 1264
Wallace DP *See* Sullivan LP et al ..... 1369
Wang BZ (abst) ..... 1255
Wang MX (abst) ..... 1269, 1270, 1277
Wang S *See* Pimentel JL Jr. et al ..... 1614
Wang T *See* Capasso G et al ..... 1543
Wardener HE: Acceptance of the 1993 Jean Hamburger Award ..... 44:S-115
Warr K (abst) ..... 1263, 1274, 1275
Warr KJ (abst) ..... 1259
Warram JH *See* Krolewski AS et al ..... 45:S-125
Waugh D (abst) ..... 1253
Waugh DA *See* Pollock CA et al ..... 897
Wauters JP (abst) ..... 1786, 1787, 1790
Webb K (abst) ..... 1267
Weber M *See* Kalluri R et al ..... 721
Wee PM, Donker AJM: Pharmacologic manipulation of glomerular function ..... 417
Weening JJ *See* Brouwer E et al ..... 1120
Wegmann W (abst) ..... 1790
Weinreich T *See* Ritz E et al ..... 438
Weisberg LS, Kurnik PB, Kurnik BRC: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus ..... 259
Weiser E *See* Tönshoff B et al ..... 1085
Weiss RM *See* Smith SD et al ..... 586
Wellard RM (abst) ..... 1255
Welsch C *See* Michel B et al ..... 1587
Welsh JE *See* Gagnon AM et al ..... 95
Werner U (abst) ..... 1271
Westhuyzen J (abst) ..... 1263, 1274
Westwood B (abst) ..... 1270
Weyrer K *See* Koenig P et al ..... 1507
Wheeler DC, Chana RS, Topley N, Peterson MM, Davies M, Williams JD: Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury ..... 1628
Wheeler MA *See* Smith SD et al ..... 586
Whitby M (abst) ..... 1265
Whitley GSJ *See* MacAllister RJ et al ..... 737
Whitworth JA (abst) ..... 1269, 1270, 1277
Whitworth JA *See* Becker GJ et al ..... 45:S-167
Wickman A *See* Friberg P et al ..... 485
Wicks ACB *See* Harper SJ et al ..... 836
Wiegmann TB *See* Lebovitz HE et al ..... 45:S-150
Wiest I *See* Nerlich AG et al ..... 1648
Wigg N (abst) ..... 1274
Will EJ (abst) ..... 1263, 1272, 1274
Williams JD, Coles GA: Proteinuria—A direct cause of renal morbidity? ..... 443
Williams JD *See* Coles GA et al ..... 299
Williams JD *See* Donovan KL et al ..... 1555
Williams JD *See* Thomas DM et al ..... 411
Williams JD *See* Wheeler DC et al ..... 1628
Williams RR, Hunt SC, Hopkins PN, Hasstedt SJ, Wu LL, Lalouel JM: Tabulations and expectations regarding the genetics of human hypertension ..... 44:S-57
Wilson CB *See* Tang WW et al ..... 1077
Wilson DM *See* Torres VE et al ..... 1745
Wilson HM *See* Brown PAJ et al ..... 43
Winters CJ, Reeves WB, Andreoli TE: $Cl^-$ channels in basolateral renal medullary vesicles VIII. Partial purification and functional reconstitution of basolateral mTAL $Cl^-$ channels ..... 803
Wise MG *See* Jannett TC et al ..... 912
Wishaw J (abst) ..... 1259
Wittke H (abst) ..... 1791
Woitas R *See* Morioka T et al ..... 991
Wolfe RA *See* Held PJ et al ..... 1163
Wolfe RA *See* Young EW et al ..... 907
Wong W (abst) ..... 1264, 1273
Woodroffe A (abst) ..... 1269
Woolfield N (abst) ..... 1270
Wu LL (abst) ..... 1266
Wu LL *See* Williams RR et al ..... 44:S-57
Wu V-Y *See* Cohen MP et al ..... 1673
Wüthrich R (abst) ..... 1785
Wyndham R (abst) ..... 1253
Wyndham R *See* Pollock CA et al ..... 897

X
Xavier AF (abst) ..... 287, 287
Xavier B (abst) ..... 288
Xavier E (abst) ..... 282, 286, 286, 287, 287
Xavier P (abst) ..... 285
Xia Y *See* Tang WW et al ..... 1077

Y
Yamamoto N, Smith MW, Maki A, Berezesky IK, Trump BF: Role of cytosolic $Ca^{2+}$ and protein kinases in the induction of the *hsp70* gene ..... 1093
Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-$\beta$1 underlies development of progressive kidney fibrosis ..... 916
Yan HD (abst) ..... 1273
Yandle TG (abst) ..... 1276
Yang C-W *See* Peten EP et al ..... 45:S-48
Yang T *See* Otsuka M et al ..... 1340
Yano M *See* Imanishi M et al ..... 1170
Yano S *See* Hiromura K et al ..... 1572
Yasuda T *See* Harris RC et al ..... 45:S-17
Yates J *See* Reyes AA et al ..... 782
Yohay DA *See* Quarles LD et al ..... 1710
Yokokawa K *See* Kohno M et al ..... 137
Yokoyama H, Zheng X, Strom TB, Kelley VR: $B7^+$-transfectant tubular epithelial cells induce T cell anergy, ignorance or proliferation ..... 1105
Yong LC (abst) ..... 1267
Yoshida H *See* Yoshioka T et al ..... 211

Yoshioka T, Kawamura T, Meyrick BO, Beckman JK, Hoover RL, Yoshida H, Ichikawa I: Induction of manganese superoxide dismutase by glucocorticoids in glomerular cells ..... 211
Yoshioka T *See* Ichikawa I et al ..... 1
Yoshioka T *See* Tanaka R et al ..... 537
Yoshitomi K *See* Ikeda M et al ..... 811
Young BA *See* Eng E et al ..... 45:S-45
Young EW, Mauger EA, Jiang K-H, Port FK, Wolfe RA: Socioeconomic status and end-stage renal disease in the United States ..... 907
Young VR *See* Masud T et al ..... 1182
Yui MA *See* Kelley VR et al ..... 45:S-83

Z
Zabko-Potapovich B *See* Albrightson CR et al ..... 1301
Zager RA, Iwata M, Burkhart KM, Schimpf BA: Post-ischemic acute renal failure protects proximal tubules from $O_2$ deprivation injury, possibly by inducing uremia ..... 1760
Zager RA *See* Ryan MJ et al ..... 48
Zammit VC (abst) ..... 1277
Zarama M (abst) ..... 1272
Zaruba J (abst) ..... 1785
Zatz R, Fujihara CK: Glomerular hypertrophy and progressive glomerulopathy. Is there a definite pathogenetic correlation? ..... 45:S-27
Zehnder C (abst) ..... 1786
Zeiler M (abst) ..... 1788, 1788, 1790, 1792
Zhang GY (abst) ..... 1269
Zhang Y (abst) ..... 1254, 1260
Zhang Y-B, Smogorzewski M, Ni Z, Massry SG: Altered cytosolic calcium homeostasis in rat cardiac myocytes in CRF ..... 1113
Zhao X *See* Cortes P et al ..... 45:S-11
Zheng X *See* Yokoyama H et al ..... 1105
Zhu D, Kim Y, Steffes MW, Groppoli TJ, Butkowski RJ, Mauer SM: Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry ..... 425
Zhuo J (abst) ..... 1254
Ziyadeh FN *See* Bleyer AJ et al ..... 659
Ziyadeh FN *See* Cohen MP et al ..... 475
Zoja C *See* Remuzzi G et al ..... 44:S-8
Zou J-N *See* Nath KA et al ..... 166
Zózimo N (abst) ..... 286, 288, 288
Zucker K *See* Roth D et al ..... 238
Zürcher R (abst) ..... 1788
Zürcher RM (abst) ..... 1793

# Subject Index For Volume 45


A
Aboriginal renal failure (abst) ..... 1274
Acetate dialysis, compared to bicarbonate (abst)... 283, 1784
Acidification in cortical distal tubule ..... 1543
Acidosis alters ammoniagenesis, LLC-PK$_1$ cells ..... 1014
Acute renal failure
  atrial natriuretic peptide..... 1730
  biopsy assessment, transplantation..... 44:S-65
  clinical studies (abst)..... 284
  contrast media-induced, theophylline ..... 1425
  dichromate, thyroid hormone, EGF ..... 1622
  graft rejection, steroid-resistant nephroses ..... 1440
  IGF-1, body growth, rat (abst) ..... 1277
  mixed cryoglobulinemia, interferon $\alpha$2a (abst) ..... 1790
  pathophysiology..... 1355
  tubular protection, ischemic injury, uremia ..... 1759
Adenocarcinoma, renal..... 23
Adenoviral-mediated gene transfer, renal tubular cells .. 1220
Adhesion molecule expression, deoxyspergualin (abst).. 1257
Adriamycin nephropathy..... 525
AIDS, renal opportunistic infection (abst) ..... 287
Albumin
  excretion, DM, antihypertensive agents (abst)..... 1270
  excretion, pregnancy (abst)..... 1269
  glycated, diabetic nephropathy ..... 1673
  transferrin synthesis..... 1381
  tubular catabolism, inflammatory lipid release ..... 1697
Albuminuria
  ambulatory BP, type 1 diabetes ..... 45:S-134
  enalapril, hypertensive NIDDM ..... 45:S-150
  reduction, diabetic nephropathy ..... 45:S-145
Allografts
  elderly as donors (abst)..... 1265
  hepatitis C virus..... 238
  mesangial IgA deposits, recurrence (abst) ..... 1269
  prednisolone withdrawal, children (abst) ..... 1264
  rejection, T cell receptor gene expression (abst) ..... 1254
  rejection, T cells in autoimmunity ..... 44:S-50
  tolerance ..... 44:S-40
  vascular thrombosis (abst)..... 1254
Alport syndrome
  $\alpha$5 chain, collagen type IV..... 1504
  anti-$\alpha$3 alloantibodies, collagen type IV ..... 721
Aluminoxamine kinetics ..... 76
Aluminum alters Fe metabolism in Friend cells..... 636
Amadori glucose adducts, mesangial cell biology ..... 475
Ambulatory blood pressure
  24-hour monitoring, circadian rhythms (abst)..... 1791
  24-hour monitoring (abst) ..... 284
  type 1 diabetes, albuminuria ..... 45:S-134
Amino acids
  ketoacids, very low protein diet ..... 1182
  pharmacology, glomerular function..... 417
  transport systems..... 110
Aminoglycoside effects, urine and glycine betaine (abst)..... 1256
Ammoniagenesis, renal pathways..... 1014
Amyloid nephropathy, Muckle-Wells syndrome (abst) ... 282
Amyloidosis, familial (abst)..... 287
AN69 membranes, anaphylaxis, bradykinin..... 1497
Analgesic nephropathy ..... 1785
Anaphylaxis, HD with AN69 membranes, bradykinin... 1497
ANCA-positive glomerulonephritis (abst)..... 1790
Anemia
  HD, intravenous iron (abst)..... 285
  immunopotentiation by RBC, uremia, cytokines ..... 224
Aneurysms, intracranial, in ADPKD ..... 1140
Angioaccess catheter sepsis (abst) ..... 282
Angioplasty, central venous stenoses..... 1177
Angiotensin converting enzyme (ACE)
  dietary protein, uninephrectomy, rat..... 1587
  in kidneys, diabetic and hypertensive rats (abst) ..... 1268
Angiotensin converting enzyme (ACE) inhibition
  Ang II antagonism, antiproteinuric effects ..... 861
  diabetic nephropathy..... 45:S-156, 45:S-161
  glomerular function, PAN..... 537
  glomerular function, pharmacology..... 417
  renal abnormalities and..... 485
  renal cystic disease (abst) ..... 1266
Angiotensin II
  antagonism, renal abnormalities ..... 485
  binding to AT$_1$ receptors..... 177
  bradykinin, PAN ..... 537
  NO synthesis inhibition (abst)..... 1255
  tubulointerstitial nephritis, osteopontin..... 515
Angiotensin II receptor
  gene regulation, ureteral obstruction..... 1614
  glomerular, diabetic nephropathy (abst) ..... 1276
Anti-GBM glomerulonephritis
  $\beta_2$ integrin molecules, neutrophil accumulation (abst) . 1256
  crescentic (abst)..... 1260
  ICAM-1, interstitial leukocytes..... 32
  ICAM-1/LFA-1 interaction ..... 700
  T helper/suppressor cells, injury (abst)..... 1260
Anti-neutrophil proteinase 3 antibodies, ELISA (abst) .. 1257
Anti-platelet therapy, graft thrombosis..... 1477
Anti-Thy-1 nephritis, tubulointerstitial injury (abst)..... 1272
Anti-TNF antibody, MC proliferation (abst) ..... 1783
Antibodies
  IL-6, pyelonephritis, pregnancy ..... 571
  neutrophil cytoplasm antigen (abst)..... 1257
Anticoagulation
  continuous veno-venous hemofiltration (abst)..... 1784
  during HD ..... 912
  hirudin, thrombin inhibition, HD..... 1753
  oral prophylactic, nephrotic patients..... 578
  prothrombin changes, heparin, HD (abst)..... 1784
Antidiuresis, cyclosporine induced..... 1203
Antihypertensive therapy
  antiproteinuric response, GFR decline ..... 45:S-174
  microalbuminuria, essential hypertension..... 45:S-171
  microalbuminuria, normotensive, DM (abst) ..... 1270
Antioxidants, PAN, glomerular morphology (abst) ..... 1271
Antiplatelet therapy, rHuEPO, hypertension..... 845
Antiproteinuric response, GFR decline ..... 45:S-174
Antithymocyte globulin induction therapy (abst)..... 288

Arginine vasopressin (AVP)
EGF antagonizes ... 1028
interaction, EGF (abst) ... 1262
nonpeptide orally active (abst) ... 1261
reduced oropharyngeal inhibition, elderly (abst) ... 1261
Arterial pressure, NO inhibition (abst) ... 1258
Arteriovenous fistulae, MRI measures flow ... 884
Aspirin
renal function, rabbits (abst) ... 1785
renography ... 1170
$AT_1$ receptors, Ang II binding ... 177
Atherosclerosis, LDL oxidation, uremia ... 876
Atomic absorption analysis, tubular fluid electrolytes ... 1211
Atrial natriuretic factor receptor (abst) ... 1259
Atrial natriuretic peptide (ANP)
clinical ARF ... 1730
hyperosmolality, stimulated cGMP ... 1362
inhibits $Na^+/H^+$ antiporter, VSMC ... 66
proximal tubular intracellular electrolytes (abst) ... 1260
Autoimmunity
allograft rejection ... 44:S-50
glomerular injury, T cell activation ... 44:S-8
Autosomal dominant polycystic kidney disease (ADPKD)
anticipation, evidence for ... 1153
intracranial aneurysms ... 1140
renal ammonia ... 1744
Autosomal dominant primary hyperoxaluria (abst) ... 1782
Avascular osteonecrosis, transplantation (abst) ... 290
Azathioprine (abst) ... 1264
Azobenzenearsonate induced acute nephritis ... 1044

B
$\beta_2$ microglobulin, vesico-ureteric reflux (abst) ... 1273
Balkan endemic nephropathy ... 1680
Bartter's syndrome, mental development (abst) ... 290
$\beta_2$ integrin, neutrophil accumulation, anti-GBM GN (abst) ... 1256
Bicarbonate dialysis, compared to acetate (abst) ... 283, 1784
Bilateral ureteral obstruction ... 1346
Biliary excretion, aluminoxamine/ferrioxamine ... 76
Biochemical markers of bone disease, children ... 253
Bioimpedance, circulatory evaluation (abst) ... 1788
Bioincompatibility perspectives ... 1993, 44:S-77
Biopsy
cell proliferation, post-transplant (abst) ... 285
estimating glomerular number, MRI and ... 1668
macroscopic hematuria after (abst) ... 286
nephropathology diagnosis (abst) ... 284
pathology, implantation graft (abst) ... 1278
percutaneous (abst) ... 288
percutaneous techniques compared (abst) ... 1789
skin, nephropathology diagnosis (abst) ... 284
techniques compared (abst) ... 1258
Trucut needle and Biopty gun (abst) ... 1267
Blood flow properties, IgA nephropathy (abst) ... 1266
Blood pressure
ambulatory, 24-hour monitoring (abst) ... 284, 1791
ambulatory, type 1 diabetes, albuminuria ... 45:S-134
cyclosporin induced antidiuresis ... 1203
pre/post-dialytic, mean interdialytic (abst) ... 286
rHuEPO, intracellular calcium, uremia (abst) ... 1268
Blood viscosity, diabetic nephropathy (abst) ... 1273
Blood volume measurement
evaluation with bioimpedance, HD (abst) ... 1788
noninvasive, HD (abst) ... 1262
Bone disease, renal
biochemical markers, children ... 253
osteocalcin as marker (abst) ... 1785
Bone marrow transplantation, renal transplant after ... 1791
Bone mineral density (BMD)
calcitriol, ESRD ... 245
calcitriol, HD (abst) ... 1786
BQ-123, renal effects ... 131
Bradykinin, anaphylaxis, AN69 membranes ... 1497
Brain lesions, excessive correction of hyponatremia ... 193
Bronchiolitis obliterans/organizing pneumonia (abst) ... 1790
Brush border membranes, urate transporters ... 727

C
C4 null phenotype, IgA nephropathy (abst) ... 1259
C9, 254 mAb detects neoepitope (abst) ... 1266
$Ca^{2+}$
cardiac monocytes and CRF ... 1113
cellular, luminal $V_1$-receptor, collecting duct ... 811
protein kinases, *hsp70* gene induction ... 1093
transport, calbindin 9K ... 469
transport, calbindin 28K ... 461
Calbindin 9K, $Ca^{2+}$ transport ... 469
Calbindin 28K, $Ca^{2+}$ transport ... 461
Calbindin D-28K, vitamin D ... 95
Calcitonin, endogenous, rat renal function (abst) ... 1255
Calcitriol
bone mineral density, ESRD ... 245
degradative enzymes, renal failure ... 509
protein intake, idiopathic calcium stones (abst) ... 1784
receptor regulation, mRNA, RF ... 1020
Calcitriol therapy
bone mineral density, HD (abst) ... 1786
oral, HD, children (abst) ... 1264
oral, IV, hyperparathyroidism, ESRD ... 1710
secondary hyperparathyroidism (abst) ... 1789
Calcium
homeostasis and the kidney ... 44:S-97
hypertonicity-stimulated urea transport (abst) ... 1254
intracellular, insulin, MC function ... 1318
intracellular, Na/H exchange, essential hypertension ... 1037
intracellular, rHuEPO, hypertension, uremia (abst) ... 1268
oral, suppresses PTH, mild CRF (abst) ... 1275
renal content, hypercalciuria ... 58
streptomycin alters free transients (abst) ... 1277
Calcium antagonists, pharmacology, glomerular function ... 417
Calcium nephrolithiasis, idiopathic (abst) ... 1782
Calcium oxalate stones, prognosis ... 1721
Calcium reabsorption, vitamin $D_3$
effect of CaBP 9K ... 469
effect of CaBP 28K ... 461
Calcium renal stones
calcitriol, protein intake (abst) ... 1784
prognosis ... 1721
Cancer, renal, retinoic acid, cell growth ... 23
Capillary wall distension, counteraction by podocytes ... 369
Cardiac function, fractional shortening, HD (abst) ... 285
Cardiac monocytes, $Ca^{2+}$, and CRF ... 1113
Cardiac surgery, tubular nephrotoxicity (abst) ... 1274
Cardiovascular disease, smoking, transplantation (abst) ... 1263
Carpal tunnel syndrome, HD (abst) ... 284
Catheterization, subclavian occlusion after (abst) ... 286
Catheters, temporary angioaccess, sepsis (abst) ... 282
CD45 isoforms, post-transplant (abst) ... 283

Cell-mediated immune injury ..... 1044
Central venous stenoses, PTA and vascular Wallstents.. 1177
cGMP
  inhibits $Na^+/H^+$ antiporter, VSMC ..... 66
  stimulated, hyperosmolality of ANP..... 1362
Chelators, mucormycosis, deferoxamine therapy ..... 667
Children
  catch-up growth, renal tubular acidosis (abst) ..... 1782
  chronic renal failure (abst)..... 290
  diabetes, juxtaglomerular body abnormalities..... 1132
  growth hormone, dietary therapy, CRF (abst) ..... 1273
  high dose oral calcitriol, HD (abst)..... 1264
  lupus nephritis, cyclophosphamide therapy (abst) ..... 289
  osteodystrophy biochemical markers ..... 253
  prednisolone withdrawal (abst) ..... 1264
  pyelonephritis, dimercaptosuccinic acid scan (abst)... 1790
  transplantation (abst) ..... 282, 290, 1264
  urolithiasis (abst) ..... 1790
  vesico-ureteric reflux (abst)..... 1273
Chinese herbs nephropathy..... 1680
Cholesterol synthesis inhibitors ..... 45:S-51
Chronic ambulatory peritoneal dialysis (CAPD)
  early discharge program (abst) ..... 1259
  plasma cytokines, inhibitors ..... 890
Chronic renal failure
  calcitriol, bone mineral density..... 245
  cardiac monocytes and $Ca^{2+}$..... 1113
  children (abst) ..... 290
  cytokine autoantibodies..... 1484
  decreased LDL clearance, uremia ..... 561
  glycine betaine, sorbitol, DM (abst) ..... 1267
  growth, GH and IGF-1 therapy (abst)..... 1275
  *Helicobacter Pylori*, HD (abst)..... 283
  low protein-normal Na diet..... 852
  luteinizing hormone, pubertal patients ..... 1465
  lysosomal iron accumulation (abst)..... 1268
  mild, oral calcium suppresses PTH (abst)..... 1275
  mild, serum and urinary ET-1 (abst)..... 1274
  muscle protein turnover..... 1432
  non-diabetic, prevention of progression ..... 45:S-167
  plasma cytokines and inhibitors ..... 890
  PTH/PTHrP receptor down-regulation ..... 605
  renin-angiotensin system..... 403
Circadian blood pressure, monitoring, post-transplant (abst)..... 1791
Circulatory investigations, HD (abst)..... 1788
Cirrhosis
  acute saline loading response (abst) ..... 1276
  vasoactive intestinal peptide antagonist (abst) ..... 1261
$Cl^-$ channels, basolateral renal medullary vesicles ..... 803
Clusterin depletion
  experimental nephritis..... 817
  perfused plasma, immune glomerular injury (abst).... 1278
Clusterin expression in human renal diseases ..... 828
Cognitive functions, PTH, HD (abst)..... 291
COL4A5 gene deletion, Alport syndrome ..... 721
Collagen
  gene expression, MC growth..... 475
  polyol pathway mediates synthesis, DM..... 659
Collagen type IV
  Alport syndrome ..... 721, 1504
  distribution in IDDM..... 425
  enalapril reduces synthesis ..... 1637
Collagen type VI, diabetic glomeruli ..... 1648
Collagenase type IV, MC synthesis (abst) ..... 1782
Collapsing glomerulopathy ..... 1416
Collecting ducts
  Ca mediated hypertonicity, urea transport (abst)..... 1254
  octopal cells, EGF, TGF-$\alpha$ ..... 1510
Colony stimulating factor-1, lupus nephritis ..... 45:S-83
Complement activation
  mAb 254 detects neoepitope on C9 (abst)..... 1266
  proximal tubular epithelial cells ..... 451
Congenital nephrotic syndrome, Finnish type ..... 986
Continuous ambulatory peritoneal dialysis (CAPD)
  children, bone disease biochemical markers..... 253
  glucose oxidation, peritoneal/oral glucose load..... 1147
  heme biosynthesis, uremia ..... 220
  insufficient vitamin B1 and B6 (abst)..... 1786
  lipid profile (abst)..... 291
  normalized PCR as nutrition marker..... 103
  patient mortality..... 1163
  peritoneal access (abst)..... 287
  peritoneal transport study ..... 1738
Continuous veno-venous hemofiltration (abst)..... 1784
Coronary angiography, post-transplant (abst)..... 1258
Cortical collecting duct
  $Ca^{2+}$ response, luminal vasopressin ..... 811
  metabolic support of $Na^+$ transport ..... 743
Cortical distal tubule, acidification ..... 1543
Creatinine
  serum, GFR recovery after CsA (abst)..... 1787
  serum, renal EGF, dichromate effect ..... 1622
Crescentic glomerulonephritis
  delayed type hypersensitivity (abst) ..... 1260
  multinucleated giant cells (abst) ..... 1260
Cryoglobulinemia, ARF, interferon $\alpha$2a (abst)..... 1790
Cryoglobulins, IgG3 anti-TNP monoclonal, glomerulopathy ..... 962
Cuprophan membranes increase phospholipase $A_2$ (abst)..... 1788
Cyclooxygenase 2, IL-1, CsA, rat MC..... 150
Cyclophilin localization in the kidney..... 1340
Cyclophosphamide, lupus nephritis, children (abst)..... 289
Cyclosporin
  BQ-123 effects, renal dysfunction..... 131
  compared to prednisolone, azathioprine (abst)..... 1264
  renal functional reserve, transplantation..... 1657
  steroid dependent nephrotic syndrome (abst)..... 1267
Cyclosporin A
  GFR, hyperuricemia (abst) ..... 1792
  GFR recovery, serum creatinine (abst)..... 1787
  inhibits IL-1-induced COX2 expression ..... 150
  long-term benefits/risks (abst) ..... 1792
  long-term renal tolerance..... 1446
  nephrotoxicity, dopamine excretion (abst) ..... 290
  pharmacokinetics, compared CsG..... 684
Cyclosporine
  induces antidiuresis ..... 1203
  induction therapy, transplantation (abst) ..... 288
  modulation of endothelin..... 592
  pharmacokinetics, pre-transplant (abst) ..... 286
  pharmacology, glomerular function..... 417
Cystic disease, renal, ACE inhibition (abst)..... 1266
Cystinosis, diagnosis (abst)..... 1269
Cystitis, women, lomefloxacin, trimethoprim (abst)..... 1267
Cytokines
  autoantibodies, CRF ..... 1484
  immunopotentiation by RBC, anemia, uremia ..... 224
  induce leukemia inhibitory factor, MC ..... 1562

induction in high-flux HD (abst) ..... 291
inhibit mesangial cell proliferation ..... 159
specific inhibitors, CRF, CAPD, HD ..... 890
Cytosolic calcium
altered homeostasis, cardiac monocytes, CRF ..... 1113
protein kinases, *hsp70* gene induction ..... 1093

D
de Wardener, Hugh E. ..... 44:S-114, 44:S-115
Decidual capillary endothelial cells (abst) ..... 1278
Deferoxamine therapy, *Rhizopus* pathogenicity ..... 667
Dementia of HD, PTH, cognitive functions (abst) ..... 291
Deoxyspergualin
does not inhibit monokine induction (abst) ..... 1257
effects, rat MC (abst) ..... 1271
suppresses adhesion molecule expression (abst) ..... 1257
suppresses ICAM-1, GN (abst) ..... 1272
Desferrioxamine, reduces tubular damage (abst) ..... 1277
Diabetes
ACE in kidneys, hypertension (abst) ..... 1268
ambulatory BP, albuminuria ..... 45:S-134
elevated collagen VI in glomeruli ..... 1648
fish oil supplements, renal function (abst) ..... 287
LDL influence, glomerular prostaglandins (abst) ..... 1258
microalbuminuria, antihypertensive agents (abst) ..... 1270
renal function, uninephrectomy (abst) ..... 287
youth-onset, juxtaglomerular body abnormalities ..... 1132
Diabetes mellitus
ACE inhibition, nephropathy ..... 45:S-161
glomerular distribution, type IV collagen ..... 425
glycine betaine, sorbitol, CRF (abst) ..... 1267
radiocontrast nephropathy ..... 259
regulation, vasopressin receptors (abst) ..... 1275
thromboxane $A_2$ inhibition, renal hemodynamics ..... 794
Diabetic nephropathy
ACE inhibition ..... 45:S-156, 45:S-161
clinical experience, treatment ..... 45:S-165
enalapril, long-term treatment ..... 45:S-141
glomerular Ang II receptors (abst) ..... 1276
hypercholesterolemia, renal function ..... 45:S-125
localization ECM components (abst) ..... 1271
monoclonal antibody treatment ..... 1673
pathogenesis, blood viscosity (abst) ..... 1273
polyol pathway, collagen synthesis ..... 659
predisposition to ..... 434
progression, assessment ..... 45:S-121
progression, reduced albuminuria ..... 45:S-145
proximal tubular iron (abst) ..... 1271
structural, functional correlations, Nephrology Forum ..... 612
Dialysate, low calcium, PTH rise (abst) ..... 1253
Dialysis
disequilibrium syndrome ..... 629
immunological considerations, uremia ..... 44:S-92
metastatic endophthalmitis (abst) ..... 1262
mortality, dysautonomia predicts (abst) ..... 1274
mortality, high-flux, hypotension (abst) ..... 1789
neutropenia, neutrophil F-actin (abst) ..... 1253
peritoneal, Nephrology Forum ..... 1226
plasmapheresis, plasma flux (abst) ..... 289
PTH, molecule assays (abst) ..... 1262
thrombolysis, thrombosed access grafts ..... 1401
Dialyzer
clearance measurement accuracy, HD, K t/v (abst) ..... 1785
manual reprocessing, peracetic acid (abst) ..... 1262
reuse system, evaluation (abst) ..... 1788
Diastolic dysfunction, ventricular hypertrophy, EPO ..... 1275
Dichromate, serum creatinine, renal EGF ..... 1622
Dietary
fiber, idiopathic calcium nephrolithiasis (abst) ..... 1782
fish oil, DM, renal function (abst) ..... 287
protein, glomerular gene expression ..... 1593
protein, low, adaptation, RF ..... 1182
protein, low, normal Na in CRF ..... 852
protein, serum calcitriol, calcium stones (abst) ..... 1784
protein, tubular iron ..... 1006
protein, tubular iron (abst) ..... 1255
protein, uninephrectomy, ACE ..... 1587
Dimercaptosuccinic acid scan, pyelonephritis (abst) ..... 1790
Distal human tubular cells, characterization ..... 85
Diuresis
natriuresis with EGF (abst) ..... 1276
osmotic, before Homer W. Smith ..... 1241
Diuretics, loop, hypoxic damage, proximal tubules ..... 981
DNA
histone, DNA-anti-DNA immune complex ..... 991
oxidant-induced injury, pyruvate ..... 166
Donors, transplant, eligibility of elderly (abst) ..... 1265
Dopamine
pharmacology, glomerular function ..... 417
urinary excretion, CsA nephrotoxicity (abst) ..... 290
Duodenal J chain expression in IgAN ..... 836
Dysautonomia, predicts dialysis mortality (abst) ..... 1274

E
Efferent arterioles, glomerular PGs, vascular activity ..... 650
Eicosanoid biosynthesis and leukocyte adhesion ..... 45:S-90
Elastase, GBM degradation, ROS, neutrophils ..... 1555
Elderly as eligible transplant donors (abst) ..... 1265
Electrolytes, tubular fluid, absorption analysis ..... 1211
ELISA, anti-neutrophil proteinase 3 antibodies (abst) ..... 1257
Enalapril
long-term treatment, diabetic nephropathy ..... 45:S-141
reduces interstitial fibrosis ..... 1637
renal effects in hypertensive IDDM ..... 45:S-150
End-stage renal disease (ESRD)
calcitriol, bone mineral density ..... 245
calcitriol, hyperparathyroidism ..... 1710
EPO therapy, lipid profile ..... 897
EPO therapy, lipid profile (abst) ..... 1253
incidence, cumulative rates (abst) ..... 1268
socioeconomic status, United States ..... 907
sotalol and (abst) ..... 1268
vocational rehabilitation, HD (abst) ..... 1792
Endophthalmitis, metastatic, HD (abst) ..... 1262
Endothelial cells
biology, glomerular ..... 314
decidual capillary, pregnancy (abst) ..... 1278
glomerular injury ..... 45:S-37
glomerular injury, lipopolysaccharide (abst) ..... 1783
IGF-1 induces NO production ..... 598
Endothelin
renal actions in disease ..... 336
urine, HD, transplantation (abst) ..... 1787
urine, normal/hypertensive pregnancy (abst) ..... 1270
Endothelin-1 (ET-1)
endotoxin, glomerular hemodynamic resistance (abst) ..... 1783
gene expression, pre-eclamptic placenta (abst) ..... 1265
heparin inhibits, mesangial cells ..... 137
hypoxemia, renal dysfunction (abst) ..... 1788

urinary and serum, mild CRF (abst) ..... 1274
urinary excretion, essential hypertension ..... 556
Endothelin site selective modulation, cyclosporine ..... 592
Endotoxin, glomerular resistance (abst) ..... 1783
Endpoints
in non-diabetic patients ..... 45:S-118
in progressive renal disease ..... 45:S-132
Energy metabolism, renal mass reduction ..... 45:S-100
Epidermal growth factor (EGF)
antagonizes AVP ..... 1028
anti-Thy-1 nephritis (abst) ..... 1272
arginine vasopressin (abst) ..... 1262
detection in GS (abst) ..... 1256
diuresis and natriuresis (abst) ..... 1276
renal, dichromate, RF, thyroid hormone ..... 1622
renal adenocarcinoma, retinoic acid ..... 23
TGF-$\alpha$, in human kidney ..... 1510
Epithelial cells
cultured renal, fluid secretion ..... 1369
escape from TGF-$\beta_1$ ..... 642
glomerular disease ..... 300
glomerular disease, progressive ..... 45:S-58
Erythrocyte complement receptors, nephritis ..... 493
Erythropoietin (EPO)
hepatitis B prophylaxis, HD (abst) ..... 289
hypertension, calcium, uremia (abst) ..... 1268
hypertension, NO pathway, uremia (abst) ..... 1266
lipid profile, ESRD ..... 897
lipid profile, ESRD (abst) ..... 1253
promise/facts ..... 44:S-70
subcutaneous, once/twice weekly, HD (abst) ..... 1263
subcutaneous, pharmacokinetics, dosage (abst) ..... 1263
subcutaneous/intravenous efficacy, HD (abst) ..... 284
ventricular hypertrophy, diastolic dysfunction (abst) .. 1275
Essential amino acids, ketoacids, protein intake, RF ... 1182
Essential hypertension
antihypertensive agents, microalbuminuria ..... 45:S-171
intracellular Ca, $Na^+/H^+$ exchanger ..... 1037
Exercise-induced reduction RBF, indomethacin (abst) .. 1270
Extracapillary proliferative glomerulonephritis, ANCA-positive (abst) ..... 1790
Extracellular matrix
accumulation, tubulointerstitial injury ..... 1077
diabetic nephropathy (abst) ..... 1271
expansion, glomerular disease ..... 45:S-45
glomerular ..... 328
Extracellular volume, expanded, uridine metabolism (abst) ..... 1265

F

Familial amyloidotic polyneuropathy (abst) ..... 287
Familial factors, diabetic nephropathy ..... 434
Fc$\alpha$ R expression, PMNL, superoxide generation, IgAN ..... 868
Ferrioxamine kinetics ..... 76
Fiber, dietary, calcium nephrolithiasis (abst) ..... 1782
Fibronectin biosynthesis, Ang II, $At_1$ receptors ..... 177
Fine-needle aspiration biopsy
cell proliferation, post-transplant (abst) ..... 285
subcutaneous fat, nephropathology diagnosis (abst) .... 284
Finnish type congenital nephrotic syndrome ..... 986
Fish oil, renal function, diabetes (abst) ..... 287
FK506 inhibits rat glomerular thrombosis ..... 1572
Fluid
deprivation, osmoprotectant response (abst) ..... 1277
secretion, cultured renal epithelium ..... 1369
Focal glomerulosclerosis
gene expression, low protein diet ..... 1593
segmental, collapsing glomerulopathy ..... 1416
segmental, single nephron model ..... 143
Folate supplementation, maintenance HD (abst) ..... 1263
Fractional shortening, cardiac evaluation, HD (abst) .... 285
Friend erythroleukemia cells, Al, Fe metabolism ..... 636

G

Galloway-Mowat syndrome ..... 1407
Gangliosides expression, developing/adult kidney ..... 123
Gene expression
focal GS, low protein diet ..... 1593
glomerulosclerosis ..... 45:S-48
Gene transfer
adenoviral-mediated, renal tubular cells ..... 1220
metalloproteinase transin into MC ..... 1580
Genetics
congenital nephrotic syndrome, Finnish ..... 986
hypertension ..... 44:S-57
Giebisch, Gerhard ..... 44:S-106, 44:S-110
Glomerular basement membrane
degradation, ROS, elastase, neutrophils ..... 1555
distension, podocytes counteract ..... 369
minimal change disease (abst) ..... 1256
Glomerular cells
glucocorticoid-induced Mn-SOD ..... 211
lipopolysaccharide, EC injury, MC contraction (abst) . 1783
*in vitro* versus *in vivo* ..... 360
Glomerular deposition, DNA-anti-DNA immune complex, histone ..... 991
Glomerular disease
extracellular matrix and MC expansion ..... 45:S-45
podocyte dysfunction ..... 300
progressive, epithelial cell injury ..... 45:S-58
Glomerular distribution, type IV collagen, IDDM ..... 425
Glomerular epithelial cells
injury, glomerulosclerosis ..... 45:S-58
urokinase-plasminogen activator synthesis ..... 43
Glomerular expansion and mesangial cell strain ..... 45:S-11
Glomerular extracellular matrix ..... 328
Glomerular filtration rate
cyclosporin A, hyperuricemia (abst) ..... 1792
long-term decline, antiproteinuric response ..... 45:S-174
recovery after CsA, plasma creatinine (abst) ..... 1787
reduction, contrast media, theophylline ..... 1425
renal functional reserve ..... 411
Glomerular function
endothelin, renal actions in disease ..... 336
loss of, tubulointerstitial fibrosis ..... 345
modulated by ACE inhibition, PAN ..... 537
pharmacologic manipulation ..... 417
renin-angiotensin system, CRF ..... 403
single nephron studies, human ..... 384
Glomerular gangliosides ..... 123
Glomerular gene expression, dietary protein, focal GS .. 1593
Glomerular hemodynamic resistance, endotoxin (abst) .. 1783
Glomerular hypertension
progression, versus systemic ..... 438
progressive glomerular injury ..... 45:S-6
Glomerular hypertrophy
progression ..... 45:S-30
progressive glomerulopathy ..... 45:S-27
Glomerular hypofiltration ..... 390
Glomerular injury
cellular mechanisms ..... 45:S-78

cellular mechanisms, metabolic factors ... 45:S-54, 45:S-56
clusterin depletion, perfused plasma ... 817
clusterin depletion, perfused plasma (abst) ... 1278
inflammation, macrophages in ... 945
leukocyte adhesion molecules ... 45:S-98
macrophages, role of ... 45:S-98
oxidants and proteases ... 352
proinflammatory mediators, T cell activation ... 44:S-8
promoted by MC oxidation of LDL ... 1628
response to, Nephrology Forum ... 1768
tumor necrosis factor alpha ... 45:S-32
vascular endothelial cell activation ... 45:S-37
Glomerular leukocytic accumulation, ICAM-1/LFA-1, anti-GBM GN ... 700
Glomerular macrophage phagocytosis ... 1326
Glomerular number from MRI and biopsy ... 1668
Glomerular permeability ... 398
Glomerular prostaglandins
afferent and efferent arterioles ... 650
production, lipoproteins, DM (abst) ... 1258
Glomerular sclerosis, podocyte role ... 45:S-64
Glomerular thrombosis
FK506, nephrotoxic serum, lipopolysaccharide ... 1572
NO role, pregnancy ... 775
Glomeruli
biology of, endothelial cells ... 314
diabetic, elevated collagen VI ... 1648
normal/pathologic, tenascin ... 201
normal/sclerotic, mesangial matrix ... 45:S-73
Glomerulonephritis
ANCA-positive (abst) ... 1790
anti-GBM, $\beta_2$ integrin, glomerular neutrophils (abst) ... 1256
anti-GBM, ICAM-1 ... 32
anti-GBM, ICAM-1/LFA-1 interaction ... 700
anti-GBM, T helper/suppressor cells (abst) ... 1260
attenuated by 5-LO inhibition ... 1301
crescentic (abst) ... 1260
deoxyspergualin suppresses ICAM-1 (abst) ... 1272
IL-6 exacerbates (abst) ... 1787
immune complex, erythrocyte CR1 ... 493
immune complex, NO-synthase induced, rat ... 1215
immune events in lymphoid tissue (abst) ... 1259
immunogenetics ... 377
Glomerulopathy
collapsing ... 1416
IgG3 anti-TNP monoclonal cryoglobulins ... 962
minimal change, with bronchiolitis obliterans/organizing pneumonia (abst) ... 1790
progressive, glomerular hypertrophy and ... 45:S-27
Glomerulosclerosis
adriamycin nephropathy, TGF-$\beta$1 ... 525
epidermal growth factor (abst) ... 1256
epithelial cell injury ... 45:S-58
focal, glomerular gene expression, low protein diet ... 1593
focal segmental, collapsing glomerulopathy ... 1416
focal segmental, single nephron model ... 143
molecular analysis ... 45:S-48
spontaneous, rats ... 45:S-2
Glucocorticoid-induced Mn-SOD ... 211
Glucose oxidation in dialyzed patients ... 1147
Glycated albumin, diabetic nephropathy ... 1673
Glycine betaine
urine, aminoglycosides (abst) ... 1256
urine and blood levels, human (abst) ... 1275
urine levels, sorbitol, DM, CRF (abst) ... 1267
Growth, body
catch-up, children, renal tubular acidosis (abst) ... 1782
IGF-1, renal function, ARF (abst) ... 1277
Growth factors
autocrine for MC in vitro, IL-1 (abst) ... 1257
epidermal, interaction, AVP (abst) ... 1262
hypertrophy/hyperplasia, proximal tubular epithelium (abst) ... 1261
internephron heterogeneity, sclerosis ... 45:S-24
Growth hormone
gene activation, glomerulosclerosis ... 45:S-48
receptor expression, uremia ... 1085
therapy, short children, CRF (abst) ... 1273
therapy, with IGF-1, CRF (abst) ... 1275
Guanidino, NO synthase inhibition, uremic toxins ... 737

**H**

H4 cells, albumin and transferrin synthesis ... 1381
Haemorheology
altered, pathogenesis of diabetic nephropathy (abst) ... 1273
changes in IgA nephropathy (abst) ... 1266
Hamburger Award, 1993 ... 44:S-112, 44:S-113, 44:S-114, 44:S-115
Hantavirus disease, hemorragic fever, renal syndrome (abst) ... 291
Heart transplantation, simultaneous with kidney (abst) ... 1254
*Helicobacter Pylori* infection, chronic HD (abst) ... 283
Hematuria, macroscopic after renal biopsy (abst) ... 286
Heme biosynthesis in uremia ... 220
Hemodialysis
acetate vs. bicarbonate (abst) ... 1784
AN69 membranes, bradykinin mediates anaphylaxis ... 1497
anemia, intravenous iron (abst) ... 285
anticoagulation control ... 912
blood volume measurements, noninvasive (abst) ... 1262
calcitriol, bone mineral density (abst) ... 1786
calcitriol, high dose oral, children, (abst) ... 1264
carpal tunnel syndrome (abst) ... 284
circulatory evaluation with bioimpedance (abst) ... 1788
cuprophan membranes, phospholipase $A_2$ (abst) ... 1788
dementia, PTH, cognitive functions (abst) ... 291
EPO, HBV prophylaxis (abst) ... 289
EPO, subcutaneous, once/twice weekly (abst) ... 1263
EPO, subcutaneous/intravenous efficacy (abst) ... 284
fistulae, measuring flow with MRI ... 884
folate supplementation (abst) ... 1263
fractional shortening, cardiac evaluation (abst) ... 285
HCV, NS5 antigen (abst) ... 289
HCV (abst) ... 282
HCV marker (abst) ... 1786
*Helicobacter Pylori* infection (abst) ... 283
heme biosynthesis, uremia ... 220
high-flux, cytokine induction (abst) ... 291
high-flux, vancomycin dosing ... 232
hirudin, thrombin, anticoagulation ... 1753
infants under five kilograms ... 903
iron load, hepatotropic viruses (abst) ... 289
iron status parameters (abst) ... 1786
Kt/v measurement, dialyzer clearance (abst) ... 1785
left ventricular hypertrophy (abst) ... 285
low molecular weight proteins ... 1689
nutritional status ... 44:S-85
nutritional status, residual renal function (abst) ... 292
osteocalcin as renal bone disease marker (abst) ... 1785
patient mortality ... 1163

plasma cytokines and inhibitors ..... 890
prothrombin changes, heparin (abst)..... 1784
sepsis, temporary angioaccess catheters (abst)..... 282
silent myocardial ischemia, nephropathy (abst) ..... 1272
smoking, cardiovascular disease (abst)..... 1263
subclavian vein occlusion after catheterization (abst) .. 286
urea modeling to assess adequacy, Nephrology Forum..... 1522
urine endothelin, transplantation (abst)..... 1787
vessel wall properties..... 1397
vocational rehabilitation, ESRD (abst) ..... 1792
Hemodynamics, renal
diabetic nephropathy, predisposing factors..... 434
thromboxane $A_2$ inhibition, DM ..... 794
Hemofiltration
continuous veno-venous (abst) ..... 1784
hyperkalemia after (abst)..... 1784
Hemorragic fever, Hantavirus disease, renal syndrome (abst) ..... 291
Heparin
inhibits ET-1, mesangial cells ..... 137
prothrombin fragment changes, HD (abst) ..... 1784
Hepatic growth hormone, plasma GH binding protein, uremia..... 1085
Hepatitis B virus (HBV)
iron load, HD (abst)..... 289
prophylaxis, HD (abst) ..... 289
Hepatitis C virus (HCV)
allograft recipients..... 238
hemodialysis (abst) ..... 282
interferon therapy, uremia..... 1507
iron load, HD (abst)..... 289
marker in HD patients (abst)..... 1786
NS5 band, HD..... 289
transplantation..... 551
Hepatotoxicity, CsA vs. CsG..... 684
Hepatotropic viruses, iron load, HD (abst) ..... 289
15-HETE uptake, renal tubular epithelial cells ..... 972
Heymann's nephritis (abst)..... 1272
High-flux hemodialysis
cytokine induction (abst)..... 291
mortality, hypotensive episodes (abst) ..... 1789
vancomycin dosing ..... 232
Hirudin, recombinant ..... 1753
Histone, glomerular deposition, DNA-anti-DNA immune complex ..... 991
HIV infection post-transplant (abst)..... 286
HK-2, adult proximal tubular cell line ..... 48
HMG-CoA reductase inhibitors ..... 45:S-51
*hsp70* gene induction, cytosolic $Ca^{2+}$, protein kinases .. 1093
Hydrogen peroxide detection ..... 788
11$\beta$-hydroxysteroid dehydrogenase, developmental changes..... 679
15-hydroxyeicosatetraenoic acid (15-HETE) ..... 972
Hydroxypyridinone chelators, mucormycosis, deferoxamine therapy ..... 667
Hypercalcemia, hyperparathyroidism, calcitriol (abst)... 1789
Hypercalciuria, urine saturation..... 58
Hypercholesterolemia, renal function loss, IDDM .. 45:S-125
Hyperkalemia, after hemofiltration (abst)..... 1784
Hyperosmolality of ANP-stimulated cGMP ..... 1362
Hyperoxaluria, primary, autosomal dominant (abst) .... 1782
Hyperparathyroidism
secondary, 1$\alpha$-OH-$D_3$ therapy (abst)..... 1792
secondary, calcitriol therapy, ESRD..... 1710
secondary, calcitriol therapy (abst)..... 1789
secondary, pathogenesis ..... 953
Hyperphosphatemia, hyperparathyroidism, calcitriol (abst)..... 1789
Hypertension
ACE in kidneys of diabetic rats (abst) ..... 1268
essential, antihypertensive agents, micro-albuminuria..... 45:S-171
essential, Ca, $Na^+/H^+$ exchanger ..... 1037
human, genetics..... 44:S-57
intraglomerular, in progression vs. systemic ..... 438
NIDDM, enalapril, albuminuria ..... 45:S-150
pregnancy, albumin excretion (abst)..... 1269
pregnancy, endothelin excretion (abst)..... 1270
progressive, glomerular injury ..... 45:S-6
rHuEPO therapy, antiplatelet therapy ..... 845
rHuEPO therapy, calcium, uremia (abst) ..... 1268
rHuEPO therapy, NO pathway, uremia (abst) ..... 1266
systemic versus intraglomerular, in progression..... 438
unilateral renovascular, aspirin renography ..... 1170
urinary endothelin-1..... 556
ventricular hypertrophy, diastolic dysfunction, EPO (abst)..... 1275
Hyperuricemia, CsA therapy, GFR (abst) ..... 1792
Hypofiltration, glomerular, membranous nephropathy ... 390
Hyponatremia, chronic, brain demyelination..... 193
Hypotensive episodes, high-flux dialysis (abst) ..... 1789
Hypothermic renal storage/transplantation..... 1489
Hypoxia
proximal tubule, loop diuretics ..... 981
renal dysfunction, ET-1 (abst)..... 1788

I

Idiopathic calcium nephrolithiasis (abst)..... 1782
Idiopathic membranous nephropathy
prophylactic oral anticoagulants ..... 578
therapy ..... 1193
Idiopathic nephrotic syndrome, CsA ..... 1446
IgA nephropathy
C4 phenotype, genotypically heterogenous (abst)..... 1259
changes, blood flow properties (abst) ..... 1266
clinical outcome (abst)..... 1273
duodenal J chain expression ..... 836
gene expression, T cell receptor (abst)..... 1260
mesangial deposits, renal allografts (abst)..... 1269
neutrophil-derived superoxide..... 868
prognosis (abst) ..... 1269
IgG3 anti-trinitrophenyl cryoglobulins, glomerulopathy... 962
Immune complex nephritis
erythrocyte complement receptors ..... 493
glomerular, NO-synthase induced..... 1215
glomerular macrophage phagocytosis ..... 1326
Immune events in lymphoid tissue, GN (abst)..... 1259
Immune renal injury, cell mediated ..... 1044
Immunogenetics of glomerulonephritis..... 377
Immunohistochemical localization, collagen VI, diabetic glomeruli..... 1648
Immunological considerations, uremia and dialysis... 44:S-92
Immunopotentiation by red blood cells ..... 224
Immunosuppression
pneumocystis carinii pneumonia (abst)..... 1790
prednisolone, cyclosporin, azathioprine (abst)..... 1264
prednisolone withdrawal, children (abst) ..... 1264
renal transplant, post-bone marrow transplant (abst).. 1791
Indomethacin, exercise-induced reduction RBF (abst) .. 1270

Inducible NO-synthase
glomerulonephritis . . . . . 1215
mRNA, normal kidney . . . . . 998
Infants, under five kilograms, acute hemodialysis . . . . . 903
Infection
renal opportunistic, AIDS (abst) . . . . . 287
temporary vascular access catheters, HD (abst) . . . . . 282
urinary, NO synthase, nitrite . . . . . 586
Injury
anti-GBM GN, $\beta_2$ integrin independent glomerular neutrophil (abst) . . . . . 1256
glomerular, cellular mechanisms . 45:S-54, 45:S-56, 45:S-78
glomerular, endothelial cell activation . . . . . 45:S-37
glomerular, hypertension and . . . . . 45:S-6
glomerular, leukocyte adhesion molecules . . . . . 45:S-98
glomerular, macrophages and . . . . . 45:S-98
glomerular, oxidants/proteases and . . . . . 352
glomerular, promoted by MC oxidation of LDL . . . . . 1628
glomerular, T cell activation . . . . . 44:S-8
glomerular, TNF-alpha . . . . . 45:S-32
glomerular endothelial cell, lipopolysaccharide induces (abst) . . . . . 1783
glomerular epithelial cell . . . . . 45:S-58
glomerular immune, clusterin depletion . . . . . 817
glomerular pressure . . . . . 45:S-11
glomerular response to, Nephrology Forum . . . . . 1768
oxidant-induced, DNA, pyruvate . . . . . 166
renal, cell-mediated immune . . . . . 1044
renal, integrin matrix receptors . . . . . 45:S-86
renal, macrophages in . . . . . 45:S-79
renal, osteopontin expression . . . . . 515
renal, progressive, mechanisms . . . . . 45:S-22
renal, progressive, metabolic factors . . . . . 45:S-54
renal, progressive, oxidants and . . . . . 45:S-111
tubular protection, ischemic ARF, uremia . . . . . 1759
tubulointerstitial, EGF, anti-Thy-1 nephritis (abst) . . . . 1272
tubulointerstitial, matrix accumulation . . . . . 1077
tubulointerstitial, progressive renal damage . . . . . 45:S-116
Insulin dependent diabetes mellitus (IDDM)
glomerular distribution, type IV collagen . . . . . 425
renal failure progression (abst) . . . . . 1790
renal function loss, hypercholesterolemia . . . . . 45:S-125
Insulin-like growth factor-1 (IGF-1)
GH therapy, CRF (abst) . . . . . 1275
NO production, endothelial cells . . . . . 598
renal function, body growth, ARF (abst) . . . . . 1277
Insulin modifies mesangial cell function . . . . . 1318
Integrins
matrix receptors in renal injury . . . . . 45:S-86
types/function . . . . . 44:S-17
Intercellular adhesion molecule-1 (ICAM-1)
anti-GBM GN . . . . . 32
LFA-1 interaction, anti-GBM GN . . . . . 700
suppressed by deoxyspergualin, GN (abst) . . . . . 1272
Interferon $\alpha$2a, mixed cryoglobulinemia, ARF (abst) . . . . 1790
Interferon therapy, chronic HCV, uremia . . . . . 1507
Interleukin-1 (IL-1)
cyclooxygenase 2, CsA, mesangial cells . . . . . 150
inhibits MC proliferation . . . . . 159
not an autocrine growth factor, MC (abst) . . . . . 1257
Interleukin-1$\beta$, specific inhibitors, CRF, CAPD, HD . . . . 890
Interleukin-6 (IL-6)
exacerbates glomerulonephritis (abst) . . . . . 1787
inhibits MC proliferation . . . . . 159
responses, pyelonephritis in pregnancy . . . . . 571
Interleukin-8 (IL-8) production, PBMC . . . . . 1311
International Society of Nephrology, reports . . . . . 44:S-116, 44:S-119, 44:S-121, 44:S-123, 44:S-125
Internephron heterogeneity and growth factors . . . . . 45:S-24
Interstitial cells, renal cortex of rats . . . . . 709
Interstitial fibrosis
adriamycin nephropathy, TGF-$\beta$1 . . . . . 525
progression and lymphocytes . . . . . 45:S-106
reduced by enalapril . . . . . 1637
Intracranial aneurysms in ADPKD . . . . . 1140
Intraglomerular hypertension . . . . . 438
Iron
intravenous, anemia, HD (abst) . . . . . 285
load, hepatotropic viruses, HD (abst) . . . . . 289
metabolism, aluminum alters in Friend cells . . . . . 636
reliable parameters of, during HD (abst) . . . . . 1786
tubular accumulation, desferrioxamine . . . . . 1277
tubular accumulation, diabetic nephropathy (abst) . . . . 1271
tubular accumulation, dietary protein . . . . . 1006
tubular accumulation, dietary protein (abst) . . . . . 1255
tubular accumulation, lysosomal, CRF (abst) . . . . . 1268
Isoprenoids in glomerular mesangial cells . . . . . 45:S-51

J
J chain mRNA expression, IgA nephropathy . . . . . 836
Juxtaglomerular body
abnormalities, youth-onset diabetes . . . . . 1132
sodium intake, renin content (abst) . . . . . 1254

K
$K^+$-sparing diuresis, trimethoprim . . . . . 1070
K t/v measurement, dialyzer clearance, HD (abst) . . . . . 1785
72 kDa type IV collagenase, TGF-$\beta$1, MC (abst) . . . . . 1782
Ketoacids, essential amino acids, protein intake . . . . . 1182
Kindergarten screening program, renal disease (abst) . . . 1274

L
L-arginine
macrophage infiltration, PAN and BUO . . . . . 1346
NO pathway, glomerular thrombosis, pregnancy . . . . . 775
obstructive nephropathy . . . . . 782
Left ventricular hypertrophy, HD (abst) . . . . . 285
Leukemia inhibitory factor, cytokines, MC . . . . . 1562
Leukocyte adhesion and eicosanoid biosynthesis . . . . 45:S-90
Leukocyte adhesion molecules
glomerular injury . . . . . 45:S-98
renal disease . . . . . 1285
Light-chain deposition disease (abst) . . . . . 285
Lipid, inflammatory, albumin tubular catabolism . . . . . 1697
Lipid profile
CAPD (abst) . . . . . 291
EPO therapy, ESRD . . . . . 897
EPO therapy, ESRD (abst) . . . . . 1253
5-lipoxygenase inhibition, renal function . . . . . 1301
Lipopolysaccharide
FK506, glomerular thrombosis, nephrotoxic serum . . . 1572
glomerular EC injury, MC contraction (abst) . . . . . 1783
renal extracellular proteolysis . . . . . 500
Lipoproteins
glomerular prostaglandins, diabetes (abst) . . . . . 1258
interaction, tubular cells . . . . . 753
Lipoxygenase, biosynthesis, leukocyte adhesion . . . . . 45:S-90
LLC-$PK_1$ cells
acidosis alters renal ammoniagenesis . . . . . 1014
streptomycin, free calcium transients (abst) . . . . . 1277

Lomefloxacin, trimethoprim, cystitis in women (abst)... 1267
Loop diuretics, hypoxic damage, proximal tubules..... 981
Low-density lipoproteins
glomerular prostaglandins, diabetes (abst)..... 1258
metabolism, uremia, CRF..... 561
oxidation, uremia..... 876
oxidation by MC, glomerular injury..... 1628
Low molecular weight proteins, maintenance HD..... 1689
Luminal $V_1$-receptor, collecting duct..... 811
Lupus nephritis
children, cyclophosphamide (abst)..... 289
pathology, Nephrology Forum..... 928
predicting renal outcomes..... 544
role of CSF-1..... 45:S-83
Luteinizing hormone, pubertal patients, CRF..... 1465
Lymphocytes
function-associated antigen, ICAM-1, anti-GBM GN... 700
interstitial disease progression..... 45:S-106
subsets evolution, transplantation (abst)..... 283
Lymphoid tissue immune events, GN (abst)..... 1259
Lymphomas, renal disease (abst)..... 290
Lysosomal iron accumulation, human CRF (abst)..... 1268

M
Macrophages
acute glomerular inflammation..... 945
glomerular injury..... 45:S-98
renal injury..... 45:S-79
Magnetic resonance imaging
estimating glomerular number, biopsy and..... 1668
measures flow, hemodialysis fistulae..... 884
Manganese superoxide dismutase, glucocorticoids..... 211
MDBK cells, calbindin D-28K, $1,25(OH)_2D_3$..... 95
MDCK cells, 15-HETE, tubular epithelial cells..... 972
Mechanical thrombolysis, thrombosed dialysis access grafts..... 1401
Medullary vesicles, bilateral, $Cl^-$ channels..... 803
Membranes, hemodialysis
AN69, bradykinin mediates anaphylaxis..... 1497
cuprophan, phospholipase $A_2$ (abst)..... 1788
Membranous nephropathy
glomerular hypofiltration..... 390
idiopathic, therapy..... 1193
Mental retardation, Bartter's syndrome (abst)..... 290
Mesangial cells
CsA, IL-1-induced COX2 expression..... 150
cytokines, leukemia inhibitory factor..... 1562
deoxyspergualin, in vitro (abst)..... 1271
function, alterations..... 45:S-17
growth modulated, Amadori glucose adducts..... 475
heparin inhibits ET-1..... 137
IL-1 and IL-6 inhibit proliferation..... 159
IL-1 is not autocrine growth factor (abst)..... 1257
insulin modifies function..... 1318
lipopolysaccharide induces contraction (abst)..... 1783
mechanical strain, glomerular expansion..... 45:S-11
metalloproteinase transin gene transfer..... 1580
oxidation of LDL, promotes glomerular injury..... 1628
proliferation, Ang II, $At_1$ receptors..... 177
proliferation, anti-TNF antibody (abst)..... 1783
proliferation, glomerular disease..... 45:S-45
proliferation, HMG-CoA reductase inhibitors..... 45:S-51
T-lymphocyte activation..... 763
TGF-$\beta$1, 72 kDa type IV collagenase synthesis (abst)..... 1782
tissue culture view..... 320
urokinase-plasminogen activator synthesis..... 43
Mesangial expansion, glomerular extracellular matrix..... 328
Mesangial IgA allograft deposits, recurrent (abst)..... 1269
Mesangial matrix in the glomerulus..... 45:S-73
Metabolism
diabetic nephropathy, predisposition..... 434
Na transport and..... 743
Metalloproteinase transin gene transfer into MC..... 1580
Metastatic endophthalmitis (abst)..... 1262
Methylprednisolone induction therapy (abst)..... 288
MHC class II antigen-positive cells (abst)..... 1791
Microalbuminuria
antihypertensive agents, essential hypertension... 45:S-171
antihypertensive agents, normotensive DM (abst)..... 1270
Minimal change disease
bronchiolitis obliterans/organizing pneumonia (abst).. 1790
glomerular basement membrane (abst)..... 1256
Mitochondrial DNA depletion..... 1388
Mitochondrial sequestration of potassium (abst)..... 1255
Mixed cryoglobulinemia, ARF, interferon $\alpha$2a (abst)..... 1790
Molecular biology of Na, K-ATPase..... 44:S-32
Monoclonal antibody
254 mAb detects neoepitope, complement C9 (abst).. 1266
cryoglobulins, IgG3 anti-TNP, glomerulopathy..... 962
marker, Alport syndrome, type IV collagen..... 1504
Monoclonal antibody therapy
diabetic nephropathy..... 1673
Heymann's nephritis (abst)..... 1272
Monocytes
cardiac, $Ca^{2+}$ and CRF..... 1113
function and deoxyspergualin (abst)..... 1257
Mortality
CAPD, HD..... 1163
dysautonomia, dialysis (abst)..... 1274
high-flux dialysis, hypotensive episodes (abst)..... 1789
mRNA
calcitriol receptor regulation, RF..... 1020
inducible NO synthase, location normal kidney..... 998
J chain expression, IgA nephropathy..... 836
Muckle-Wells syndrome (abst)..... 282
Mucormycosis, deferoxamine therapy..... 667
Multinucleated giant cells, crescentic GN (abst)..... 1260
Muscle protein synthesis/degradation with CRF..... 1432
Myocardial ischemia, autonomic nephropathy, HD (abst)..... 1272

N
N acetyl beta glucosaminidase, vesico-ureteric reflux (abst)..... 1273
Na, K-ATPase
expression in uremia..... 672
isoforms identified, rat nephron (abst)..... 1788
molecular biology..... 44:S-32
tubular, neuropeptide Y, norepinephrine..... 1606
$Na^+$ channels, trimethoprim, $K^+$-sparing diuresis..... 1070
$Na^+/H^+$ antiporter in VSMC..... 66
Na/H-exchange
intracellular calcium, hypertension..... 1037
regulatory control..... 44:S-23
$Na^+$ transport, metabolic support, CCD..... 743
Natriuresis
diuresis with EGF (abst)..... 1276
postnephrectomy, neurohypophyseal antagonists..... 692
pre-eclampsia, renin, frusemide (abst)..... 1277
Necrosis, acute tubular, transplant donor risk (abst)..... 288
Neonatal ureteral obstruction, renin secretion..... 1333

Nephrectomy
ACE, dietary protein, rat ... 1587
natriuresis, neurohypophyseal antagonists ... 692
unilateral, renal function, DM (abst) ... 287
Nephritis
anti-Thy-1, EGF, tubulointerstitial injury (abst) ... 1272
azobenzenearsonate induces ... 1044
Heymann's (abst) ... 1272
immune complex, glomerular macrophage phagocytosis ... 1326
lupus, Nephrology Forum ... 928
lupus, predicting renal outcomes ... 544
Nephrolithiasis, idiopathic calcium (abst) ... 1782
Nephropathology diagnosis, skin/subcutaneous fat aspiration biopsy (abst) ... 284
Nephropathy
adriamycin, TGF-$\beta$1 ... 525
analgesic, incidence (abst) ... 1785
autonomic, silent myocardial ischemia, HD (abst) ... 1272
Balkan endemic ... 1680
Chinese herbs ... 1680
diabetic, albuminuria ... 45:S-145
diabetic, assessment ... 45:S-121
diabetic, ECM components localized (abst) ... 1271
diabetic, glomerular Ang II receptors (abst) ... 1276
diabetic, hypercholesterolemia ... 45:S-125
diabetic, long-term enalapril ... 45:S-141
diabetic, monoclonal antibody treatment ... 1673
diabetic, Nephrology Forum ... 612
diabetic, pathogenesis (abst) ... 1273
diabetic, predisposition ... 434
diabetic, proximal tubular iron (abst) ... 1271
familial amyloidotic polyneuropathy (abst) ... 287
idiopathic membranous, anticoagulants ... 578
idiopathic membranous, therapy ... 1193
IgA, C4 phenotype, genotypically heterogenous (abst) ... 1259
IgA, changes in blood flow properties (abst) ... 1266
IgA, clinical outcome (abst) ... 1273
IgA, duodenal J chain expression ... 836
IgA, neutrophil-derived superoxide ... 868
IgA, prognosis (abst) ... 1269
IgA, recurrent allograft mesangial deposits (abst) ... 1269
membranous, glomerular hypofiltration ... 390
obstructive, L-arginine plasma/tissue levels ... 782
post-obstructive, $TxA_2$ blockade ... 185
radiocontrast, risk with/without DM ... 259
tubulointerstitial, mitochondrial DNA depletion ... 1388
Nephrosis
puromycin aminonucleoside (PAN) ... 1057
puromycin-induced, L-arginine, BUO ... 1346
Nephrotic edema, Nephrology Forum ... 266
Nephrotic syndrome
bronchiolitis obliterans/organizing pneumonia (abst) ... 1790
congenital, Finnish type ... 986
H4 cells, albumin, transferrin synthesis ... 1381
idiopathic, renal tolerance, CsA ... 1446
IL-8 production, PBMC ... 1311
prophylactic oral anticoagulants ... 578
steroid dependent, cyclosporin (abst) ... 1267
steroid-resistant, rejection, ARF ... 1440
Nephrotoxicity
CsA, decreased dopamine excretion (abst) ... 290
CsA vs. CsG ... 684
FK506, glomerular thrombosis, lipopolysaccharide ... 1572
Neurohormones, cyclosporine, antidiuresis ... 1203
Neurohypophyseal antagonists, postnephrectomy natriuresis ... 692
Neuropeptide Y, norepinephrine, tubular Na, K-ATPase ... 1606
Neutropenia, dialysis, neutrophil F-actin (abst) ... 1253
Neutrophils
$\beta_2$ integrin independent glomerular, anti-GBM GN (abst) ... 1256
cytoplasm, antigen antibody detection (abst) ... 1257
derived superoxide, IgAN ... 868
F-actin, dialysis neutropenia (abst) ... 1253
GBM degradation, ROS, elastase ... 1555
Wegener's granulomatosis ... 1120
Nitric oxide (NO)
glomerular thrombosis, pregnancy ... 775
hypertension, uremia, rHuEPO therapy (abst) ... 1266
IGF-1 induces production, endothelial cells ... 598
inhibition, arterial pressure (abst) ... 1258
synthase, induction, immune complex glomerulonephritis ... 1215
synthase, inhibition by uremic toxins, guanidino ... 737
synthase, mRNA inducible, normal kidney ... 998
synthase, urinary infection, nitrite ... 586
synthesis inhibition, renal vasoconstrictor response, Ang II (abst) ... 1255
Nitrite, NO synthase, urinary infection ... 586
NMR microscopy, renal (abst) ... 1271
Non-diabetic patients
antihypertensive therapy, GFR decline ... 45:S-174
CRF, prevention of progression ... 45:S-167
renal disease, clinical treatment ... 45:S-179
renal endpoints in ... 45:S-118
Non-insulin-dependent diabetes mellitus, hypertension, enalapril ... 45:S-150
Non-steroidal anti-inflammatory drugs, pharmacology, glomerular function ... 417
Norepinephrine, neuropeptide Y, tubular Na, K-ATPase ... 1606
NS5 antigen, hepatitis C virus, HD (abst) ... 289
Nutrition
CAPD, PCR as marker ... 103
status, residual renal function, HD (abst) ... 292
status with HD ... 44:S-85

O

Obstructive nephropathy
L-arginine, macrophage infiltration, PAN ... 1346
L-arginine plasma/tissue levels ... 782
$1,25(OH)_2D_3$, calbindin D-28K, bovine renal cells ... 95
OKT3
reduced viral mortality (abst) ... 1265
single transplant experience (abst) ... 1264
Opportunistic renal infection in AIDS (abst) ... 287
Oral anticoagulants, prophylactic, nephrotic patients ... 578
Oral glucose load, glucose oxidation, CAPD ... 1147
Osmoprotectant response, fluid deprivation (abst) ... 1277
Osmotic diuresis before Homer W. Smith ... 1241
Osteocalcin as renal bone disease marker, HD (abst) ... 1785
Osteodystrophy biochemical markers, children ... 253
Osteonecrosis, avascular (abst) ... 290
Osteopontin expression, renal injury ... 515
Ouabain, effects in healthy volunteers (abst) ... 1276
Oxidant injury
DNA, pyruvate effect ... 166

progressive renal ..... 45:S-111
proteases in glomerular ..... 352
Oxidation of LDL by mesangial cells ..... 1628
Oxygen deprivation, post-ischemic ARF, tubular protection, uremia ..... 1759

P
PAF, endotoxin, glomerular hemodynamics (abst) ..... 1783
Parathyroid hormone (PTH)
cognitive functions, dementia, HD (abst) ..... 291
low dialysate calcium, Ca and Phos control (abst) .... 1253
molecule assays, dialysis (abst) ..... 1262
oral calcium, mild CRF (abst) ..... 1275
receptor down-regulation, CRF ..... 605
Peracetic acid, dialyser manual reprocessing (abst) ..... 1262
Percutaneous renal biopsy (abst) ..... 1789
Percutaneous transluminal angioplasty, central venous stenoses ..... 1177
Peripheral blood mononuclear cells produce IL-8 ..... 1311
Peritoneal dialysis
children, bone disease markers ..... 253
Nephrology Forum ..... 1226
Peritoneal glucose load, glucose oxidation, CAPD ..... 1147
Peritoneal transport, CAPD patients ..... 1738
Pharmacokinetics, CsA, compared to CsG ..... 684
Pharmacologic manipulation of glomerular function ..... 417
Pharmacomechanical thrombolysis, thrombosed dialysis access grafts ..... 1401
Phospholipase $A_2$, cuprophan membranes (abst) ..... 1788
Phospholipids, inositol, 15-HETE uptake ..... 972
Placenta
ischemia, renal lesions (abst) ..... 1256
pre-eclamptic, ET-1 gene expression (abst) ..... 1265
Plasma flux, plasmapheresis, dialysis (abst) ..... 289
Plasminogen activator
effects of LPS ..... 500
urokinase, synthesis in cultured glomerular cells ..... 43
Pneumocystis carinii pneumonia, immunosuppression (abst) ..... 1790
Pneumonia
bronchiolitis obliterans/organizing pneumonia (abst) .. 1790
pneumocystis carinii (abst) ..... 1790
Podocytes
counteract capillary wall distension ..... 369
dysfunction in glomerular disease ..... 300
glomerular sclerosis, role in ..... 45:S-64
Polymorphonuclear leukocytes
cystinosis diagnosis (abst) ..... 1269
Fc$\alpha$ R expression, IgAN ..... 868
Polyol pathway, glucose, collagen synthesis, proximal tubule ..... 659
Post-obstructive nephropathy, thromboxane $A_2$ receptor ..... 185
Potassium
cellular uptake after K loading (abst) ..... 1255
renal tubular fluid ..... 1211
sparing diuretic actions, trimethoprim ..... 1070
Pre-eclampsia
placenta, ET-1 gene expression (abst) ..... 1265
renal dysfunction, natriuresis, renin, frusemide (abst) . 1277
Pre-Smithian osmotic diuresis ..... 1241
Prednisolone
compared, cyclosporin, azathioprine (abst) ..... 1264
withdrawal, children, transplantation (abst) ..... 1264
Pregnancy
decidual capillary endothelial cells produce vasoactive substances (abst) ..... 1278
hypertensive, albumin excretion (abst) ..... 1269
hypertensive, endothelin excretion (abst) ..... 1270
NO, glomerular thrombosis ..... 775
pre-eclampsia, natriuresis, renin, frusemide (abst) .... 1277
pyelonephritis, antibody and IL-6 ..... 571
transplantation (abst) ..... 288
Primary hyperoxaluria, autosomal dominant (abst) ..... 1782
Progressive kidney fibrosis, TGF-$\beta$1 ..... 916
Progressive renal diseases, injury mechanisms ..... 45:S-22
Prostacyclin, $PGE_1$, renal effects ..... 1457
Prostaglandins
afferent and efferent arterioles ..... 650
cytokines inhibit MC proliferation ..... 159
production, lipoproteins, diabetes (abst) ..... 1258
prostacyclin, renal effects ..... 1457
Proteases, oxidants in glomerular injury ..... 352
Protein
excretion estimated (abst) ..... 1789
low molecular weight, maintenance HD ..... 1689
skeletal muscle, turnover in CRF ..... 1432
Protein, dietary
glomerular gene expression, focal GS ..... 1593
normal sodium diet, CRF ..... 852
serum calcitriol, calcium stones (abst) ..... 1784
tubular iron, remnant kidney (abst) ..... 1255
tubular iron accumulation ..... 1006
uninephrectomy, ACE ..... 1587
very low, adaptive responses, RF ..... 1182
Protein catabolic rate normalized, nutrition, CAPD ..... 103
Protein kinases, cytosolic $Ca^{2+}$, *hsp70* gene induction .. 1093
Proteinuria
ACE inhibition, Ang II antagonism ..... 861
associated inflammatory lipid ..... 1697
renal morbidity and ..... 443
Prothrombin changes, heparin anticoagulation, HD (abst) ..... 1784
Proximal tubular cells
pure, heterogenous distal human, in culture ..... 85
Proximal tubular epithelial cells
complement activation ..... 451
HK-2, adult human ..... 48
hypertrophy/hyperplasia, growth factors (abst) ..... 1261
Proximal tubule
intracellular electrolytes, ANP (abst) ..... 1260
iron accumulation, diabetic nephropathy (abst) ..... 1271
loop diuretics reduce hypoxic damage ..... 981
Na/H-exchange regulation ..... 44:S-23
polyol mediates collagen synthesis, DM ..... 659
Puberty, LH and CRF ..... 1465
Puromycin aminonucleoside nephrosis (PAN)
angiotensin II and bradykinin ..... 537
glomerular morphology, antioxidants (abst) ..... 1271
L-arginine, macrophage infiltration, BUO ..... 1346
reactive oxygen species ..... 1057
Pyelonephritis
children, dimercaptosuccinic acid scan (abst) ..... 1790
pregnancy, antibody, IL-6 responses ..... 571
Pyruvate, oxidant-induced DNA injury ..... 166

R
Radiocontrast nephropathy
prevention with theophylline ..... 1425
risk, with/without diabetes mellitus ..... 259
Reactive oxygen species (ROS)
GBM degradation, elastase, neutrophils ..... 1555
PAN, culture studies ..... 1057

Recombinant growth hormone, children, CRF (abst).... 1273
Recombinant hirudin ..... 1753
Recombinant human erythropoietin (rHuEPO)
hypertension, antiplatelet therapy, uremia ..... 845
hypertension, intracellular calcium, uremia (abst) .... 1268
hypertension, NO pathway, uremia (abst) ..... 1266
subcutaneous, once/twice weekly, HD (abst)..... 1263
Red blood cells, immunopotentiation, cytokines, uremia ..... 224
Rejection
allografts, T cell receptor gene expression (abst)..... 1254
allografts, T cells in autoimmunity ..... 44:S-50
ARF, steroid-resistant nephroses ..... 1440
Renal adenocarcinoma, retinoic acid ..... 23
Renal ammonia in ADPKD..... 1744
Renal ammoniagenesis..... 1014
Renal antioxidant enzymes, regulation/function ..... 1
Renal artery stenosis, renal duplex scanning (abst)..... 1266
Renal $B7^+$-transfectants, T cell activation ..... 1105
Renal biopsy
assessment, ARF..... 44:S-65
estimating glomerular number, MRI and..... 1668
macroscopic hematuria after (abst)..... 286
percutaneous, single kidney (abst) ..... 288
percutaneous techniques compared (abst)..... 1789
techniques compared (abst)..... 1258
Trucut needle and Biopty gun (abst)..... 1267
Renal blood flow, exercise-induced reduction, indomethacin (abst) ..... 1270
Renal bone disease, osteocalcin as marker, HD (abst) .. 1785
Renal cysts, cell volume, fluid secretion ..... 1369
Renal disease
adult spina bifida patients (abst) ..... 1270
children, dimercaptosuccinic acid scan, ultrasound (abst)..... 1790
clusterin expression..... 828
cystic, ACE inhibition (abst)..... 1266
distribution, renal graft recipients (abst)..... 1785
endothelin, renal actions of..... 336
fibrosis, TGF-$\beta$1 expression ..... 916
Galloway-Mowat syndrome..... 1407
Hantavirus disease (abst)..... 291
hypoxemia-induced, not modulated by ET-1 (abst) ... 1788
kindergarten screening program (abst) ..... 1274
leukocyte adhesion molecules ..... 1285
lymphomas (abst)..... 290
progressive..... 45:S-22
progressive, endpoint assessment..... 45:S-132
progressive, tubulointerstitial injury ..... 45:S-116
proteinuria, role of..... 443
tubular lipidosis ..... 753
Renal duplex scanning, renal artery stenosis (abst)..... 1266
Renal endpoints in non-diabetic patients ..... 45:S-118
Renal extracellular proteolysis, modified by LPS ..... 500
Renal failure
Aboriginal (abst)..... 1274
calcitriol degradative enzymes, vitamin D metabolites..... 509
calcitriol regulation and its mRNA ..... 1020
progression, IDDM (abst) ..... 1790
secondary hyperparathyroidism ..... 953
Renal function
ACE inhibition, Ang II antagonism..... 485
aspirin, acute effects (abst) ..... 1785
calcium homeostasis ..... 44:S-97
cyclosporin, BQ-123 effects..... 131
cyclosporine induced antidiuresis ..... 1203
endogenous calcitonin (abst) ..... 1255
fish oil supplements, DM (abst)..... 287
IGF-1, body growth, ARF (abst)..... 1277
improved by 5-LO inhibition..... 1301
loss in diabetic nephropathy ..... 45:S-125
nutritional status, HD (abst) ..... 292
$PGE_1$ and $PGI_2$, effects on..... 1457
pre-eclampsia, natriuresis, renin, frusemide (abst).... 1277
prognosis, severe lupus nephritis ..... 544
rickets (abst) ..... 288
uninephrectomy, DM (abst)..... 287
Renal functional reserve, cyclosporin, post-transplant .. 1657
Renal 11$\beta$-hydroxysteroid dehydrogenase ..... 679
Renal injury
integrin matrix receptors..... 45:S-86
macrophages in ..... 45:S-79
osteopontin expression ..... 515
progressive, metabolic factors ..... 45:S-54
progressive, oxidants and ..... 45:S-111
Renal interstitial cells ..... 709
Renal mass
reduction, energy metabolism and ..... 45:S-100
serum calcitriol, calcium stones (abst) ..... 1784
Renal NMR microscopy (abst) ..... 1271
Renal osteodystrophy markers, children, CAPD/CCPD .. 253
Renal physiology, osmotic diuresis before Homer W. Smith ..... 1241
Renal reserve..... 411
Renal stone formers
calcium, calcitriol, protein intake (abst) ..... 1784
calcium oxalate, prognosis..... 1721
Renal tubular acidosis, children, body growth (abst).... 1782
Renal tubule cells, taurine in rat..... 10
Renal vasoconstriction, NO synthesis inhibition, Ang II (abst)..... 1255
Renin-angiotensin system
ACE inhibition, antiproteinuric effect..... 861
ACEi, Ang II antagonism, renal abnormalities..... 485
chronic renal disease ..... 403
Renin content, juxtaglomerular apparatus, Na (abst).... 1254
Renin secretion
natriuresis, frusemide, pre-eclampsia (abst) ..... 1277
post-obstruction ..... 1333
Renography, aspirin..... 1170
Respiratory chain dysfunction, noninvasive measurement ..... 1489
Retinoic acid, renal adenocarcinoma, EGF ..... 23
Retinol binding protein, vesico-ureteric reflux (abst).... 1273
*Rhizopus*, chelators effect on ..... 667
Richards Award, 1993..... 44:S-106, 44:S-110
Richet, Gabriel ..... 44:S-112, 44:S-113
Rickets of renal origin (abst)..... 288
Ritz, Eberhard..... 44:S-112, 44:S-114

S
Saline loading, acute, response in cirrhosis (abst)..... 1276
Salt sensitivity, urinary ET-1, and hypertension ..... 556
Sclerosis, internephron heterogeneity and growth factors ..... 45:S-24
Secondary hyperparathyroidism
1$\alpha$-OH-$D_3$ therapy (abst) ..... 1792
calcitriol therapy (abst) ..... 1789
pathogenesis..... 953

Seldin, Donald W. ... 44:S-106
Skeletal muscle protein turnover, CRF ... 1432
Skin biopsy, nephropathology diagnosis (abst) ... 284
Smith, Homer W. ... 1241
Smoking, cardiovascular risk, HD, transplantation (abst) ... 1263
Socioeconomic status and ESRD in U.S. ... 907
Sodium
  chronic hyponatremia, brain lesions ... 193
  dietary, low-protein diet, CRF ... 852
  intake, renin, juxtaglomerular apparatus (abst) ... 1254
  renal tubular fluid, atomic absorption analysis ... 1211
Sorbinil and renal collagen ... 659
Sorbitol, glycine betaine, DM, CRF (abst) ... 1267
Sotalol, end-stage renal disease (abst) ... 1268
Spina bifida, renal involvement, adults (abst) ... 1270
Spontaneous glomerulosclerosis ... 45:S-2
Stents
  ureteric, post-transplant (abst) ... 1264
  vascular Wallstents, central venous stenoses ... 1177
Steroid dependent nephrotic syndrome, cyclosporin (abst) ... 1267
Steroid-resistant nephrotic syndrome, rejection, ARF ... 1440
Stone formers
  calcium oxalate, prognosis ... 1721
  calcium renal, calcitriol, protein intake (abst) ... 1784
Streptomycin alters free calcium transients (abst) ... 1277
Subclavian vein occlusion after catheterization (abst) ... 286
Superoxide, neutrophil-derived and IgAN ... 868

T
T cells
  activation, mediate glomerular injury ... 44:S-8
  activation, renal B7$^+$ transfectants ... 1105
  activation by mesangial cells ... 763
  autoimmune function, allograft rejection ... 44:S-50
T helper cells, injury, anti-GBM GN (abst) ... 1260
T lymphocyte receptor (TCR)
  V alpha gene expression, allograft rejection (abst) ... 1254
  V alpha gene expression, IgA nephropathy biopsies (abst) ... 1260
T suppressor cell injury, anti-GBM GN (abst) ... 1260
Taurine in rat renal tubule cells ... 10
Tenascin, normal/pathologic glomeruli ... 201
Theophylline prevents contrast media-induced ARF ... 1425
Thrombin inhibition, hirudin, anticoagulation, HD ... 1753
Thrombosed dialysis access grafts
  anti-platelet therapy ... 1477
  mechanical/pharmacomechanical thrombolysis ... 1401
Thrombosis
  glomerular, FK506, lipopolysaccharide ... 1572
  glomerular, NO, pregnancy ... 775
  renal graft vascular (abst) ... 1254
Thromboxane $A_2$
  endotoxin, glomerular hemodynamics (abst) ... 1783
  inhibition in DM rats ... 794
  receptor blockade, post-obstructive nephropathy ... 185
Thyroid hormone, dichromate, RF, EGF ... 1622
Transferrin and albumin synthesis ... 1381
Transforming growth factor-$\alpha$
  EGF, human kidney ... 1510
Transforming growth factor-$\beta$1
  adriamycin nephropathy ... 525
  escape from, in renal cells ... 642
  glomerular MC synthesis (abst) ... 1782
  kidney fibrosis ... 916
Transin gene transfer into mesangial cells ... 1580
Transplantation
  acute tubular necrosis, donor risk (abst) ... 288
  avascular osteonecrosis (abst) ... 290
  biopsy assessment, ARF ... 44:S-65
  bone marrow (abst) ... 1791
  CD45 isoforms, early post-transplant (abst) ... 283
  cell proliferation, fine-needle aspiration biopsy (abst) ... 285
  children (abst) ... 282, 290
  circadian BP monitoring (abst) ... 1791
  coronary angiography after (abst) ... 1258
  cyclosporine pharmacokinetics before (abst) ... 286
  elderly donors (abst) ... 1265
  hepatitis C virus ... 238, 551
  hepatitis C virus (abst) ... 286
  hypothermic storage, respiratory chain dysfunction ... 1489
  induction therapy, ATG, CsA, methylprednisolone (abst) ... 288
  lymphocyte subsets evolution (abst) ... 283
  OKT3 experience (abst) ... 1264
  pathology, implantation graft biopsies (abst) ... 1278
  prednisolone withdrawal, children (abst) ... 1264
  pregnancy (abst) ... 288
  rejection, ARF, steroid-resistant nephroses ... 1440
  renal disease distribution, graft recipients (abst) ... 1785
  renal functional reserve, cyclosporin ... 1657
  simultaneous heart/kidney (abst) ... 1254
  smoking, cardiovascular disease, HD (abst) ... 1263
  ureteric stents reduce urologic complications (abst) ... 1264
  urine endothelin, HD patients, normal subjects (abst) ... 1787
  without immunosuppression, post-bone marrow transplant (abst) ... 1791
Trimethoprim
  K$^+$-sparing diuretic actions ... 1070
  lomefloxacin, cystitis in women (abst) ... 1267
Triple immunosuppression, prednisolone withdrawal (abst) ... 1264
Tubular catabolism, albumin, inflammatory lipid release ... 1697
Tubular cells, adenoviral-mediated gene transfer ... 1220
Tubular epithelial cells
  15-HETE uptake ... 972
  renal B7$^+$-transfectant, T cell activation ... 1105
Tubular fluid electrolyte analysis ... 1211
Tubular lipidosis, renal disease ... 753
Tubular necrosis, transplant donor risk (abst) ... 288
Tubular nephrotoxicity after cardiac surgery (abst) ... 1274
Tubular protection, post-ischemic ARF, uremia ... 1759
Tubulointerstitial fibrosis, glomerular function loss ... 345
Tubulointerstitial injury
  EGF, anti-Thy-1 nephritis (abst) ... 1272
  immune-mediated, matrix accumulation ... 1077
  progressive renal damage ... 45:S-116
Tubulointerstitial nephritis, Ang II, osteopontin ... 515
Tubulointerstitial nephropathy, mitochondrial DNA ... 1388
Tumor necrosis factor$\alpha$ (TNF$\alpha$)
  glomerular injury ... 45:S-32
  specific inhibitors, CRF, CAPD, HD ... 890

U
Ultrasonography, pyelonephritis, children (abst) ... 1790
Unilateral renovascular hypertension, aspirin renography ... 1170
Unilateral ureteral obstruction, Ang II receptor gene ... 1614
Uninephrectomy
  dietary protein and ACE in rats ... 1587

natriuresis, neurohypophyseal antagonist effects ..... 692
renal function, DM (abst) ..... 287
Urate transporters, renal brush border membranes ..... 727
Urea extraction, acetate/bicarbonate HD (abst) ..... 1784
Urea modeling, Nephrology Forum ..... 1522
Urea transport, intracellular Ca (abst) ..... 1254
Uremia
antiplatelet therapy, rHuEPO, hypertension ..... 845
decreased LDL clearance, CRF ..... 561
GH receptor, plasma GH binding protein ..... 1085
heme biosynthesis, hemodialysis, CAPD ..... 220
immunological considerations, HD ..... 44:S-92
interferon therapy, HCV ..... 1507
low-density lipoprotein oxidation ..... 876
Na, K-ATPase expression ..... 672
NO pathway, hypertension, rHuEPO (abst) ..... 1266
NO synthase inhibition, guanidino ..... 737
RBC immunopotentiation, anemia, cytokines ..... 224
rHuEPO, intracellular calcium, hypertension (abst) ... 1268
Ureteral obstruction
acute unilateral, Ang II receptor gene ..... 1614
L-arginine, macrophage infiltration, PAN ..... 1346
neonatal, renin secretion ..... 1333
Ureteric stents reduce urologic complications (abst) .... 1264
Uridine metabolism, expanded extracellular volume (abst) ..... 1265
Urinary citrate, idiopathic calcium nephrolithiasis (abst) ..... 1782
Urinary endothelin
excretion, normal/hypertensive pregnancy (abst) ..... 1270
HD, transplantation, normal subjects (abst) ..... 1787
hypertension ..... 556
Urinary excretion, aluminoxamine, ferrioxamine ..... 76
Urinary infection, NO synthase and nitrite ..... 586
Urine
low volume, idiopathic calcium nephrolithiasis (abst) . 1782
preservation, diagnostic microscopy (abst) ..... 1273
saturation, genetic hypercalciuric rats ..... 58
Urokinase, cultured glomerular cells ..... 43
Urolithiasis, children (abst) ..... 1790
Urologic complications, ureteric stents post-transplant (abst) ..... 1264

V
V alpha gene expression
T lymphocyte receptor, allograft rejection (abst) ..... 1254
T lymphocyte receptor, IgA nephropathy (abst) ..... 1260
$V_1$, oxytocin-antagonist, uninephrectomy ..... 692
Vancomycin dosing, high-flux HD ..... 232
Vascular access
sepsis, temporary catheters, HD (abst) ..... 282
subclavian occlusion, HD catheterization (abst) ..... 286
thrombosed grafts, anti-platelet therapy ..... 1477
thrombosed grafts, mechanical/pharmacomechanical thrombolysis ..... 1401
Vascular endothelial cell activation ..... 45:S-37
Vascular smooth muscle cells, ANP, cGMP, $Na^+/H^+$ antiporter ..... 66
Vascular Wallstents, central venous stenoses ..... 1177
Vasoactive agents, insulin modifies MC function ..... 1318
Vasoactive intestinal peptide antagonist, cirrhosis (abst) ..... 1261
Vasoactive substances, decidual capillary endothelial cells, pregnancy (abst) ..... 1278
Vasopressin receptors, V1, V2 regulation, DM (abst) ... 1275
Venous stenoses, PTA and vascular Wallstents ..... 1177
Ventricular hypertrophy, diastolic dysfunction, EPO (abst) ..... 1275
Vesico-ureteric reflux, children (abst) ..... 1273
Vessel wall properties, HD ..... 1397
Viral mortality reduced with OKT3 (abst) ..... 1265
Vitamin B1 and B6, insufficient on CAPD (abst) ..... 1786
Vitamin D
calbindin D-28K, bovine kidney cells ..... 95
metabolites, calcitriol degradative enzymes, RF ..... 509
Vitamin $D_3$-dependent calcium binding proteins
calcium reabsorption, CaBP 9K ..... 469
calcium reabsorption, CaBP 28K ..... 461
Vocational rehabilitation, ESRD, HD (abst) ..... 1792

W
Wallstents, vascular, central venous stenosis ..... 1177
Wegener's granulomatosis ..... 1120